Magnesium

Evidence-based effects and studies

← Back to Supplements
Effects
667
Total evidences
779

Effects and Evidences

Detailed analysis of research findings

SDQ total difficulties score

1 evidences

Eight-week co-supplementation with vitamin D and magnesium in vitamin-D–insufficient children with ADHD improved several mental health/behavioral scores (emotional, peer problems, internalizing, total difficulties) vs placebo.

Trust comment: Double-blind RCT with validated outcomes and complete follow-up (n=66) but combined vitamin D+magnesium prevents isolating magnesium-specific effects; sample small.

Study Details

PMID:33865361
Participants:66
Impact:−3.76 points (intervention vs control, adjusted means)
Trust score:4/5

SDQ internalizing score

1 evidences

Eight-week co-supplementation with vitamin D and magnesium in vitamin-D–insufficient children with ADHD improved several mental health/behavioral scores (emotional, peer problems, internalizing, total difficulties) vs placebo.

Trust comment: Double-blind RCT with validated outcomes and complete follow-up (n=66) but combined vitamin D+magnesium prevents isolating magnesium-specific effects; sample small.

Study Details

PMID:33865361
Participants:66
Impact:−2.44 points (intervention vs control, adjusted means)
Trust score:4/5

SDQ peer problems score

1 evidences

Eight-week co-supplementation with vitamin D and magnesium in vitamin-D–insufficient children with ADHD improved several mental health/behavioral scores (emotional, peer problems, internalizing, total difficulties) vs placebo.

Trust comment: Double-blind RCT with validated outcomes and complete follow-up (n=66) but combined vitamin D+magnesium prevents isolating magnesium-specific effects; sample small.

Study Details

PMID:33865361
Participants:66
Impact:−1.16 points (intervention vs control, adjusted means)
Trust score:4/5

Migraine days

1 evidences

In ~112 evaluable adults with episodic migraine, 3 months of a supplement (600 mg magnesium plus riboflavin and Q10) reduced maximal pain intensity and HIT-6 headache impact versus placebo; reduction in migraine days was not statistically significant.

Trust comment: Well-designed multicenter double-blind RCT; combination product and possible underpowering for primary endpoint limit attribution to magnesium alone.

Study Details

PMID:25916335
Participants:112
Impact:−1.8 days (verum change from baseline to month 3; not significant vs placebo, p=0.23)
Trust score:4/5

Maximal pain intensity per migraine day

1 evidences

In ~112 evaluable adults with episodic migraine, 3 months of a supplement (600 mg magnesium plus riboflavin and Q10) reduced maximal pain intensity and HIT-6 headache impact versus placebo; reduction in migraine days was not statistically significant.

Trust comment: Well-designed multicenter double-blind RCT; combination product and possible underpowering for primary endpoint limit attribution to magnesium alone.

Study Details

PMID:25916335
Participants:112
Impact:−0.24 points (3‑point scale; verum vs baseline; p=0.03 vs placebo)
Trust score:4/5

HIT-6 headache impact score

1 evidences

In ~112 evaluable adults with episodic migraine, 3 months of a supplement (600 mg magnesium plus riboflavin and Q10) reduced maximal pain intensity and HIT-6 headache impact versus placebo; reduction in migraine days was not statistically significant.

Trust comment: Well-designed multicenter double-blind RCT; combination product and possible underpowering for primary endpoint limit attribution to magnesium alone.

Study Details

PMID:25916335
Participants:112
Impact:−4.8 points (verum change from baseline to month 3; p=0.01 vs placebo)
Trust score:4/5

DASS-42 stress score

1 evidences

In 100 chronically stressed but otherwise healthy adults, 28 days of Mg-Teadiola (magnesium plus B vitamins, rhodiola, green tea/L‑theanine) produced a clinically meaningful ~3‑point greater reduction in DASS-42 stress score versus placebo and reduced cold pain sensitivity.

Trust comment: Randomized trial with validated endpoints and consistent effects, though single-blind and multi-ingredient formulation limit attribution to magnesium alone.

Study Details

PMID:35565828
Participants:100
Impact:−3.0 points (Mg-Teadiola vs placebo at Day 28; clinically and statistically significant)
Trust score:4/5

Cold pain sensitivity (QST)

1 evidences

In 100 chronically stressed but otherwise healthy adults, 28 days of Mg-Teadiola (magnesium plus B vitamins, rhodiola, green tea/L‑theanine) produced a clinically meaningful ~3‑point greater reduction in DASS-42 stress score versus placebo and reduced cold pain sensitivity.

Trust comment: Randomized trial with validated endpoints and consistent effects, though single-blind and multi-ingredient formulation limit attribution to magnesium alone.

Study Details

PMID:35565828
Participants:100
Impact:Reduced sensitivity (effect size −0.36, p=0.01 at Day 28)
Trust score:4/5

PSQI component 7 (daytime dysfunction)

1 evidences

In 100 chronically stressed but otherwise healthy adults, 28 days of Mg-Teadiola (magnesium plus B vitamins, rhodiola, green tea/L‑theanine) produced a clinically meaningful ~3‑point greater reduction in DASS-42 stress score versus placebo and reduced cold pain sensitivity.

Trust comment: Randomized trial with validated endpoints and consistent effects, though single-blind and multi-ingredient formulation limit attribution to magnesium alone.

Study Details

PMID:35565828
Participants:100
Impact:Improved daytime dysfunction (significant on Day 56; ES −0.54, p<0.001)
Trust score:4/5

memory quotient (MQ)

1 evidences

Healthy adults took a magnesium L‑threonate + phosphatidylserine formula for 30 days and showed significant improvements in multiple memory and cognitive test scores vs placebo.

Trust comment: Double-blind randomized placebo-controlled trial with clear cognitive test improvements, though formula contained multiple active ingredients and brain Mg was not measured.

Study Details

PMID:36558392
Participants:102
Impact:increase (significant vs placebo)
Trust score:4/5

IRLS symptom severity score

1 evidences

In 75 patients with restless legs syndrome, two months of oral magnesium (plus standard pramipexole) reduced symptom severity and improved sleep quality more than control (pramipexole plus placebo).

Trust comment: Randomized single-blind trial showing clinically large improvements, but small sample, single-blind design, and co-administration with pramipexole limit certainty about standalone magnesium effect.

Study Details

PMID:36587225
Participants:75
Impact:−14.9 points (magnesium group change from baseline to 2 months; baseline 30.96 → 16.08)
Trust score:3/5

PSQI global sleep quality score

1 evidences

In 75 patients with restless legs syndrome, two months of oral magnesium (plus standard pramipexole) reduced symptom severity and improved sleep quality more than control (pramipexole plus placebo).

Trust comment: Randomized single-blind trial showing clinically large improvements, but small sample, single-blind design, and co-administration with pramipexole limit certainty about standalone magnesium effect.

Study Details

PMID:36587225
Participants:75
Impact:−12.4 points (magnesium group change from baseline to 2 months; baseline 18.28 → 5.92)
Trust score:3/5

Maternal well-being (WHO-5)

1 evidences

In 1,521 pregnant women, higher dietary magnesium intake was positively associated with better mental well-being after adjustment for confounders.

Trust comment: Large observational cohort with multivariable adjustment supports association but cannot prove causation and residual confounding is possible.

Study Details

PMID:35149320
Participants:1521
Impact:Positive association (regression B=0.08 for magnesium intake, p<0.01)
Trust score:3/5

erythrocyte magnesium

1 evidences

Older adults with poor sleep took 320 mg/day magnesium or placebo for 7 weeks; magnesium improved magnesium status and reduced inflammation in those with high CRP.

Trust comment: Randomized placebo-controlled trial with 96 completers showing biochemical and inflammatory changes, though sleep improvement attribution to magnesium was uncertain.

Study Details

PMID:21199787
Participants:96
Impact:increase
Trust score:4/5

plasma C-reactive protein (CRP) in participants with CRP >3.0 mg/L

1 evidences

Older adults with poor sleep took 320 mg/day magnesium or placebo for 7 weeks; magnesium improved magnesium status and reduced inflammation in those with high CRP.

Trust comment: Randomized placebo-controlled trial with 96 completers showing biochemical and inflammatory changes, though sleep improvement attribution to magnesium was uncertain.

Study Details

PMID:21199787
Participants:96
Impact:decrease
Trust score:4/5

Sleep quality (PSQI)

3 evidences

Older adults with poor sleep took 320 mg/day magnesium or placebo for 7 weeks; magnesium improved magnesium status and reduced inflammation in those with high CRP.

Trust comment: Randomized placebo-controlled trial with 96 completers showing biochemical and inflammatory changes, though sleep improvement attribution to magnesium was uncertain.

Study Details

PMID:21199787
Participants:96
Impact:-3.8 points (10.4 to 6.6) — improvement (uncertain attribution)
Trust score:4/5

Small randomized dietary trial in women with fibromyalgia found that a Mediterranean diet enriched with tryptophan and magnesium modestly improved anxiety, depression, fatigue and some mood/eating measures but did not change sleep quality.

Trust comment: Randomized dietary intervention but small sample, unblinded diet-based exposure and combined tryptophan+magnesium make isolated magnesium effects uncertain.

Study Details

PMID:32224987
Participants:22
Impact:no change
Trust score:3/5

A two-week randomized trial of a multi-ingredient supplement (contains magnesium) did not improve overall sleep quality versus placebo; small transient improvements in some secondary measures were observed.

Trust comment: Well-conducted, randomized double-blind trial with adequate size, but magnesium is one component of a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:28218661
Participants:160
Impact:no treatment effect vs placebo (no significant difference)
Trust score:3/5

serum cortisol

2 evidences

Large randomized trial in diabetic patients found that magnesium (and magnesium+potassium) supplementation reduced insomnia severity and altered sleep hormones (lower cortisol, higher melatonin) compared with placebo.

Trust comment: Large randomized trial with objective hormone measures and clear pre/post changes, but single-blind design and some baseline imbalances and methodological limitations reduce certainty.

Study Details

PMID:39534260
Participants:290
Impact:decrease (e.g., T2: 40.71 → 24.75 μg/dL; T4: 41.57 → 22.70 μg/dL)
Trust score:3/5

Randomized controlled trial where IV magnesium during robotic prostatectomy reduced perioperative blood pressure rises, lowered cortisol, decreased opioid use, and reduced early postoperative pain.

Trust comment: Randomized, double-blind clinical trial with objective hemodynamic and hormonal measures and moderate sample size (n=52) supporting physiologic effects.

Study Details

PMID:33611742
Participants:52
Impact:decreased from baseline to 24 h in magnesium group (no change in control; group×time P=0.006)
Trust score:4/5

serum melatonin

1 evidences

Large randomized trial in diabetic patients found that magnesium (and magnesium+potassium) supplementation reduced insomnia severity and altered sleep hormones (lower cortisol, higher melatonin) compared with placebo.

Trust comment: Large randomized trial with objective hormone measures and clear pre/post changes, but single-blind design and some baseline imbalances and methodological limitations reduce certainty.

Study Details

PMID:39534260
Participants:290
Impact:increase (notably T4: 6.12 → 15.37 pg/mL)
Trust score:3/5

insomnia severity (ISI categories)

1 evidences

Large randomized trial in diabetic patients found that magnesium (and magnesium+potassium) supplementation reduced insomnia severity and altered sleep hormones (lower cortisol, higher melatonin) compared with placebo.

Trust comment: Large randomized trial with objective hormone measures and clear pre/post changes, but single-blind design and some baseline imbalances and methodological limitations reduce certainty.

Study Details

PMID:39534260
Participants:290
Impact:reduction in clinical insomnia prevalence / more participants classified as no clinically significant insomnia post-treatment
Trust score:3/5

plasma magnesium concentration

4 evidences

In CKD patients, oral magnesium raised plasma magnesium but did not slow coronary artery calcification and had more serious adverse events.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size and clear endpoints, though CKD-specific population limits generalizability.

Study Details

PMID:36749131
Participants:148
Impact:significant increase (during treatment)
Trust score:4/5

In healthy male volunteers, magnesium supplementation during prolonged reduced movement (hypokinesia) was associated with larger decreases in muscle magnesium and increased plasma and excreted magnesium compared with controls.

Trust comment: Controlled human study but small sample, long duration and specific conditions (hypokinesia) limit generalizability.

Study Details

PMID:20363596
Participants:40
Impact:increased (P<0.05) compared with pre-experimental and control groups
Trust score:3/5

In 62 healthy adults, high phosphorus (1000 mg/day) with differing calcium (0, 500, 1000 mg/day) altered mineral handling: fasting plasma phosphate unchanged, high P without Ca reduced renal calcium excretion and disturbed calcium balance, while calcium supplementation mitigated negative effects; transient FGF23 rise at 4 weeks and modest decreases in some bone turnover markers with Ca supplementation.

Trust comment: Randomized, double-blind, placebo-controlled human intervention (62 completers) measuring Mg outcomes though Mg was not the intervention target.

Study Details

PMID:26786148
Participants:62
Impact:No change (≈0.82–0.83 mmol/L across interventions)
Trust score:4/5

During surgery plasma magnesium fell; low magnesium levels were associated with prolongation of some atracurium recovery phases.

Trust comment: Prospective randomized study with objective lab and neuromuscular measures, reported as associations.

Study Details

PMID:19856686
Participants:119
Impact:decreased during surgery
Trust score:4/5

coronary artery calcification progression

1 evidences

In CKD patients, oral magnesium raised plasma magnesium but did not slow coronary artery calcification and had more serious adverse events.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size and clear endpoints, though CKD-specific population limits generalizability.

Study Details

PMID:36749131
Participants:148
Impact:no slowing vs placebo (no significant between-group difference at 12 months)
Trust score:4/5

serious adverse events (including GI events, deaths, CV events)

1 evidences

In CKD patients, oral magnesium raised plasma magnesium but did not slow coronary artery calcification and had more serious adverse events.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate sample size and clear endpoints, though CKD-specific population limits generalizability.

Study Details

PMID:36749131
Participants:148
Impact:increased incidence in magnesium group (GI events 35 vs 9; more deaths and cardiovascular events)
Trust score:4/5

imidazole propionate (ImP)

1 evidences

In a metabolomics subset of a randomized trial, magnesium treatment substantially reduced circulating imidazole propionate (a microbially produced metabolite linked to insulin resistance) compared with placebo.

Trust comment: Randomized trial but metabolomics results are from a small subset (n=68) and represent secondary analyses, limiting certainty.

Study Details

PMID:33487303
Participants:68
Impact:reduced by 39.9% with magnesium vs +6.0% in placebo (P = 0.02)
Trust score:3/5

glutarate

1 evidences

In a metabolomics subset of a randomized trial, magnesium treatment substantially reduced circulating imidazole propionate (a microbially produced metabolite linked to insulin resistance) compared with placebo.

Trust comment: Randomized trial but metabolomics results are from a small subset (n=68) and represent secondary analyses, limiting certainty.

Study Details

PMID:33487303
Participants:68
Impact:reduced by 17.9% with magnesium vs placebo (P = 0.04)
Trust score:3/5

propionic acid (InP)

1 evidences

In a metabolomics subset of a randomized trial, magnesium treatment substantially reduced circulating imidazole propionate (a microbially produced metabolite linked to insulin resistance) compared with placebo.

Trust comment: Randomized trial but metabolomics results are from a small subset (n=68) and represent secondary analyses, limiting certainty.

Study Details

PMID:33487303
Participants:68
Impact:increased by 27.5% with magnesium (P = 0.07, borderline)
Trust score:3/5

hospitalization rate within 24 hours

1 evidences

In children with refractory acute asthma, nebulized magnesium added to albuterol did not significantly reduce 24‑hour hospitalization rates or improve clinical measures versus placebo.

Trust comment: Large multicenter randomized double-blind trial with robust sample size and clinically relevant endpoints.

Study Details

PMID:33231663
Participants:816
Impact:no significant reduction (magnesium 43.5% vs placebo 47.7%; absolute difference −4.2%; P = 0.26)
Trust score:5/5

clinical respiratory outcomes (PRAM, RR, SpO2, albuterol use)

1 evidences

In children with refractory acute asthma, nebulized magnesium added to albuterol did not significantly reduce 24‑hour hospitalization rates or improve clinical measures versus placebo.

Trust comment: Large multicenter randomized double-blind trial with robust sample size and clinically relevant endpoints.

Study Details

PMID:33231663
Participants:816
Impact:no significant between-group differences through 240 minutes
Trust score:5/5

treatment-related GI symptoms

1 evidences

In children with refractory acute asthma, nebulized magnesium added to albuterol did not significantly reduce 24‑hour hospitalization rates or improve clinical measures versus placebo.

Trust comment: Large multicenter randomized double-blind trial with robust sample size and clinically relevant endpoints.

Study Details

PMID:33231663
Participants:816
Impact:more nausea/vomiting or sore throat/nose with magnesium (4% vs 1%)
Trust score:5/5

ionized magnesium

1 evidences

In patients with metabolic syndrome, 12 weeks of 400 mg oral magnesium raised ionized magnesium, lowered blood pressure and IL-6, and increased serum vitamin D levels.

Trust comment: Randomized double‑blind design with modest sample size and consistent biochemical and clinical effects on BP and inflammation.

Study Details

PMID:39380547
Participants:54
Impact:↑ from 0.56 ± 0.05 to 0.63 ± 0.08 mmol/L (significant)
Trust score:4/5

blood pressure (systolic and diastolic)

2 evidences

In patients with metabolic syndrome, 12 weeks of 400 mg oral magnesium raised ionized magnesium, lowered blood pressure and IL-6, and increased serum vitamin D levels.

Trust comment: Randomized double‑blind design with modest sample size and consistent biochemical and clinical effects on BP and inflammation.

Study Details

PMID:39380547
Participants:54
Impact:systolic ↓ 134.6 → 126.3 mmHg; diastolic ↓ 84.1 → 79.4 mmHg after 12 weeks (P<0.01)
Trust score:4/5

Four weeks of oral magnesium increased urinary magnesium and lowered both systolic and diastolic blood pressure and improved some lipid markers compared with placebo.

Trust comment: Double-blind placebo-controlled trial but very small sample size, limiting generalizability despite randomized design.

Study Details

PMID:9389897
Participants:33
Impact:significant decrease in both systolic and diastolic BP in Mg group (exact mmHg not provided in excerpt)
Trust score:3/5

interleukin‑6 (IL‑6)

1 evidences

In patients with metabolic syndrome, 12 weeks of 400 mg oral magnesium raised ionized magnesium, lowered blood pressure and IL-6, and increased serum vitamin D levels.

Trust comment: Randomized double‑blind design with modest sample size and consistent biochemical and clinical effects on BP and inflammation.

Study Details

PMID:39380547
Participants:54
Impact:↓ 4.94 → 3.01 pg/mL after 12 weeks (P<0.01)
Trust score:4/5

vitamin D

1 evidences

In patients with metabolic syndrome, 12 weeks of 400 mg oral magnesium raised ionized magnesium, lowered blood pressure and IL-6, and increased serum vitamin D levels.

Trust comment: Randomized double‑blind design with modest sample size and consistent biochemical and clinical effects on BP and inflammation.

Study Details

PMID:39380547
Participants:54
Impact:↑ 17.93 → 24.41 ng/mL after 12 weeks (P<0.05)
Trust score:4/5

urinary magnesium excretion

12 evidences

Doubling magnesium intake for 28 days increased urinary and erythrocyte magnesium but did not change serum minerals, bone turnover markers, or blood pressure in healthy young women.

Trust comment: Randomized, double-blind, placebo-controlled crossover with objective biochemical measures, but small sample limits generalizability.

Study Details

PMID:10334649
Participants:26
Impact:+36%
Trust score:4/5

A low-sodium diet in pregnancy reduced magnesium intake but maternal magnesium homeostasis was maintained via reduced urinary excretion.

Trust comment: Randomized dietary trial with modest sample size and biochemical measures, but indirect assessment of magnesium effects and limited numeric detail in excerpt.

Study Details

PMID:9175991
Participants:94
Impact:decreased (reduction in urinary Mg excretion helped maintain Mg homeostasis)
Trust score:3/5

In EDTA chelation-treated patients, urinary magnesium excretion decreased (indicating magnesium retention) while blood lead fell substantially.

Trust comment: Double-blind placebo-controlled trial with clear urinary and blood measures but focused on EDTA chelation rather than magnesium supplementation per se.

Study Details

PMID:8969629
Participants:60
Impact:reduced by ~33% after the first EDTA infusion compared with placebo
Trust score:3/5

One-year calcium supplementation in lactating Gambian women did not change urinary magnesium excretion or iron/zinc blood markers.

Trust comment: Randomized double-blind, placebo-controlled trial with complete compliance and repeated measures supports reliability.

Study Details

PMID:9014651
Participants:60
Impact:no significant change vs placebo
Trust score:4/5

A 2-week application of 56 mg/day transdermal magnesium cream produced a non-significant serum Mg rise overall and a significant serum Mg increase in non-athlete subgroup.

Trust comment: Checklist: confirm human Mg effect; focus on serum/urine markers; verify completions n=24. Randomized single-blind pilot with small sample and low topical dose—signals seen in non-athletes but limited power and external validity.

Study Details

PMID:28403154
Participants:24
Impact:small increase in Mg group (+9.1% all subjects; +11.3% non-athletes), not statistically significant
Trust score:3/5

In type 2 diabetics with normal magnesium, 360 mg Mg daily for 3 months raised urinary Mg but did not improve blood sugar or insulin sensitivity.

Trust comment: Randomized, crossover, double-blind placebo-controlled trial with moderate completion (56 completers) — good internal validity.

Study Details

PMID:25204013
Participants:56
Impact:increased (p=0.0002)
Trust score:4/5

Oral magnesium reduced distress from pregnancy-related leg cramps compared with placebo over 3 weeks.

Trust comment: Prospective, double-blind randomized trial with clear patient-reported outcome and supporting lab data, moderate sample size.

Study Details

PMID:7631676
Participants:73
Impact:increased (p < 0.002)
Trust score:4/5

In controlled metabolic-balance studies of adolescent girls, blacks excreted less urinary magnesium than whites and magnesium retention was higher on a low-sodium diet.

Trust comment: Controlled metabolic-balance crossover study with objective intake/excretion measures in a reasonably sized cohort, supporting internal validity.

Study Details

PMID:23553157
Participants:67
Impact:lower in black girls (83.8 ± 25.6 mg/d) than white girls (94.9 ± 27.3 mg/d); p<0.05
Trust score:4/5

In middle-aged adults with low urinary magnesium, mineral water high in magnesium (and other minerals) increased urinary magnesium excretion and reduced blood pressure (notably with multi-mineral water C).

Trust comment: Randomized intervention with physiological and clinical outcomes but small sample, subgroup exclusions, and exploratory analyses limit certainty.

Study Details

PMID:15571635
Participants:70
Impact:increased (water B: 0.28 → 0.34 mmol/L, p = 0.009; water C: 0.30 → 0.35 mmol/L, p = 0.019)
Trust score:3/5

Adding magnesium to the bypass prime kept magnesium levels during surgery and reduced potassium loss after surgery in children.

Trust comment: Randomized pediatric RCT with clear biochemical outcomes but modest sample size (n=40).

Study Details

PMID:12760983
Participants:40
Impact:increased during and after CPB in magnesium group (vs placebo)
Trust score:4/5

Four weeks of oral magnesium increased urinary magnesium and lowered both systolic and diastolic blood pressure and improved some lipid markers compared with placebo.

Trust comment: Double-blind placebo-controlled trial but very small sample size, limiting generalizability despite randomized design.

Study Details

PMID:9389897
Participants:33
Impact:significant increase during supplementation
Trust score:3/5

Randomized double-blind crossover trial in 85 women testing magnesium vs sorbitol placebo for premenstrual symptoms; sorbitol unexpectedly reduced symptoms.

Trust comment: Well-designed randomized double-blind crossover with 85 participants and significant p-values, but an active placebo complicates interpretation of magnesium's effect.

Study Details

PMID:12018972
Participants:85
Impact:reduced by sorbitol vs baseline and magnesium (P=0.005)
Trust score:4/5

Hirsutism

2 evidences

In women with PCOS, 8 weeks of magnesium plus melatonin reduced hirsutism more and increased total antioxidant capacity and reduced TNF-α (melatonin and combo) versus baseline.

Trust comment: Randomized, double-blind design but small sample and combined supplementation confound attribution to magnesium alone.

Study Details

PMID:34009514
Participants:84
Impact:Greater reduction with magnesium + melatonin compared with other groups (P < 0.001)
Trust score:3/5

Magnesium plus vitamin E for 12 weeks reduced hirsutism and inflammation markers and increased nitric oxide and antioxidant capacity in women with PCOS.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate reporting of effect sizes.

Study Details

PMID:30565017
Participants:60
Impact:reduced (β −0.37; 95% CI −0.70, −0.05; P=0.02)
Trust score:5/5

TNF-α (inflammation biomarker)

1 evidences

In women with PCOS, 8 weeks of magnesium plus melatonin reduced hirsutism more and increased total antioxidant capacity and reduced TNF-α (melatonin and combo) versus baseline.

Trust comment: Randomized, double-blind design but small sample and combined supplementation confound attribution to magnesium alone.

Study Details

PMID:34009514
Participants:84
Impact:Significant decline in melatonin and magnesium+melatonin groups versus baseline (P < 0.05)
Trust score:3/5

total antioxidant capacity (TAC)

2 evidences

In women with PCOS, 8 weeks of magnesium plus melatonin reduced hirsutism more and increased total antioxidant capacity and reduced TNF-α (melatonin and combo) versus baseline.

Trust comment: Randomized, double-blind design but small sample and combined supplementation confound attribution to magnesium alone.

Study Details

PMID:34009514
Participants:84
Impact:Greater increase with magnesium + melatonin compared with other groups (P = 0.001)
Trust score:3/5

Magnesium plus vitamin E for 12 weeks reduced hirsutism and inflammation markers and increased nitric oxide and antioxidant capacity in women with PCOS.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate reporting of effect sizes.

Study Details

PMID:30565017
Participants:60
Impact:increased (β +66.32 mmol/L; 95% CI 43.80, 88.84; P<0.001)
Trust score:5/5

LPR symptom score (RSI)

1 evidences

Single-assessor–blinded RCT (40 completers) comparing a magnesium-alginate suspension to omeprazole: both treatments similarly reduced LPR symptoms and laryngoscopic signs after 2 months.

Trust comment: Randomized RCT but underpowered (stopped early, 40 completers) and not fully patient-blinded, limiting confidence in non-inferiority claim.

Study Details

PMID:35032204
Participants:40
Impact:Gastrotuss: −8.5 points; PPI: −7.2 points (no significant between-group difference)
Trust score:3/5

Laryngoscopic signs (RFS)

1 evidences

Single-assessor–blinded RCT (40 completers) comparing a magnesium-alginate suspension to omeprazole: both treatments similarly reduced LPR symptoms and laryngoscopic signs after 2 months.

Trust comment: Randomized RCT but underpowered (stopped early, 40 completers) and not fully patient-blinded, limiting confidence in non-inferiority claim.

Study Details

PMID:35032204
Participants:40
Impact:Gastrotuss: −1.8 points; PPI: −1.5 points (no significant between-group difference)
Trust score:3/5

Serum magnesium concentration

10 evidences

Randomized trial in patients with alcohol withdrawal: IV magnesium (alone or with thiamine) raised serum Mg, led to more consistent plasma lactate normalization and faster initial resolution of withdrawal scores compared with thiamine alone; ETKA did not improve overall.

Trust comment: Randomized trial (n=115) with comprehensive biochemical and clinical measures; subgroup analyses support biochemical plausibility though not all endpoints changed.

Study Details

PMID:35484175
Participants:115
Impact:increase (~+0.25 mmol/L in magnesium arms)
Trust score:4/5

In pooled T2D trial patients, dapagliflozin increased serum magnesium modestly and a higher proportion of patients corrected baseline hypomagnesemia versus placebo over 24 weeks.

Trust comment: Large pooled post hoc analysis of randomized trials yielding precise estimates, but analysis is post hoc and not designed primarily to test magnesium outcomes.

Study Details

PMID:31375422
Participants:4398
Impact:mean increase vs placebo +0.06 mmol/L (95% CI 0.05, 0.06)
Trust score:4/5

Randomized double-blind trial in carotid endarterectomy patients: high‑dose IV magnesium raised serum Mg but did not increase need for vasopressor support.

Trust comment: Well-designed randomized, double-blind, placebo-controlled trial with adequate sample (n=80); outcomes directly measured and clinically relevant.

Study Details

PMID:16385331
Participants:80
Impact:↑ (significantly elevated at 12 and 24 h vs baseline)
Trust score:4/5

Oral magnesium reduced distress from pregnancy-related leg cramps compared with placebo over 3 weeks.

Trust comment: Prospective, double-blind randomized trial with clear patient-reported outcome and supporting lab data, moderate sample size.

Study Details

PMID:7631676
Participants:73
Impact:no significant increase
Trust score:4/5

Case–control study comparing serum minerals between newly diagnosed hemifacial spasm patients and healthy volunteers; reported significant differences in serum calcium, phosphate and magnesium between groups.

Trust comment: Prospective case-control comparison with modest sample size; labeling as randomized appears inconsistent with design.

Study Details

PMID:30417857
Participants:86
Impact:lower in hemifacial spasm patients vs controls (P<0.05)
Trust score:3/5

Oral magnesium (300 mg/day) in hospitalized moderate COVID-19 patients increased serum magnesium, improved oxygenation, reduced need for oxygen therapy, and improved quality of life and depression scores compared with placebo.

Trust comment: Double-blind randomized trial with appropriate outcomes but single-center and modest sample (n=60) limits generalizability.

Study Details

PMID:38654355
Participants:60
Impact:magnesium group change +0.09 (2.25→2.34) vs placebo change -0.21 (2.28→2.07); between-group P=0.004
Trust score:4/5

Newborns with severe birth asphyxia received IV magnesium sulphate; serum Mg rose into a neuroprotective range with no significant adverse effects on vital signs.

Trust comment: Randomized clinical trial in neonates with clear, significant biochemical effects and safety monitoring though sample size was modest.

Study Details

PMID:16567913
Participants:40
Impact:increased to ~1.49–1.92 mmol/L at measured times (significantly higher than control, P<0.001)
Trust score:4/5

In 100 cardiac surgery patients, perioperative IV magnesium raised serum Mg and substantially reduced ventricular tachyarrhythmias and early CK-MB release.

Trust comment: Randomized controlled trial with 100 patients and clear clinically relevant endpoints, though single-center.

Study Details

PMID:7847975
Participants:100
Impact:increased postoperatively in magnesium group (e.g., 1.49 ± 0.34 vs 0.70 ± 0.12 mmol/L on POD1; p < 0.0001)
Trust score:4/5

IV magnesium sulphate 64 mmol/day achieved target serum magnesium (1.0-2.0 mmol/L) in most SAH patients with few discontinuations due to side effects.

Trust comment: Prospective dose-evaluation within a randomized placebo-controlled trial framework with objective lab measurements and clear reporting of discontinuations.

Study Details

PMID:16164489
Participants:94
Impact:mean 1.47 ± 0.32 mmol/L during treatment (target 1.0–2.0 mmol/L)
Trust score:4/5

In patients receiving large-volume IV fluids during anesthesia, magnesium-free fluids diluted serum Mg2+; adding magnesium to fluids prevented the serum decrease, with serum Mg unchanged at 2.0 mmol·L⁻¹ supplementation.

Trust comment: Randomized groups but small and uneven group sizes; direct physiological measurements support conclusions.

Study Details

PMID:9311207
Participants:38
Impact:Decreased with Mg-free fluid (Group I); reduction prevented by Mg supplementation; unchanged at 2.0 mmol·L⁻¹ (Group IV)
Trust score:3/5

DASS-42 anxiety score

1 evidences

In 264 stressed adults with suboptimal magnesemia, 8 weeks of magnesium (with or without vitamin B6) markedly reduced anxiety and depression scores and improved mental quality-of-life domains.

Trust comment: Large randomized, investigator-blinded trial with robust measures; post-hoc analyses and no true placebo arm (all received magnesium) limit attribution solely to magnesium.

Study Details

PMID:33864354
Participants:264
Impact:−8.74 points (overall group change from baseline to Week 8)
Trust score:4/5

DASS-42 depression score

1 evidences

In 264 stressed adults with suboptimal magnesemia, 8 weeks of magnesium (with or without vitamin B6) markedly reduced anxiety and depression scores and improved mental quality-of-life domains.

Trust comment: Large randomized, investigator-blinded trial with robust measures; post-hoc analyses and no true placebo arm (all received magnesium) limit attribution solely to magnesium.

Study Details

PMID:33864354
Participants:264
Impact:−8.08 points (overall group change from baseline to Week 8)
Trust score:4/5

SF-36 mental summary score

1 evidences

In 264 stressed adults with suboptimal magnesemia, 8 weeks of magnesium (with or without vitamin B6) markedly reduced anxiety and depression scores and improved mental quality-of-life domains.

Trust comment: Large randomized, investigator-blinded trial with robust measures; post-hoc analyses and no true placebo arm (all received magnesium) limit attribution solely to magnesium.

Study Details

PMID:33864354
Participants:264
Impact:+12.5 points (change from baseline to Week 8)
Trust score:4/5

total quality of life (SF-36 total score)

1 evidences

Women with PCOS took 250 mg magnesium oxide daily for 10 weeks; magnesium improved multiple components of quality of life versus placebo but effects on acne, alopecia and AUB were inconclusive.

Trust comment: Randomized clinical trial with ITT analysis showing statistically significant QoL benefits, but modest sample size and some outcomes were non-significant between groups after adjustment.

Study Details

PMID:35918728
Participants:54
Impact:+9.35 points (improvement)
Trust score:4/5

energy / fatigue (SF-36 subscale)

1 evidences

Women with PCOS took 250 mg magnesium oxide daily for 10 weeks; magnesium improved multiple components of quality of life versus placebo but effects on acne, alopecia and AUB were inconclusive.

Trust comment: Randomized clinical trial with ITT analysis showing statistically significant QoL benefits, but modest sample size and some outcomes were non-significant between groups after adjustment.

Study Details

PMID:35918728
Participants:54
Impact:improvement (adjusted p=0.010)
Trust score:4/5

emotional wellbeing / role limitations due to emotional problems

1 evidences

Women with PCOS took 250 mg magnesium oxide daily for 10 weeks; magnesium improved multiple components of quality of life versus placebo but effects on acne, alopecia and AUB were inconclusive.

Trust comment: Randomized clinical trial with ITT analysis showing statistically significant QoL benefits, but modest sample size and some outcomes were non-significant between groups after adjustment.

Study Details

PMID:35918728
Participants:54
Impact:improvement (adjusted p≤0.001)
Trust score:4/5

hematoma expansion

2 evidences

Exploratory analysis found higher serum magnesium (in magnesium-treated patients) associated with less hematoma expansion and less early neurological deterioration after intracerebral hemorrhage.

Trust comment: Secondary/exploratory analysis of randomized trial data showing associations but limited by biased imaging availability and post-hoc nature.

Study Details

PMID:38126183
Participants:189
Impact:associated with less HE in magnesium-treated group (adjusted OR 0.64 per mg/dL serum Mg; 95% CI 0.42–0.93)
Trust score:3/5

Ancillary analysis of FAST-MAG found intravenous magnesium sulfate given early after stroke did not reduce hematoma expansion or improve 90-day functional outcomes in patients with intracerebral hemorrhage.

Trust comment: Ancillary analysis of a large randomized prehospital trial with prospectively collected data; retrospective subanalysis but adequate sample for the question.

Study Details

PMID:35380053
Participants:268
Impact:median 2.0 mL (magnesium) vs 1.5 mL (placebo); P=0.5 (no significant difference)
Trust score:4/5

early neurological deterioration

1 evidences

Exploratory analysis found higher serum magnesium (in magnesium-treated patients) associated with less hematoma expansion and less early neurological deterioration after intracerebral hemorrhage.

Trust comment: Secondary/exploratory analysis of randomized trial data showing associations but limited by biased imaging availability and post-hoc nature.

Study Details

PMID:38126183
Participants:189
Impact:associated with less deterioration in magnesium-treated group (adjusted OR 0.54 per mg/dL serum Mg; 95% CI 0.33–0.82)
Trust score:3/5

Fasting plasma glucose (FPG)

3 evidences

In women with T2DM and CHD, 12-week combined magnesium and zinc supplementation modestly improved fasting glucose, insulin, HDL, inflammatory marker CRP, antioxidant markers, and depression/anxiety scores versus placebo.

Trust comment: Randomized, double-blind trial but small sample (n=55, females only) limits power and generalizability.

Study Details

PMID:32466773
Participants:55
Impact:decrease β −9.44 mg/dL (95% CI −18.30, −0.57); P=0.03
Trust score:3/5

In women with gestational diabetes, 6 weeks of magnesium+vitamin E improved fasting glucose, insulin resistance measures and several lipid parameters compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified metabolic outcomes; moderate sample (n=60) supports efficacy but size limits precision.

Study Details

PMID:30025522
Participants:60
Impact:decreased (β −5.20 mg/dL; p=0.002)
Trust score:4/5

250 mg/day magnesium oxide for 6 weeks in women with GDM decreased fasting glucose and modulated insulin/lipid‑related gene expression in PBMCs.

Trust comment: Randomized double-blind placebo-controlled trial with biologically plausible molecular and glucose changes but small sample (n=40).

Study Details

PMID:29256406
Participants:40
Impact:decreased (−9.7 ± 5.6 mg/dL vs −0.1 ± 8.5; P < 0.001)
Trust score:4/5

insulin concentration

1 evidences

In women with T2DM and CHD, 12-week combined magnesium and zinc supplementation modestly improved fasting glucose, insulin, HDL, inflammatory marker CRP, antioxidant markers, and depression/anxiety scores versus placebo.

Trust comment: Randomized, double-blind trial but small sample (n=55, females only) limits power and generalizability.

Study Details

PMID:32466773
Participants:55
Impact:decrease β −1.37 μIU/mL (95% CI −2.57, −0.18); P=0.02
Trust score:3/5

CRP (inflammation)

1 evidences

In women with T2DM and CHD, 12-week combined magnesium and zinc supplementation modestly improved fasting glucose, insulin, HDL, inflammatory marker CRP, antioxidant markers, and depression/anxiety scores versus placebo.

Trust comment: Randomized, double-blind trial but small sample (n=55, females only) limits power and generalizability.

Study Details

PMID:32466773
Participants:55
Impact:decrease β −0.85 mg/L (95% CI −1.26, −0.45); P<0.001
Trust score:3/5

cisplatin‑associated acute kidney disease (cis‑AKD)

1 evidences

In 30 head-and-neck cancer patients randomized to IV magnesium preloading (16 mEq) vs standard saline, magnesium markedly reduced subacute cisplatin-associated kidney disease (AKD) and prevented rises in creatinine and falls in eGFR without reducing chemotherapy efficacy.

Trust comment: Randomized, single‑blinded pilot RCT with intention‑to‑treat analysis and significant AKD effect, but limited by small sample and early termination.

Study Details

PMID:34953401
Participants:30
Impact:↓ incidence from 46.7% (control) to 6.7% (Mg); HR 0.082, P=0.03
Trust score:4/5

cisplatin‑associated acute kidney injury (cis‑AKI)

1 evidences

In 30 head-and-neck cancer patients randomized to IV magnesium preloading (16 mEq) vs standard saline, magnesium markedly reduced subacute cisplatin-associated kidney disease (AKD) and prevented rises in creatinine and falls in eGFR without reducing chemotherapy efficacy.

Trust comment: Randomized, single‑blinded pilot RCT with intention‑to‑treat analysis and significant AKD effect, but limited by small sample and early termination.

Study Details

PMID:34953401
Participants:30
Impact:No statistically significant difference (4.6% control vs 1.3% Mg; HR 0.19, P=0.2)
Trust score:4/5

serum creatinine / eGFR change

1 evidences

In 30 head-and-neck cancer patients randomized to IV magnesium preloading (16 mEq) vs standard saline, magnesium markedly reduced subacute cisplatin-associated kidney disease (AKD) and prevented rises in creatinine and falls in eGFR without reducing chemotherapy efficacy.

Trust comment: Randomized, single‑blinded pilot RCT with intention‑to‑treat analysis and significant AKD effect, but limited by small sample and early termination.

Study Details

PMID:34953401
Participants:30
Impact:Control: mean SCr increase +0.36 mg/dL and eGFR −24.7 mL/min; Mg group: no significant change (P<0.001 for control pre‑post SCr)
Trust score:4/5

Beck Depression Inventory (depressive symptoms)

1 evidences

In people with long-COVID, magnesium plus vitamin D led to much larger reductions in depression scores and higher remission rates than vitamin D alone.

Trust comment: Randomized but open‑label trial with moderate sample size; positive clinical effect on depression but limited blinding and combined treatment with vitamin D.

Study Details

PMID:39846976
Participants:60
Impact:Intervention BDI 28.8 → 9.2 (mean); 73.2% reached BDI<11 vs 34.5% in control (P=0.006)
Trust score:3/5

adverse events

2 evidences

In people with long-COVID, magnesium plus vitamin D led to much larger reductions in depression scores and higher remission rates than vitamin D alone.

Trust comment: Randomized but open‑label trial with moderate sample size; positive clinical effect on depression but limited blinding and combined treatment with vitamin D.

Study Details

PMID:39846976
Participants:60
Impact:Mild AEs in 20% (intervention) vs 10% (control); no withdrawals due to AEs
Trust score:3/5

In 52 laboring patients, adding 50 mg intrathecal magnesium to fentanyl prolonged median spinal analgesia duration from 60 to 75 minutes without increased side effects.

Trust comment: Prospective randomized controlled trial with clear clinical endpoint and reported median difference; sample moderate but appropriate for the setting.

Study Details

PMID:12198056
Participants:52
Impact:no increase in adverse events observed
Trust score:4/5

HOMA-IR (insulin resistance)

2 evidences

In adults with impaired glucose tolerance, 12 weeks of deep-seawater magnesium (350 mg/day) improved measures of insulin sensitivity but did not change 2‑hour glucose or HbA1c.

Trust comment: Randomized, double-blind, placebo-controlled and registered trial with clinically relevant endpoints but moderate sample size and 12-week duration.

Study Details

PMID:39202546
Participants:71
Impact:Decrease −0.29 (mean change at 12 weeks in test group vs baseline; significant between-group difference)
Trust score:4/5

Higher dietary magnesium intake was associated with lower insulin resistance (HOMA-IR) over 12 months in non-diabetic adults with metabolic syndrome.

Trust comment: Longitudinal analysis of a randomized dietary trial with moderate sample size and multivariable adjustment, showing consistent associations.

Study Details

PMID:24084051
Participants:234
Impact:inverse association (Model 2 β for ln HOMA-IR = -0.00110; P<0.001)
Trust score:4/5

Time to medical readiness for discharge

1 evidences

Adding a single nebulized magnesium dose to standard bronchodilator and steroid therapy for moderate/severe pediatric asthma raised blood Mg but did not significantly shorten time to medical readiness for discharge.

Trust comment: Large randomized double-blind multicenter trial with objective outcomes; negative primary result but well conducted.

Study Details

PMID:25652104
Participants:365
Impact:Mean 14.7 hr (magnesium) vs 15.6 hr (placebo); non-significant difference (P = 0.41)
Trust score:4/5

Blood magnesium level

1 evidences

Adding a single nebulized magnesium dose to standard bronchodilator and steroid therapy for moderate/severe pediatric asthma raised blood Mg but did not significantly shorten time to medical readiness for discharge.

Trust comment: Large randomized double-blind multicenter trial with objective outcomes; negative primary result but well conducted.

Study Details

PMID:25652104
Participants:365
Impact:Increased at 2 hr to 0.85 vs 0.82 mmol/L (magnesium vs placebo; P = 0.001)
Trust score:4/5

length of stay

1 evidences

In children hospitalized for sickle cell pain crisis, intravenous magnesium added to standard care did not shorten hospital length of stay, reduce opioid use, or improve quality of life.

Trust comment: Large multicenter randomized double-blind trial with robust endpoints and negative findings.

Study Details

PMID:26232172
Participants:204
Impact:Median 56.0 hr (magnesium) vs 47.0 hr (placebo); no significant difference (P = .24)
Trust score:4/5

Opioid use (morphine equivalents)

1 evidences

In children hospitalized for sickle cell pain crisis, intravenous magnesium added to standard care did not shorten hospital length of stay, reduce opioid use, or improve quality of life.

Trust comment: Large multicenter randomized double-blind trial with robust endpoints and negative findings.

Study Details

PMID:26232172
Participants:204
Impact:1.46 mg/kg (magnesium) vs 1.28 mg/kg (placebo); no significant difference (P = .12)
Trust score:4/5

health-related quality of life (HRQL)

1 evidences

In children hospitalized for sickle cell pain crisis, intravenous magnesium added to standard care did not shorten hospital length of stay, reduce opioid use, or improve quality of life.

Trust comment: Large multicenter randomized double-blind trial with robust endpoints and negative findings.

Study Details

PMID:26232172
Participants:204
Impact:No significant between-group differences before discharge or at 1 week
Trust score:4/5

magnesium balance (effluent loss)

1 evidences

Randomized ICU trial comparing high vs low citrate dose during CVVH and measured calcium/magnesium balance and PTH/vitamin D over 24 h.

Trust comment: Prospective randomized controlled ICU study with direct balance measurements and clear between-group differences, though single-center and short (24 h) duration.

Study Details

PMID:34895160
Participants:33
Impact:24-h Mg balance −25.99 mmol/d (high citrate) vs −17.63 mmol/d (low citrate); both negative and significantly more negative in high citrate group (p=0.0081)
Trust score:4/5

systemic total magnesium concentration

1 evidences

Randomized ICU trial comparing high vs low citrate dose during CVVH and measured calcium/magnesium balance and PTH/vitamin D over 24 h.

Trust comment: Prospective randomized controlled ICU study with direct balance measurements and clear between-group differences, though single-center and short (24 h) duration.

Study Details

PMID:34895160
Participants:33
Impact:total Mg decreased in both groups, with faster decline in high citrate group (−0.024 vs −0.014 mmol/L/h, p<0.0001)
Trust score:4/5

functional neurological recovery (good neurologic performance)

1 evidences

Long-term use of potassium-and-magnesium-enriched salt improved the likelihood of good neurological recovery at 6 months compared with regular salt.

Trust comment: Multicenter, double-blind randomized trial with clinically meaningful endpoints, but intervention combined potassium and magnesium so effect not attributable to magnesium alone.

Study Details

PMID:28877896
Participants:291
Impact:K/Mg salt group had increased odds of good neurologic performance vs regular salt at 6 months: OR 2.25 (95% CI 1.09–4.67)
Trust score:4/5

Insulin secretion (FPIR)

1 evidences

Open-label RCT in hypomagnesemic kidney transplant recipients: oral magnesium oxide supplementation did not improve insulin secretion or glycemic control over 6 months.

Trust comment: Randomized controlled trial (n=52) with clear endpoints but limited by persistent hypomagnesemia in many participants reducing treatment effect potential.

Study Details

PMID:28848225
Participants:52
Impact:no change
Trust score:4/5

Glycemic control (fasting glucose / HbA1c / HOMA-IR)

1 evidences

Open-label RCT in hypomagnesemic kidney transplant recipients: oral magnesium oxide supplementation did not improve insulin secretion or glycemic control over 6 months.

Trust comment: Randomized controlled trial (n=52) with clear endpoints but limited by persistent hypomagnesemia in many participants reducing treatment effect potential.

Study Details

PMID:28848225
Participants:52
Impact:no change
Trust score:4/5

Leg cramp frequency

1 evidences

Double-blind RCT in older adults with nocturnal leg cramps: 5 days of IV magnesium sulfate did not significantly reduce weekly cramp frequency vs placebo.

Trust comment: Double-blind randomized trial (n=46) with a clear negative result, moderate sample size for symptomatic outcome.

Study Details

PMID:21289017
Participants:46
Impact:no significant reduction (mean change Mg −2.4 vs placebo −1.7; p=0.51)
Trust score:4/5

Diastolic blood pressure increase

1 evidences

In healthy first-time pregnant women, daily 400 mg oral magnesium did not prevent blood pressure increases versus placebo; gestational length was slightly longer in the magnesium group.

Trust comment: Randomized double-blind multicenter RCT with adequate sample and pre-specified outcomes but allowed additional Mg-containing multivitamins and incomplete blood sampling reducing certainty.

Study Details

PMID:30002931
Participants:199
Impact:No significant difference between Mg and placebo (primary outcome: no prevention)
Trust score:4/5

systolic blood pressure increase

1 evidences

In healthy first-time pregnant women, daily 400 mg oral magnesium did not prevent blood pressure increases versus placebo; gestational length was slightly longer in the magnesium group.

Trust comment: Randomized double-blind multicenter RCT with adequate sample and pre-specified outcomes but allowed additional Mg-containing multivitamins and incomplete blood sampling reducing certainty.

Study Details

PMID:30002931
Participants:199
Impact:No significant difference between Mg and placebo
Trust score:4/5

Gestational length at birth

1 evidences

In healthy first-time pregnant women, daily 400 mg oral magnesium did not prevent blood pressure increases versus placebo; gestational length was slightly longer in the magnesium group.

Trust comment: Randomized double-blind multicenter RCT with adequate sample and pre-specified outcomes but allowed additional Mg-containing multivitamins and incomplete blood sampling reducing certainty.

Study Details

PMID:30002931
Participants:199
Impact:+0.3 weeks (mean 40.2 vs 39.9 weeks; p=0.03 PP, p=0.048 ITT)
Trust score:4/5

Migraine attacks per month

1 evidences

In a randomized clinical trial of migraine patients, oral magnesium (500 mg/day) reduced migraine frequency, days and severity over 12 weeks compared with control/other arms when analysed accounting for confounders.

Trust comment: Randomized trial with moderate sample size showing positive effects, but details on blinding, comparator treatment and effect sizes are limited and larger trials are needed.

Study Details

PMID:22895810
Participants:133
Impact:Significant reduction with magnesium supplementation (p<0.05; group ANOVA p=0.008)
Trust score:3/5

Migraine days per month

1 evidences

In a randomized clinical trial of migraine patients, oral magnesium (500 mg/day) reduced migraine frequency, days and severity over 12 weeks compared with control/other arms when analysed accounting for confounders.

Trust comment: Randomized trial with moderate sample size showing positive effects, but details on blinding, comparator treatment and effect sizes are limited and larger trials are needed.

Study Details

PMID:22895810
Participants:133
Impact:Significant reduction with magnesium supplementation (p<0.05)
Trust score:3/5

Headache severity

1 evidences

In a randomized clinical trial of migraine patients, oral magnesium (500 mg/day) reduced migraine frequency, days and severity over 12 weeks compared with control/other arms when analysed accounting for confounders.

Trust comment: Randomized trial with moderate sample size showing positive effects, but details on blinding, comparator treatment and effect sizes are limited and larger trials are needed.

Study Details

PMID:22895810
Participants:133
Impact:Significant reduction with magnesium supplementation (p<0.05)
Trust score:3/5

carotid-femoral pulse wave velocity (PWVc-f)

1 evidences

Daily magnesium (350 mg) for 24 weeks reduced arterial stiffness (pulse-wave velocity) in overweight/obese adults without changing blood pressure.

Trust comment: Well-conducted randomized double-blind trial with objective vascular outcome but small sample size (n=52).

Study Details

PMID:27053384
Participants:52
Impact:improved by 1.0 m/s versus placebo after 24 weeks (95% CI 0.4–1.6; P=0.001)
Trust score:4/5

directed memory, paired-association learning, free recall, recognition, portrait-features memory

1 evidences

Healthy adults took a magnesium L‑threonate + phosphatidylserine formula for 30 days and showed significant improvements in multiple memory and cognitive test scores vs placebo.

Trust comment: Double-blind randomized placebo-controlled trial with clear cognitive test improvements, though formula contained multiple active ingredients and brain Mg was not measured.

Study Details

PMID:36558392
Participants:102
Impact:improvement (significant vs placebo)
Trust score:4/5

fat mass

1 evidences

74 overweight middle-aged women received 250 mg Mg/day or placebo for 8 weeks; small within-group changes occurred but no significant benefits versus placebo.

Trust comment: Double-blind randomized placebo-controlled trial of moderate size; outcomes largely not significant between groups.

Study Details

PMID:23619906
Participants:74
Impact:decrease vs baseline (P=0.02) but not significant versus placebo
Trust score:4/5

trait anxiety

1 evidences

Small randomized dietary trial in women with fibromyalgia found that a Mediterranean diet enriched with tryptophan and magnesium modestly improved anxiety, depression, fatigue and some mood/eating measures but did not change sleep quality.

Trust comment: Randomized dietary intervention but small sample, unblinded diet-based exposure and combined tryptophan+magnesium make isolated magnesium effects uncertain.

Study Details

PMID:32224987
Participants:22
Impact:decrease (improvement)
Trust score:3/5

fatigue and depression (POMS)

1 evidences

Small randomized dietary trial in women with fibromyalgia found that a Mediterranean diet enriched with tryptophan and magnesium modestly improved anxiety, depression, fatigue and some mood/eating measures but did not change sleep quality.

Trust comment: Randomized dietary intervention but small sample, unblinded diet-based exposure and combined tryptophan+magnesium make isolated magnesium effects uncertain.

Study Details

PMID:32224987
Participants:22
Impact:decrease (improvement)
Trust score:3/5

serum 25-hydroxyvitamin D (25OHD)

1 evidences

Combined magnesium + vitamin D increased serum 25OHD more than vitamin D alone over 12 weeks, with no significant changes in PTH or inflammatory markers.

Trust comment: Double-blind randomized trial showing a modest, clinically plausible increase in 25OHD with magnesium co-supplementation; inflammatory outcomes were null.

Study Details

PMID:35576873
Participants:95
Impact:+6.3 ± 8.36 ng/mL (greater increase vs vitamin D alone)
Trust score:4/5

markers of systemic inflammation

1 evidences

Combined magnesium + vitamin D increased serum 25OHD more than vitamin D alone over 12 weeks, with no significant changes in PTH or inflammatory markers.

Trust comment: Double-blind randomized trial showing a modest, clinically plausible increase in 25OHD with magnesium co-supplementation; inflammatory outcomes were null.

Study Details

PMID:35576873
Participants:95
Impact:no significant change
Trust score:4/5

parathyroid hormone (PTH)

1 evidences

Combined magnesium + vitamin D increased serum 25OHD more than vitamin D alone over 12 weeks, with no significant changes in PTH or inflammatory markers.

Trust comment: Double-blind randomized trial showing a modest, clinically plausible increase in 25OHD with magnesium co-supplementation; inflammatory outcomes were null.

Study Details

PMID:35576873
Participants:95
Impact:no significant change
Trust score:4/5

migraine frequency (magnesium alone)

1 evidences

In migraine patients, oral magnesium alone reduced attacks versus baseline but was less effective than valproate; adding magnesium to low‑dose valproate improved several outcomes compared with valproate alone.

Trust comment: Large randomized double-blind trial with good follow-up (222 completers); single-center and some missing biomarker data limit broader inference.

Study Details

PMID:33827421
Participants:222
Impact:reduced from 7.06 to 3.91 attacks/month (−3.15 attacks, ≈−44.7% vs baseline)
Trust score:4/5

headache severity (valproate + magnesium vs valproate)

1 evidences

In migraine patients, oral magnesium alone reduced attacks versus baseline but was less effective than valproate; adding magnesium to low‑dose valproate improved several outcomes compared with valproate alone.

Trust comment: Large randomized double-blind trial with good follow-up (222 completers); single-center and some missing biomarker data limit broader inference.

Study Details

PMID:33827421
Participants:222
Impact:greater reduction at 3 months (additional −0.45 points on severity scale; p=0.002)
Trust score:4/5

analgesic use (valproate + magnesium vs valproate)

1 evidences

In migraine patients, oral magnesium alone reduced attacks versus baseline but was less effective than valproate; adding magnesium to low‑dose valproate improved several outcomes compared with valproate alone.

Trust comment: Large randomized double-blind trial with good follow-up (222 completers); single-center and some missing biomarker data limit broader inference.

Study Details

PMID:33827421
Participants:222
Impact:fewer painkillers used at 3 months (mean difference ≈−0.46 uses/month; p<0.001)
Trust score:4/5

perceived stress (DASS-42) overall

1 evidences

In adults with low serum magnesium and elevated stress, both magnesium alone and magnesium+vitamin B6 reduced perceived stress substantially; the combination showed greater benefit in those with severe/extremely severe stress.

Trust comment: Large, randomized, double-blind, well-powered trial with validated psychometric primary outcome and prespecified subgroup analyses.

Study Details

PMID:30562392
Participants:260
Impact:Mg–vitB6: −12.44 points (−44.9%); Mg alone: −11.72 points (−42.4%) from baseline to Week 8 (difference not significant overall)
Trust score:5/5

perceived stress (severe/extremely severe subgroup)

1 evidences

In adults with low serum magnesium and elevated stress, both magnesium alone and magnesium+vitamin B6 reduced perceived stress substantially; the combination showed greater benefit in those with severe/extremely severe stress.

Trust comment: Large, randomized, double-blind, well-powered trial with validated psychometric primary outcome and prespecified subgroup analyses.

Study Details

PMID:30562392
Participants:260
Impact:Mg–vitB6 superior to Mg alone by +3.16 points at Week 8 (23.9% greater improvement; p=0.0203 mITT)
Trust score:5/5

safety profile (AEs)

1 evidences

In adults with low serum magnesium and elevated stress, both magnesium alone and magnesium+vitamin B6 reduced perceived stress substantially; the combination showed greater benefit in those with severe/extremely severe stress.

Trust comment: Large, randomized, double-blind, well-powered trial with validated psychometric primary outcome and prespecified subgroup analyses.

Study Details

PMID:30562392
Participants:260
Impact:similar and acceptable incidence of adverse events between arms
Trust score:5/5

HbA1c

2 evidences

In 40 completers (newly diagnosed T2D), daily oral magnesium (250 mg elemental/day) for 3 months significantly improved HbA1c, fasting insulin, C‑peptide, HOMA‑IR and HOMA‑β% versus controls and produced a small increase in serum magnesium.

Trust comment: Randomized controlled trial with dietary stabilization and good follow‑up (40 completers); modest size but multiple consistent metabolic improvements.

Study Details

PMID:30587761
Participants:40
Impact:↓ 0.36% (intervention vs control; P<0.001)
Trust score:4/5

In type 2 diabetics with normal magnesium, 360 mg Mg daily for 3 months raised urinary Mg but did not improve blood sugar or insulin sensitivity.

Trust comment: Randomized, crossover, double-blind placebo-controlled trial with moderate completion (56 completers) — good internal validity.

Study Details

PMID:25204013
Participants:56
Impact:no significant change
Trust score:4/5

fasting insulin

2 evidences

In 40 completers (newly diagnosed T2D), daily oral magnesium (250 mg elemental/day) for 3 months significantly improved HbA1c, fasting insulin, C‑peptide, HOMA‑IR and HOMA‑β% versus controls and produced a small increase in serum magnesium.

Trust comment: Randomized controlled trial with dietary stabilization and good follow‑up (40 completers); modest size but multiple consistent metabolic improvements.

Study Details

PMID:30587761
Participants:40
Impact:↓ 3.47 μIU/mL (P<0.001)
Trust score:4/5

In adults with impaired glucose tolerance, 12 weeks of deep-seawater magnesium (350 mg/day) improved measures of insulin sensitivity but did not change 2‑hour glucose or HbA1c.

Trust comment: Randomized, double-blind, placebo-controlled and registered trial with clinically relevant endpoints but moderate sample size and 12-week duration.

Study Details

PMID:39202546
Participants:71
Impact:Decrease −2.47 μU/mL (mean change at 12 weeks in test group; significant between-group difference)
Trust score:4/5

C‑peptide

2 evidences

In 40 completers (newly diagnosed T2D), daily oral magnesium (250 mg elemental/day) for 3 months significantly improved HbA1c, fasting insulin, C‑peptide, HOMA‑IR and HOMA‑β% versus controls and produced a small increase in serum magnesium.

Trust comment: Randomized controlled trial with dietary stabilization and good follow‑up (40 completers); modest size but multiple consistent metabolic improvements.

Study Details

PMID:30587761
Participants:40
Impact:↓ 0.38 ng/mL (P=0.001)
Trust score:4/5

In adults with impaired glucose tolerance, 12 weeks of deep-seawater magnesium (350 mg/day) improved measures of insulin sensitivity but did not change 2‑hour glucose or HbA1c.

Trust comment: Randomized, double-blind, placebo-controlled and registered trial with clinically relevant endpoints but moderate sample size and 12-week duration.

Study Details

PMID:39202546
Participants:71
Impact:Decrease −0.12 ng/mL (mean change at 12 weeks in test group; significant between-group difference)
Trust score:4/5

HOMA‑IR

1 evidences

In 40 completers (newly diagnosed T2D), daily oral magnesium (250 mg elemental/day) for 3 months significantly improved HbA1c, fasting insulin, C‑peptide, HOMA‑IR and HOMA‑β% versus controls and produced a small increase in serum magnesium.

Trust comment: Randomized controlled trial with dietary stabilization and good follow‑up (40 completers); modest size but multiple consistent metabolic improvements.

Study Details

PMID:30587761
Participants:40
Impact:Improved by 1.72 (P<0.001)
Trust score:4/5

serum magnesium

29 evidences

In 40 completers (newly diagnosed T2D), daily oral magnesium (250 mg elemental/day) for 3 months significantly improved HbA1c, fasting insulin, C‑peptide, HOMA‑IR and HOMA‑β% versus controls and produced a small increase in serum magnesium.

Trust comment: Randomized controlled trial with dietary stabilization and good follow‑up (40 completers); modest size but multiple consistent metabolic improvements.

Study Details

PMID:30587761
Participants:40
Impact:↑ 0.065 mg/dL (P=0.036)
Trust score:4/5

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Prospective multicenter randomized pilot with 105 patients showing biochemical target attainment but no benefit on primary clinical endpoint; adequately reported pilot limitations.

Study Details

PMID:40228559
Participants:105
Impact:↑ study vs control on days 2–4 (day2 2.20 ± 0.37 vs 1.93 ± 0.31 mg/dL; P<0.001)
Trust score:4/5

In pediatric cancer patients receiving cisplatin, magnesium supplementation did not significantly reduce the proportion of chemotherapy courses with increased serum creatinine; supplemented courses had higher serum Mg without reported Mg-related adverse events.

Trust comment: Randomized phase-2 multicenter trial but small sample and course-level analysis limited power to detect benefit.

Study Details

PMID:38564107
Participants:28
Impact:Significantly higher during magnesium-supplemented courses (numeric value not reported)
Trust score:3/5

In hypertensive patients, IV magnesium (with or without lidocaine) was tested to reduce the blood-pressure spike from intubation.

Trust comment: Randomized, double-blind trial in 96 patients with clear clinical endpoints though limited to peri-intubation setting.

Study Details

PMID:36857471
Participants:96
Impact:increased above baseline in all treatment groups
Trust score:4/5

Daily magnesium (350 mg) for 24 weeks reduced arterial stiffness (pulse-wave velocity) in overweight/obese adults without changing blood pressure.

Trust comment: Well-conducted randomized double-blind trial with objective vascular outcome but small sample size (n=52).

Study Details

PMID:27053384
Participants:52
Impact:tended to increase (+0.02 mmol/L; P=0.09)
Trust score:4/5

Younger adults on a 1975-style Japanese diet for 28 days showed improved lipid parameters and an increase in serum magnesium versus a modern diet.

Trust comment: Checklist: confirm dietary intervention includes Mg-related changes; extract biochemical outcomes; verify n=32. Small randomized dietary trial with statistically significant biochemical changes including serum Mg, but short duration (28 days) and modest sample size.

Study Details

PMID:29710042
Participants:32
Impact:significant increase (p<0.05) in JD group
Trust score:4/5

Systemic magnesium infusion did not reduce immediate post-tonsillectomy pain or PACU opioid use in children, though treated children had higher serum magnesium levels at surgery end.

Trust comment: Checklist: confirm human Mg infusion; extract pain/opioid and serum outcomes; verify n=60. Well-designed double-blind RCT with adequate sample for immediate outcomes showing no clinical analgesic benefit despite raised serum Mg.

Study Details

PMID:26501831
Participants:60
Impact:significantly higher in treatment group at end of surgery (p<0.001)
Trust score:4/5

Randomized double-blind trial of 400 mg/day magnesium oxide for 12 weeks increased serum magnesium modestly and showed small, non-significant changes in multiple circulating proteins after multiple-comparison correction.

Trust comment: Randomized, double-blind trial with rigorous proteomic methods but small sample and exploratory analyses with no significant results after multiple-comparison correction.

Study Details

PMID:32517192
Participants:52
Impact:+0.035 mmol/L (95% CI 0.015 to 0.06); ≈+0.6 SD; p=0.003
Trust score:3/5

Potassium‑magnesium citrate corrected thiazide-induced low potassium; higher doses modestly increased serum magnesium and urinary magnesium and dose-dependently raised urinary pH and citrate.

Trust comment: Randomized study with clear biochemical endpoints and dose-response data in humans; moderate sample size but appropriate design.

Study Details

PMID:10423646
Participants:61
Impact:small but significant increase with the two higher dosages (not with lowest dose)
Trust score:4/5

In hemodialysis patients, oral magnesium carbonate for 6 months effectively reduced serum phosphate similar to calcium carbonate, produced lower serum calcium and was generally well tolerated with few cases of hypermagnesemia when combined with low-dialysate magnesium.

Trust comment: Randomized controlled design with complete biochemical follow-up but single-center, partial non-random allocations and small sample limit generalizability.

Study Details

PMID:18193489
Participants:43
Impact:+0.19 mg/dL at 6 months (2.59 vs 2.40 mg/dL; not significant)
Trust score:3/5

In glucose-intolerant adults, 12 weeks of pioglitazone (30 mg/day) significantly increased serum magnesium compared with lifestyle intervention.

Trust comment: Randomized controlled trial with blinded outcome assessment and clear, statistically significant biochemical effect.

Study Details

PMID:12746760
Participants:60
Impact:+0.20 mg/dL increase (from 1.73 to 1.93 mg/dL) in pioglitazone group; between-group P<0.0001
Trust score:4/5

In patients with type 2 diabetes, combined choline+magnesium supplementation improved markers of inflammation and endothelial dysfunction more than either alone or placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clinically relevant endpoints.

Study Details

PMID:31012803
Participants:96
Impact:significant increase in serum magnesium in magnesium and choline-magnesium groups (exact values not provided here)
Trust score:4/5

Compared normal vs low dialysate magnesium in hemodialysis; changing dialysate Mg did not significantly alter QTc dispersion.

Trust comment: Small within-subject dialysis study (n=22) with appropriate measurements but limited power to detect small QTcd differences.

Study Details

PMID:22299661
Participants:22
Impact:decreased post-dialysis (statistically significant)
Trust score:3/5

500 mg magnesium oxide daily for 8 weeks in depressed patients improved depression scores and serum magnesium but did not change BDNF.

Trust comment: Double-blind randomized clinical trial with clear outcomes but small sample (n=46) limits generalizability.

Study Details

PMID:33745609
Participants:46
Impact:increased (significant, P = 0.001)
Trust score:4/5

In healthy volunteers on thiazides, potassium-magnesium citrate formulations corrected hypokalemia; two formulations modestly raised serum magnesium and urinary pH/citrate more than the third.

Trust comment: Randomized comparison in 62 healthy volunteers with objective biochemical endpoints; tolerability differences noted.

Study Details

PMID:9824785
Participants:62
Impact:small increase with K3MgHCit2 and K4MgCit2; no increase with K5MgCit2Cl
Trust score:4/5

In heart failure patients, oral magnesium raised serum and intracellular Mg and substantially lowered CRP after 5 weeks compared with untreated patients.

Trust comment: Small, non-blinded treatment comparison with limited sample size for the intervention (17 treated, 18 controls); biologic endpoints reported.

Study Details

PMID:17479208
Participants:35
Impact:increase from 0.74±0.04 to 0.88±0.08 mmol/L with Mg (P<0.001)
Trust score:3/5

Twelve-week magnesium supplementation in patients with diabetic foot ulcers increased serum magnesium and improved ulcer size, glycemic control, inflammation, and antioxidant capacity compared with placebo.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial with clear magnesium-specific supplementation and clinically meaningful metabolic and wound outcomes.

Study Details

PMID:28540570
Participants:70
Impact:increase +0.3 mg/dL vs -0.1 mg/dL (P < 0.001)
Trust score:4/5

Cross-sectional study of 90 healthy adults found higher drinking-water magnesium and serum Mg associated with lower diastolic BP and relationships with lipids and glucose indices.

Trust comment: Observational cross-sectional design with modest sample size; associations reported but not causal.

Study Details

PMID:22361711
Participants:90
Impact:independently associated with triglycerides and predicted diastolic BP (association)
Trust score:3/5

Perioperative magnesium infusion raised serum magnesium and reduced post-CABG atrial fibrillation incidence in non-diabetic patients.

Trust comment: Large randomized clinical trial in CABG patients; clinically relevant endpoints though subgroup effect by diabetes.

Study Details

PMID:17694684
Participants:345
Impact:significantly increased with supplemental magnesium (P < 0.001)
Trust score:4/5

In elderly type 2 diabetics with hypomagnesemia, oral magnesium chloride was as effective as imipramine for depression score improvement and raised serum magnesium markedly.

Trust comment: Randomized trial but small, specific population (elderly diabetics with hypomagnesemia) limits broad applicability.

Study Details

PMID:19271419
Participants:23
Impact:increased in Mg group (2.1 vs 1.5 mg/dL, p < 0.0005)
Trust score:3/5

Study of 28 patients receiving IL-2 therapy showing serum and urinary magnesium fell while lymphocyte magnesium per cell increased during treatment.

Trust comment: Clear biochemical measurements in a small clinical cohort; not a magnesium intervention study, so findings describe Mg dynamics during IL-2 therapy.

Study Details

PMID:11873239
Participants:28
Impact:decreased within 12 hours (p<.005)
Trust score:3/5

Intraoperative IV magnesium raised serum magnesium and reduced clot firmness on ROTEM, indicating reduced postoperative hypercoagulability.

Trust comment: Randomized clinical trial with objective coagulation measures and moderate sample size.

Study Details

PMID:25132158
Participants:44
Impact:+0.62 mmol/L (1.60 vs 0.98 mmol/L, p<0.001)
Trust score:4/5

A small randomized pilot found degradable magnesium alloy screws produced clinical and radiographic outcomes equivalent to titanium screws at 6 months.

Trust comment: Prospective randomized clinical trial directly testing a magnesium implant, but small sample and short (6-month) follow-up limit generalizability.

Study Details

PMID:23819489
Participants:24
Impact:No significant elevations detected postoperatively
Trust score:4/5

Perioperative IV magnesium increased serum magnesium but did not raise CSF magnesium or reduce postoperative analgesic use or pain after hysterectomy.

Trust comment: Randomized controlled perioperative trial with objective biochemical measures and analgesic outcomes; negative result.

Study Details

PMID:11575536
Participants:60
Impact:significantly increased post-infusion (P < 0.001)
Trust score:4/5

In term neonates with perinatal asphyxia, postnatal magnesium sulfate infusion improved short-term neurological outcomes at discharge versus placebo.

Trust comment: Randomized single-blind controlled neonatal trial showing clinically relevant outcomes but limited by small size and single-blind design.

Study Details

PMID:24292304
Participants:50
Impact:increased from 1.6±0.3 to 3.9±0.6 mg/dL at 48 h (experimental group)
Trust score:4/5

In borderline hypertensive adults, switching from low to high dietary sodium changed serum electrolytes and renal filtration but did not alter blood pressure.

Trust comment: Randomized 1-month dietary crossover in 48 subjects with clear biochemical measurements and reported significance levels.

Study Details

PMID:15513697
Participants:48
Impact:decrease (significant, p < 0.01)
Trust score:4/5

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Data from a randomized double-blind trial's subgroup (retrospective subgroup analysis, not randomized by acid-suppressive use) with measured serum values.

Study Details

PMID:31425366
Participants:66
Impact:maintained (mean 0.95 mmol/L at 16 weeks; 0 infants below reference)
Trust score:4/5

In volunteers on thiazide, potassium-magnesium-citrate prevented magnesium depletion and maintained potassium better than potassium chloride.

Trust comment: Double-blind randomized trial but small sample (n=22) with physiologic and biochemical endpoints reported.

Study Details

PMID:16645424
Participants:22
Impact:increase by ~10% with K-Mg-citrate (significant)
Trust score:4/5

In hemodialysis patients, a magnesium-containing phosphate binder raised serum magnesium and was associated with more radiographic improvements and a non-significant trend toward less progression of arterial calcifications.

Trust comment: Randomized pilot trial with objective radiographic endpoints but small sample and limited power.

Study Details

PMID:25118610
Participants:59
Impact:increase to 2.83 vs 2.52 mg/dl (p = 0.001)
Trust score:3/5

ICH volume (primary outcome)

1 evidences

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Prospective multicenter randomized pilot with 105 patients showing biochemical target attainment but no benefit on primary clinical endpoint; adequately reported pilot limitations.

Study Details

PMID:40228559
Participants:105
Impact:No significant difference on hospital day 2 or 3 between groups (P=0.613, P=0.671)
Trust score:4/5

clinical outcomes (ICU/hospital stay, 30‑day mRS)

1 evidences

Multicenter randomized pilot trial (n=105) testing IV calcium and magnesium correction vs placebo in acute ICH to assess safety, serum level correction, hematoma expansion, and 30‑day outcome.

Trust comment: Prospective multicenter randomized pilot with 105 patients showing biochemical target attainment but no benefit on primary clinical endpoint; adequately reported pilot limitations.

Study Details

PMID:40228559
Participants:105
Impact:No significant differences between groups
Trust score:4/5

Elevated serum creatinine (cisplatin-induced nephrotoxicity)

1 evidences

In pediatric cancer patients receiving cisplatin, magnesium supplementation did not significantly reduce the proportion of chemotherapy courses with increased serum creatinine; supplemented courses had higher serum Mg without reported Mg-related adverse events.

Trust comment: Randomized phase-2 multicenter trial but small sample and course-level analysis limited power to detect benefit.

Study Details

PMID:38564107
Participants:28
Impact:10% (no-supplement courses) vs 6% (supplemented courses); no significant difference (P = 0.465)
Trust score:3/5

ICAF fatigue item

1 evidences

In fibromyalgia patients, a 3-month combined supplement (CoQ10, tryptophan, magnesium) improved overall impact, sleep quality and functional impact but fatigue did not improve more than placebo.

Trust comment: Well-designed randomized double-blind crossover trial with good retention, but magnesium was given as part of a multi-ingredient supplement, limiting attribution to magnesium alone.

Study Details

PMID:40151031
Participants:89
Impact:No significant improvement with supplement (placebo improved)
Trust score:3/5

ICAF total score

1 evidences

In fibromyalgia patients, a 3-month combined supplement (CoQ10, tryptophan, magnesium) improved overall impact, sleep quality and functional impact but fatigue did not improve more than placebo.

Trust comment: Well-designed randomized double-blind crossover trial with good retention, but magnesium was given as part of a multi-ingredient supplement, limiting attribution to magnesium alone.

Study Details

PMID:40151031
Participants:89
Impact:Significant improvement after 3 months with the dietary supplement
Trust score:3/5

sleep quality

1 evidences

In fibromyalgia patients, a 3-month combined supplement (CoQ10, tryptophan, magnesium) improved overall impact, sleep quality and functional impact but fatigue did not improve more than placebo.

Trust comment: Well-designed randomized double-blind crossover trial with good retention, but magnesium was given as part of a multi-ingredient supplement, limiting attribution to magnesium alone.

Study Details

PMID:40151031
Participants:89
Impact:Significant improvement with the dietary supplement
Trust score:3/5

CGRP (calcitonin gene-related peptide)

1 evidences

In a 2-month trial, combined vitamin B12 + magnesium plus high-intensity interval training reduced CGRP levels and improved migraine disability, frequency, intensity and duration more than other groups.

Trust comment: Randomized trial but small size and combined interventions (exercise + B12 + magnesium) limit isolation of magnesium's specific effect.

Study Details

PMID:35112219
Participants:60
Impact:Significant decline in the HIIT + supplement (B12 + magnesium) group compared with other groups
Trust score:3/5

Migraine burden (MIDAS) and attack frequency/intensity/duration

1 evidences

In a 2-month trial, combined vitamin B12 + magnesium plus high-intensity interval training reduced CGRP levels and improved migraine disability, frequency, intensity and duration more than other groups.

Trust comment: Randomized trial but small size and combined interventions (exercise + B12 + magnesium) limit isolation of magnesium's specific effect.

Study Details

PMID:35112219
Participants:60
Impact:Reduced in the HIIT + supplement group compared with other groups
Trust score:3/5

Magnesium absorption

3 evidences

Healthy men ingested lactulose with calcium and magnesium tracers; urinary isotope ratios showed increased mineral absorption with lactulose.

Trust comment: Double-blind randomized crossover with objective isotope measures is high quality despite small n and short-term measurement.

Study Details

PMID:17484373
Participants:24
Impact:increase (dose-dependent; significant vs placebo for low- and high-dose)
Trust score:4/5

Compared liposomal vs standard multivitamin; magnesium blood levels showed no difference after ingestion.

Trust comment: Randomized, double-blind crossover with objective assays and complete data (n=25); well-conducted but low magnesium dose limits conclusions about magnesium.

Study Details

PMID:36014827
Participants:25
Impact:no significant difference in magnesium iAUC, Cmax, or Tmax between liposomal and standard MVM (p>0.05)
Trust score:4/5

In 26 adolescent girls, increasing dietary calcium did not alter magnesium absorption, excretion, or overall magnesium balance over 14 days.

Trust comment: Controlled double-blind dietary study with measured intake/excretion but small sample size.

Study Details

PMID:8644692
Participants:26
Impact:50% (low Ca) vs 55% (high Ca); no significant difference
Trust score:4/5

asthma control

1 evidences

Daily magnesium (450 mg) for 16 weeks did not improve asthma control outcomes compared with placebo.

Trust comment: Large, double-blind randomized placebo-controlled trial (n=300) with comprehensive clinical outcomes and negative results.

Study Details

PMID:14519140
Participants:300
Impact:no benefit of magnesium (450 mg/day) on FEV1, FVC, airway responsiveness, peak flow, symptom scores, or bronchodilator use (no significant differences)
Trust score:4/5

urinary magnesium

1 evidences

Study of 28 patients receiving IL-2 therapy showing serum and urinary magnesium fell while lymphocyte magnesium per cell increased during treatment.

Trust comment: Clear biochemical measurements in a small clinical cohort; not a magnesium intervention study, so findings describe Mg dynamics during IL-2 therapy.

Study Details

PMID:11873239
Participants:28
Impact:decreased (p<.005)
Trust score:3/5

urinary citrate

1 evidences

Different potassium- and magnesium-containing supplements were given to kidney stone patients for one month and urine markers of stone risk were measured.

Trust comment: Human controlled supplementation with clear urinary outcomes but small sample, short duration, and mixed multi-nutrient arms limit attribution to magnesium alone.

Study Details

PMID:15117041
Participants:61
Impact:increase (with K Na citrate and K Mg citrate); no change (with Mg glycine)
Trust score:3/5

opioid requirement

1 evidences

Randomized trial in adolescents undergoing spinal fusion: perioperative magnesium infusion produced no reduction in opioid requirements or pain scores compared with remifentanil alone.

Trust comment: Well-conducted randomized, blinded trial (n=60) but negative for magnesium effect using the tested dosing regimen.

Study Details

PMID:30078167
Participants:60
Impact:no difference vs control
Trust score:4/5

Postoperative pain scores

1 evidences

Randomized trial in adolescents undergoing spinal fusion: perioperative magnesium infusion produced no reduction in opioid requirements or pain scores compared with remifentanil alone.

Trust comment: Well-conducted randomized, blinded trial (n=60) but negative for magnesium effect using the tested dosing regimen.

Study Details

PMID:30078167
Participants:60
Impact:no difference vs control
Trust score:4/5

Lactate production

1 evidences

Randomized trial in professional volleyball players: 4 weeks of magnesium (350 mg/day) improved some anaerobic performance measures and reduced lactate, despite participants not being magnesium-deficient.

Trust comment: Small randomized athletic trial (n=25) showing performance signals but limited sample size and short duration reduce generalizability.

Study Details

PMID:24015935
Participants:25
Impact:decrease (significant within magnesium group)
Trust score:3/5

countermovement jump height

1 evidences

Randomized trial in professional volleyball players: 4 weeks of magnesium (350 mg/day) improved some anaerobic performance measures and reduced lactate, despite participants not being magnesium-deficient.

Trust comment: Small randomized athletic trial (n=25) showing performance signals but limited sample size and short duration reduce generalizability.

Study Details

PMID:24015935
Participants:25
Impact:increase (up to +3 cm)
Trust score:3/5

Maximal oxygen uptake (VO2 max)

1 evidences

Randomized trial in professional volleyball players: 4 weeks of magnesium (350 mg/day) improved some anaerobic performance measures and reduced lactate, despite participants not being magnesium-deficient.

Trust comment: Small randomized athletic trial (n=25) showing performance signals but limited sample size and short duration reduce generalizability.

Study Details

PMID:24015935
Participants:25
Impact:no change
Trust score:3/5

clinical pregnancy rate

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective cohort with multivariable adjustment and 110 participants; observational design prevents causal inference and magnesium effects are reported via Ca/Mg ratio rather than isolated Mg supplementation.

Study Details

PMID:35222266
Participants:110
Impact:Higher Ca/Mg ratio Q4 vs Q1 associated with higher odds (OR 4.85; 95% CI 1.02–23.08)
Trust score:3/5

Live birth rate

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective cohort with multivariable adjustment and 110 participants; observational design prevents causal inference and magnesium effects are reported via Ca/Mg ratio rather than isolated Mg supplementation.

Study Details

PMID:35222266
Participants:110
Impact:Higher Ca/Mg ratio Q4 vs Q1 associated with higher odds (OR 4.07; 95% CI 0.83–19.9)
Trust score:3/5

Total oocytes retrieved

1 evidences

Pre-IVF serum Ca and Mg (expressed as Ca/Mg ratio) were analyzed: a higher baseline Ca/Mg ratio was associated with higher biochemical and clinical pregnancy rates and higher (trend) live birth rates.

Trust comment: Prospective cohort with multivariable adjustment and 110 participants; observational design prevents causal inference and magnesium effects are reported via Ca/Mg ratio rather than isolated Mg supplementation.

Study Details

PMID:35222266
Participants:110
Impact:Higher serum folate (not Mg) associated with fewer oocytes; Ca/Mg ratio had no significant effect on oocyte yield
Trust score:3/5

post-intubation systolic blood pressure

1 evidences

In hypertensive patients, IV magnesium (with or without lidocaine) was tested to reduce the blood-pressure spike from intubation.

Trust comment: Randomized, double-blind trial in 96 patients with clear clinical endpoints though limited to peri-intubation setting.

Study Details

PMID:36857471
Participants:96
Impact:attenuated with 30 mg/kg MgSO4 + lidocaine and with 40 mg/kg MgSO4; 30 mg/kg MgSO4 alone not effective
Trust score:4/5

carotid intima-media thickness (CIMT)

1 evidences

In hemodialysis patients, oral magnesium reduced carotid artery thickness but did not improve flow-mediated dilation or CRP.

Trust comment: Double-blind randomized trial with measured vascular endpoints but modest sample size (n=54) limits generalizability.

Study Details

PMID:23548855
Participants:54
Impact:decreased by 0.08 mm in Mg group (0.84→0.76 mm); placebo increased (0.73→0.79 mm); p=0.001 for Mg change
Trust score:4/5

flow-mediated dilatation (FMD)

1 evidences

In hemodialysis patients, oral magnesium reduced carotid artery thickness but did not improve flow-mediated dilation or CRP.

Trust comment: Double-blind randomized trial with measured vascular endpoints but modest sample size (n=54) limits generalizability.

Study Details

PMID:23548855
Participants:54
Impact:no improvement
Trust score:4/5

C-reactive protein (CRP)

3 evidences

Combined zinc, magnesium and chromium supplementation did not change metabolic syndrome components but lowered serum C-reactive protein.

Trust comment: Double-blind randomized trial but very small sample and used combined supplements, limiting attribution to magnesium alone.

Study Details

PMID:29773176
Participants:32
Impact:decreased in mineral-supplemented group versus placebo
Trust score:3/5

In hemodialysis patients, oral magnesium reduced carotid artery thickness but did not improve flow-mediated dilation or CRP.

Trust comment: Double-blind randomized trial with measured vascular endpoints but modest sample size (n=54) limits generalizability.

Study Details

PMID:23548855
Participants:54
Impact:no improvement
Trust score:4/5

In this randomized placebo-controlled trial of oral magnesium in stable COPD, magnesium supplementation was associated with lower CRP at 6 months but no clear respiratory or functional benefits.

Trust comment: Randomized double-blind RCT with robust methods but underpowered due to incomplete enrollment, limiting conclusions.

Study Details

PMID:34260036
Participants:49
Impact:-3.2 mg/L (group*time beta −3.2; 95% CI −6.0 to −0.4; p=0.03) at 6 months
Trust score:4/5

hand pain (VAS)

1 evidences

Spa therapy using mineral water (containing calcium, magnesium, fluorides) plus mud packs improved hand pain, function and reduced symptomatic drug use versus usual care, with effects lasting months.

Trust comment: Checklist: confirm study includes magnesium as part of mineral water (indirect); identify main outcomes; confirm n=60. Well-conducted randomized trial but intervention is a multi-component spa therapy so effects cannot be attributed solely to magnesium.

Study Details

PMID:23314489
Participants:60
Impact:significant decrease after therapy and at 3 months
Trust score:3/5

functional index for hand OA (FIHOA)

1 evidences

Spa therapy using mineral water (containing calcium, magnesium, fluorides) plus mud packs improved hand pain, function and reduced symptomatic drug use versus usual care, with effects lasting months.

Trust comment: Checklist: confirm study includes magnesium as part of mineral water (indirect); identify main outcomes; confirm n=60. Well-conducted randomized trial but intervention is a multi-component spa therapy so effects cannot be attributed solely to magnesium.

Study Details

PMID:23314489
Participants:60
Impact:significant improvement up to 6 months
Trust score:3/5

symptomatic drug consumption

1 evidences

Spa therapy using mineral water (containing calcium, magnesium, fluorides) plus mud packs improved hand pain, function and reduced symptomatic drug use versus usual care, with effects lasting months.

Trust comment: Checklist: confirm study includes magnesium as part of mineral water (indirect); identify main outcomes; confirm n=60. Well-conducted randomized trial but intervention is a multi-component spa therapy so effects cannot be attributed solely to magnesium.

Study Details

PMID:23314489
Participants:60
Impact:significant reduction up to 6 months
Trust score:3/5

Serum triglycerides

3 evidences

Younger adults on a 1975-style Japanese diet for 28 days showed improved lipid parameters and an increase in serum magnesium versus a modern diet.

Trust comment: Checklist: confirm dietary intervention includes Mg-related changes; extract biochemical outcomes; verify n=32. Small randomized dietary trial with statistically significant biochemical changes including serum Mg, but short duration (28 days) and modest sample size.

Study Details

PMID:29710042
Participants:32
Impact:significant decrease (p<0.05) in JD group
Trust score:4/5

12-month randomized double-blind trial in 28 type 1 diabetics found no group differences in kidney function or most lipids; three treated patients had triglyceride increases.

Trust comment: Small randomized double-blind placebo-controlled trial but low sample size limits power to detect modest effects.

Study Details

PMID:10423707
Participants:28
Impact:increased in three magnesium-treated patients (not a consistent group effect)
Trust score:3/5

In 96 hypertensive patients, changes in serum magnesium and the Ca/Mg ratio during ACE inhibitor therapy were associated with changes in insulin sensitivity and triglycerides.

Trust comment: Analysis of 96 patients from double-blind ACE inhibitor studies showing correlations but not direct magnesium intervention causality.

Study Details

PMID:9037321
Participants:96
Impact:inverse correlation with change in serum magnesium (r = -0.35, p < 0.0005)
Trust score:3/5

serum LDL cholesterol

1 evidences

Younger adults on a 1975-style Japanese diet for 28 days showed improved lipid parameters and an increase in serum magnesium versus a modern diet.

Trust comment: Checklist: confirm dietary intervention includes Mg-related changes; extract biochemical outcomes; verify n=32. Small randomized dietary trial with statistically significant biochemical changes including serum Mg, but short duration (28 days) and modest sample size.

Study Details

PMID:29710042
Participants:32
Impact:significant decrease (p<0.05) in JD group
Trust score:4/5

all-cause mortality

2 evidences

Higher serum magnesium was associated with lower overall, cardiovascular, and sudden death risk in European hemodialysis patients.

Trust comment: Large, prospectively followed cohort with adjudicated outcomes and robust adjusted models, but observational so causality cannot be assumed.

Study Details

PMID:26600017
Participants:365
Impact:-15% per 0.1 mmol/L (HR 0.85 per 0.1 mmol/L)
Trust score:4/5

Higher dietary magnesium intake was associated with lower all-cause, cardiovascular, and cancer mortality in adults at high cardiovascular risk.

Trust comment: Large, well-characterized Mediterranean cohort from a randomized trial (PREDIMED) with multivariable adjustment and robust follow-up.

Study Details

PMID:24259558
Participants:7216
Impact:-34% risk in highest vs lowest magnesium intake tertile (HR 0.66; 95% CI 0.45–0.95)
Trust score:5/5

cardiovascular mortality

2 evidences

Higher serum magnesium was associated with lower overall, cardiovascular, and sudden death risk in European hemodialysis patients.

Trust comment: Large, prospectively followed cohort with adjudicated outcomes and robust adjusted models, but observational so causality cannot be assumed.

Study Details

PMID:26600017
Participants:365
Impact:-27% per 0.1 mmol/L (HR 0.73 per 0.1 mmol/L)
Trust score:4/5

Higher dietary magnesium intake was associated with lower all-cause, cardiovascular, and cancer mortality in adults at high cardiovascular risk.

Trust comment: Large, well-characterized Mediterranean cohort from a randomized trial (PREDIMED) with multivariable adjustment and robust follow-up.

Study Details

PMID:24259558
Participants:7216
Impact:inversely associated with magnesium intake
Trust score:5/5

sudden death

1 evidences

Higher serum magnesium was associated with lower overall, cardiovascular, and sudden death risk in European hemodialysis patients.

Trust comment: Large, prospectively followed cohort with adjudicated outcomes and robust adjusted models, but observational so causality cannot be assumed.

Study Details

PMID:26600017
Participants:365
Impact:-24% per 0.1 mmol/L (HR 0.76 per 0.1 mmol/L)
Trust score:4/5

serum magnesium over time

1 evidences

Higher serum magnesium was associated with lower overall, cardiovascular, and sudden death risk in European hemodialysis patients.

Trust comment: Large, prospectively followed cohort with adjudicated outcomes and robust adjusted models, but observational so causality cannot be assumed.

Study Details

PMID:26600017
Participants:365
Impact:decrease Δ -0.011 mmol/L/year
Trust score:4/5

bronchial reactivity to methacholine

1 evidences

Six‑month oral magnesium improved bronchial reactivity, PEFR, asthma control and quality of life versus placebo.

Trust comment: Randomized placebo-controlled trial with multiple objective and subjective outcomes over 6.5 months, though moderate sample size.

Study Details

PMID:20100026
Participants:55
Impact:improved (higher concentration required to elicit 20% fall in FEV1)
Trust score:4/5

peak expiratory flow rate (PEFR)

1 evidences

Six‑month oral magnesium improved bronchial reactivity, PEFR, asthma control and quality of life versus placebo.

Trust comment: Randomized placebo-controlled trial with multiple objective and subjective outcomes over 6.5 months, though moderate sample size.

Study Details

PMID:20100026
Participants:55
Impact:+5.8% predicted (P=0.03)
Trust score:4/5

asthma quality of life and control

1 evidences

Six‑month oral magnesium improved bronchial reactivity, PEFR, asthma control and quality of life versus placebo.

Trust comment: Randomized placebo-controlled trial with multiple objective and subjective outcomes over 6.5 months, though moderate sample size.

Study Details

PMID:20100026
Participants:55
Impact:AQLQ improved (P<0.01); ACQ improved (P=0.05)
Trust score:4/5

metabolic syndrome components

1 evidences

Combined zinc, magnesium and chromium supplementation did not change metabolic syndrome components but lowered serum C-reactive protein.

Trust comment: Double-blind randomized trial but very small sample and used combined supplements, limiting attribution to magnesium alone.

Study Details

PMID:29773176
Participants:32
Impact:no significant change post-intervention
Trust score:3/5

Serum magnesium (postoperative)

1 evidences

Intraoperative magnesium infusion reduced intraoperative opioid use and early postoperative pain scores but did not significantly improve overall recovery score or long-term chronic pain compared with control.

Trust comment: Well-conducted randomized double-blind trial with adequate size and clear perioperative endpoints; effects on long-term pain/recovery were limited.

Study Details

PMID:28253307
Participants:116
Impact:increased (group M postoperative 1.34 mg/dL vs ~0.87 mg/dL, p<0.001)
Trust score:4/5

Intraoperative opioid consumption (remifentanil)

1 evidences

Intraoperative magnesium infusion reduced intraoperative opioid use and early postoperative pain scores but did not significantly improve overall recovery score or long-term chronic pain compared with control.

Trust comment: Well-conducted randomized double-blind trial with adequate size and clear perioperative endpoints; effects on long-term pain/recovery were limited.

Study Details

PMID:28253307
Participants:116
Impact:reduced in magnesium group (374.6 µg vs 498.4 µg in control, p<0.001)
Trust score:4/5

Acute postoperative pain (NRS)

1 evidences

Intraoperative magnesium infusion reduced intraoperative opioid use and early postoperative pain scores but did not significantly improve overall recovery score or long-term chronic pain compared with control.

Trust comment: Well-conducted randomized double-blind trial with adequate size and clear perioperative endpoints; effects on long-term pain/recovery were limited.

Study Details

PMID:28253307
Participants:116
Impact:lower in magnesium group in PACU and 6–24h (PACU 2.2 vs 2.8, p<0.001; 24h 2.5 vs 2.9, p=0.046)
Trust score:4/5

Insulin resistance (HOMA-IR) / Insulin

1 evidences

In women with gestational diabetes, 6 weeks of magnesium+vitamin E improved fasting glucose, insulin resistance measures and several lipid parameters compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified metabolic outcomes; moderate sample (n=60) supports efficacy but size limits precision.

Study Details

PMID:30025522
Participants:60
Impact:HOMA-IR decreased (β −0.78; p=0.01); insulin decreased (β −2.93 μIU/mL; p=0.02)
Trust score:4/5

Triglycerides

1 evidences

In women with gestational diabetes, 6 weeks of magnesium+vitamin E improved fasting glucose, insulin resistance measures and several lipid parameters compared with placebo.

Trust comment: Randomized, double-blind, placebo-controlled trial with pre-specified metabolic outcomes; moderate sample (n=60) supports efficacy but size limits precision.

Study Details

PMID:30025522
Participants:60
Impact:decreased (β −50.31 mg/dL; p<0.001)
Trust score:4/5

myoglobin (proteomic)

1 evidences

Randomized double-blind trial of 400 mg/day magnesium oxide for 12 weeks increased serum magnesium modestly and showed small, non-significant changes in multiple circulating proteins after multiple-comparison correction.

Trust comment: Randomized, double-blind trial with rigorous proteomic methods but small sample and exploratory analyses with no significant results after multiple-comparison correction.

Study Details

PMID:32517192
Participants:52
Impact:difference −0.319 NPX units (95% CI −0.550 to −0.088; p=0.008) but not significant after multiple testing
Trust score:3/5

proteomic panel overall

1 evidences

Randomized double-blind trial of 400 mg/day magnesium oxide for 12 weeks increased serum magnesium modestly and showed small, non-significant changes in multiple circulating proteins after multiple-comparison correction.

Trust comment: Randomized, double-blind trial with rigorous proteomic methods but small sample and exploratory analyses with no significant results after multiple-comparison correction.

Study Details

PMID:32517192
Participants:52
Impact:no proteins statistically significant after Holm correction
Trust score:3/5

tramadol Cmax and AUC (single-dose)

1 evidences

Co-administering magnesium with oral tramadol did not change tramadol or O-desmethyltramadol pharmacokinetics or safety in healthy volunteers.

Trust comment: Rigorous randomized crossover pharmacokinetic studies in healthy volunteers following EMA guidelines with validated assays and clear CI-based equivalence.

Study Details

PMID:33686610
Participants:51
Impact:no change; geometric mean ratios ~97% (Cmax 97.03%; AUC0-t 97.87%), 90% CIs within 80–125%
Trust score:5/5

tramadol Cmax,ss and AUC0-τ (multiple-dose)

1 evidences

Co-administering magnesium with oral tramadol did not change tramadol or O-desmethyltramadol pharmacokinetics or safety in healthy volunteers.

Trust comment: Rigorous randomized crossover pharmacokinetic studies in healthy volunteers following EMA guidelines with validated assays and clear CI-based equivalence.

Study Details

PMID:33686610
Participants:51
Impact:no change; geometric mean ratios ~98–102% (90% CIs within 80–125%)
Trust score:5/5

safety/adverse events

1 evidences

Co-administering magnesium with oral tramadol did not change tramadol or O-desmethyltramadol pharmacokinetics or safety in healthy volunteers.

Trust comment: Rigorous randomized crossover pharmacokinetic studies in healthy volunteers following EMA guidelines with validated assays and clear CI-based equivalence.

Study Details

PMID:33686610
Participants:51
Impact:no clinically relevant difference between tramadol with and without magnesium
Trust score:5/5

postoperative hypomagnesemia incidence

1 evidences

Oral magnesium (given from admission to discharge) reduced postoperative hypomagnesemia and was associated with fewer atrial fibrillation episodes and fewer gastrointestinal complications after cardiac surgery.

Trust comment: Randomized clinical trial in surgical patients with relevant clinical endpoints, but single-blinded design and incomplete reporting of effect sizes for some outcomes reduce certainty.

Study Details

PMID:28417897
Participants:102
Impact:intervention 41.2% vs control 70.8% (reduction ≈29.6 percentage points)
Trust score:3/5

postoperative atrial fibrillation

2 evidences

Oral magnesium (given from admission to discharge) reduced postoperative hypomagnesemia and was associated with fewer atrial fibrillation episodes and fewer gastrointestinal complications after cardiac surgery.

Trust comment: Randomized clinical trial in surgical patients with relevant clinical endpoints, but single-blinded design and incomplete reporting of effect sizes for some outcomes reduce certainty.

Study Details

PMID:28417897
Participants:102
Impact:reduced in magnesium group (no exact values reported)
Trust score:3/5

A single intraoperative dose of magnesium did not reduce postoperative atrial fibrillation after off-pump CABG.

Trust comment: Prospective randomized controlled trial with adequate sample size and clear clinical outcome reporting.

Study Details

PMID:16326295
Participants:160
Impact:no significant effect (20% magnesium vs 22.5% placebo; p = 0.9)
Trust score:4/5

postoperative nausea, vomiting and constipation

1 evidences

Oral magnesium (given from admission to discharge) reduced postoperative hypomagnesemia and was associated with fewer atrial fibrillation episodes and fewer gastrointestinal complications after cardiac surgery.

Trust comment: Randomized clinical trial in surgical patients with relevant clinical endpoints, but single-blinded design and incomplete reporting of effect sizes for some outcomes reduce certainty.

Study Details

PMID:28417897
Participants:102
Impact:reduced in magnesium group (no exact values reported)
Trust score:3/5

urinary pH and citrate

2 evidences

Potassium‑magnesium citrate corrected thiazide-induced low potassium; higher doses modestly increased serum magnesium and urinary magnesium and dose-dependently raised urinary pH and citrate.

Trust comment: Randomized study with clear biochemical endpoints and dose-response data in humans; moderate sample size but appropriate design.

Study Details

PMID:10423646
Participants:61
Impact:increased in a dose-dependent manner
Trust score:4/5

In healthy volunteers on thiazides, potassium-magnesium citrate formulations corrected hypokalemia; two formulations modestly raised serum magnesium and urinary pH/citrate more than the third.

Trust comment: Randomized comparison in 62 healthy volunteers with objective biochemical endpoints; tolerability differences noted.

Study Details

PMID:9824785
Participants:62
Impact:increased with all formulations (more marked with K3 and K4)
Trust score:4/5

magnesium balance

1 evidences

In 26 adolescent girls, increasing dietary calcium did not alter magnesium absorption, excretion, or overall magnesium balance over 14 days.

Trust comment: Controlled double-blind dietary study with measured intake/excretion but small sample size.

Study Details

PMID:8644692
Participants:26
Impact:average 21 mg/day (no difference between low- and high-calcium diets)
Trust score:4/5

Withdrawal severity (CIWA-Ar)

1 evidences

Oral magnesium (426.6 mg/day) given up to 15 days did not significantly reduce alcohol withdrawal severity compared with placebo.

Trust comment: Multicenter double-blind randomized placebo-controlled trial with clear negative result and adequate sample (n=98).

Study Details

PMID:37012631
Participants:98
Impact:Mean reduction 10.1 (Mg) vs 9.2 (placebo); adjusted mean difference −0.69, P=0.34 (not significant)
Trust score:4/5

Benzodiazepine consumption

1 evidences

Oral magnesium (426.6 mg/day) given up to 15 days did not significantly reduce alcohol withdrawal severity compared with placebo.

Trust comment: Multicenter double-blind randomized placebo-controlled trial with clear negative result and adequate sample (n=98).

Study Details

PMID:37012631
Participants:98
Impact:No significant difference between groups
Trust score:4/5

Blood magnesium concentration

1 evidences

Oral magnesium (426.6 mg/day) given up to 15 days did not significantly reduce alcohol withdrawal severity compared with placebo.

Trust comment: Multicenter double-blind randomized placebo-controlled trial with clear negative result and adequate sample (n=98).

Study Details

PMID:37012631
Participants:98
Impact:No significant between-group difference reported
Trust score:4/5

Postoperative pain intensity and analgesic consumption

1 evidences

Single IV dose magnesium sulfate (4 g) given after induction did not reduce postoperative pain or analgesic use but lowered incidence of postoperative shivering.

Trust comment: Well-conducted randomized controlled trial (200 randomized; 166 completed questionnaires) with clear null effects for analgesia and a significant reduction in shivering.

Study Details

PMID:17513629
Participants:166
Impact:No difference between magnesium and placebo groups up to 72 hours
Trust score:4/5

Incidence of postoperative shivering

1 evidences

Single IV dose magnesium sulfate (4 g) given after induction did not reduce postoperative pain or analgesic use but lowered incidence of postoperative shivering.

Trust comment: Well-conducted randomized controlled trial (200 randomized; 166 completed questionnaires) with clear null effects for analgesia and a significant reduction in shivering.

Study Details

PMID:17513629
Participants:166
Impact:Magnesium 4% vs placebo 13.1% (difference ≈−9.1 percentage points), P=0.0232
Trust score:4/5

serum phosphate

2 evidences

In hemodialysis patients, oral magnesium carbonate for 6 months effectively reduced serum phosphate similar to calcium carbonate, produced lower serum calcium and was generally well tolerated with few cases of hypermagnesemia when combined with low-dialysate magnesium.

Trust comment: Randomized controlled design with complete biochemical follow-up but single-center, partial non-random allocations and small sample limit generalizability.

Study Details

PMID:18193489
Participants:43
Impact:-23% (MgCO3 group) vs -19% (CaCO3); no significant difference between groups
Trust score:3/5

In hemodialysis patients, 12 weeks of magnesium carbonate reduced phosphate and parathormone and improved calcium-phosphate balance.

Trust comment: Human clinical treatment with randomized groups but small and uneven group sizes and some non-random allocation reduce confidence.

Study Details

PMID:21812357
Participants:64
Impact:-0.5 mmol/L (~-23.8%)
Trust score:3/5

serum calcium

3 evidences

In 21 postmenopausal women, high-calcium drinks reduced bone resorption markers; adding magnesium produced no distinguishable additional effect.

Trust comment: Randomized cross-over study with direct biochemical measures but small sample size limits power to detect small magnesium-specific effects.

Study Details

PMID:12548298
Participants:21
Impact:Increased after TCP (2.12→2.21 mmol/L peak at 2 h); no overall difference between apple and milks
Trust score:4/5

In hemodialysis patients, oral magnesium carbonate for 6 months effectively reduced serum phosphate similar to calcium carbonate, produced lower serum calcium and was generally well tolerated with few cases of hypermagnesemia when combined with low-dialysate magnesium.

Trust comment: Randomized controlled design with complete biochemical follow-up but single-center, partial non-random allocations and small sample limit generalizability.

Study Details

PMID:18193489
Participants:43
Impact:-0.75 mg/dL at 6 months (8.97 vs 9.72 mg/dL; P<0.05; lower with MgCO3)
Trust score:3/5

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Data from a randomized double-blind trial's subgroup (retrospective subgroup analysis, not randomized by acid-suppressive use) with measured serum values.

Study Details

PMID:31425366
Participants:66
Impact:maintained (within reference at 16 weeks)
Trust score:4/5

post-transplant diabetes mellitus (PTDM) incidence

1 evidences

In kidney transplant recipients, lower serum magnesium during the first year was independently associated with higher risk of post-transplant diabetes mellitus (PTDM); higher tacrolimus levels were linked to lower magnesium.

Trust comment: Prospective cohort with repeated measures and multivariate analysis provides credible associations though observational for causality.

Study Details

PMID:31361318
Participants:167
Impact:17% (29/167) incidence at 1 year
Trust score:4/5

serum magnesium — association with PTDM

1 evidences

In kidney transplant recipients, lower serum magnesium during the first year was independently associated with higher risk of post-transplant diabetes mellitus (PTDM); higher tacrolimus levels were linked to lower magnesium.

Trust comment: Prospective cohort with repeated measures and multivariate analysis provides credible associations though observational for causality.

Study Details

PMID:31361318
Participants:167
Impact:Lower serum magnesium was an independent risk factor for PTDM (multivariate analysis)
Trust score:4/5

tacrolimus concentration — effect on magnesium

1 evidences

In kidney transplant recipients, lower serum magnesium during the first year was independently associated with higher risk of post-transplant diabetes mellitus (PTDM); higher tacrolimus levels were linked to lower magnesium.

Trust comment: Prospective cohort with repeated measures and multivariate analysis provides credible associations though observational for causality.

Study Details

PMID:31361318
Participants:167
Impact:Higher tacrolimus associated with lower serum magnesium and increased hypomagnesemia risk
Trust score:4/5

intracellular magnesium ([Mg2+]i)

1 evidences

In healthy adults, one month of oral magnesium oxide (higher elemental dose) increased intracellular magnesium and lowered total and LDL cholesterol more than magnesium citrate; both reduced epinephrine-induced platelet aggregation.

Trust comment: Randomized, double-blind crossover study with objective intracellular measures but short treatment periods and moderate sample size.

Study Details

PMID:22433473
Participants:41
Impact:MgO: +1.9 mEq/L (34.4 → 36.3 mEq/L, P<0.001); Mg citrate: +0.7 mEq/L (34.7 → 35.4, P=0.097)
Trust score:4/5

LDL cholesterol

1 evidences

In healthy adults, one month of oral magnesium oxide (higher elemental dose) increased intracellular magnesium and lowered total and LDL cholesterol more than magnesium citrate; both reduced epinephrine-induced platelet aggregation.

Trust comment: Randomized, double-blind crossover study with objective intracellular measures but short treatment periods and moderate sample size.

Study Details

PMID:22433473
Participants:41
Impact:MgO: -8 mg/dL (128 → 120 mg/dL, P=0.042); Mg citrate: no change
Trust score:4/5

epinephrine-induced platelet aggregation

1 evidences

In healthy adults, one month of oral magnesium oxide (higher elemental dose) increased intracellular magnesium and lowered total and LDL cholesterol more than magnesium citrate; both reduced epinephrine-induced platelet aggregation.

Trust comment: Randomized, double-blind crossover study with objective intracellular measures but short treatment periods and moderate sample size.

Study Details

PMID:22433473
Participants:41
Impact:Decrease ≈7–8 percentage points for both treatments (MgO: 78.9%→71.7%; Mg citrate: 81.3%→73.3%)
Trust score:4/5

arterial stiffness (pulse wave velocity)

1 evidences

Protocol for a 24-week randomized trial testing oral magnesium citrate (350 mg/day) ± a phosphate binder versus placebo in stage 3–4 CKD to evaluate arterial stiffness and calcification markers.

Trust comment: Well-designed, multicenter randomized controlled trial protocol with defined outcomes and sample-size calculation, but no results reported yet.

Study Details

PMID:36096824
Participants:180
Impact:no data (protocol)
Trust score:4/5

calcification propensity (T50)

1 evidences

Protocol for a 24-week randomized trial testing oral magnesium citrate (350 mg/day) ± a phosphate binder versus placebo in stage 3–4 CKD to evaluate arterial stiffness and calcification markers.

Trust comment: Well-designed, multicenter randomized controlled trial protocol with defined outcomes and sample-size calculation, but no results reported yet.

Study Details

PMID:36096824
Participants:180
Impact:no data (protocol)
Trust score:4/5

FGF23 / mineral metabolism markers

1 evidences

Protocol for a 24-week randomized trial testing oral magnesium citrate (350 mg/day) ± a phosphate binder versus placebo in stage 3–4 CKD to evaluate arterial stiffness and calcification markers.

Trust comment: Well-designed, multicenter randomized controlled trial protocol with defined outcomes and sample-size calculation, but no results reported yet.

Study Details

PMID:36096824
Participants:180
Impact:no data (protocol)
Trust score:4/5

mean arterial pressure (intraoperative)

1 evidences

Randomized controlled trial where IV magnesium during robotic prostatectomy reduced perioperative blood pressure rises, lowered cortisol, decreased opioid use, and reduced early postoperative pain.

Trust comment: Randomized, double-blind clinical trial with objective hemodynamic and hormonal measures and moderate sample size (n=52) supporting physiologic effects.

Study Details

PMID:33611742
Participants:52
Impact:attenuated increase during Trendelenburg (Mg vs control; group×time P=0.017)
Trust score:4/5

ionized magnesium (iMg)

1 evidences

Adding magnesium to the bypass prime kept magnesium levels during surgery and reduced potassium loss after surgery in children.

Trust comment: Randomized pediatric RCT with clear biochemical outcomes but modest sample size (n=40).

Study Details

PMID:12760983
Participants:40
Impact:higher during CPB in magnesium group (no difference after CPB)
Trust score:4/5

migraine attack severity

1 evidences

Double-blind randomized placebo-controlled trial (30 magnesium, 10 placebo) in migraine without aura showing reduced attack frequency, severity, and electrophysiologic measures after 3 months of oral magnesium citrate 600 mg/day.

Trust comment: Randomized placebo-controlled trial showing clinically relevant reductions, but small sample size and imbalance between arms (30 vs 10) limit precision.

Study Details

PMID:18705538
Participants:40
Impact:significant decrease with magnesium vs placebo (P<0.001)
Trust score:3/5

visual evoked potential P1 amplitude

1 evidences

Double-blind randomized placebo-controlled trial (30 magnesium, 10 placebo) in migraine without aura showing reduced attack frequency, severity, and electrophysiologic measures after 3 months of oral magnesium citrate 600 mg/day.

Trust comment: Randomized placebo-controlled trial showing clinically relevant reductions, but small sample size and imbalance between arms (30 vs 10) limit precision.

Study Details

PMID:18705538
Participants:40
Impact:decreased after magnesium (P<0.05 vs placebo)
Trust score:3/5

metabolic syndrome risk

1 evidences

In adolescents, lower serum magnesium was associated with higher cardiometabolic risk and with metabolic syndrome; magnesium appeared protective against metabolic syndrome.

Trust comment: Well-powered cross-sectional/case-control national study in adolescents but observational design limits causal inference.

Study Details

PMID:25422091
Participants:320
Impact:inverse association; magnesium a significant protective factor against MetS (P = 0.0001)
Trust score:3/5

cardiometabolic risk factors

1 evidences

In adolescents, lower serum magnesium was associated with higher cardiometabolic risk and with metabolic syndrome; magnesium appeared protective against metabolic syndrome.

Trust comment: Well-powered cross-sectional/case-control national study in adolescents but observational design limits causal inference.

Study Details

PMID:25422091
Participants:320
Impact:inverse associations with some MetS components (not quantified)
Trust score:3/5

liver enzyme levels

1 evidences

In adolescents, lower serum magnesium was associated with higher cardiometabolic risk and with metabolic syndrome; magnesium appeared protective against metabolic syndrome.

Trust comment: Well-powered cross-sectional/case-control national study in adolescents but observational design limits causal inference.

Study Details

PMID:25422091
Participants:320
Impact:inverse association reported (not quantified)
Trust score:3/5

beta-cell compensatory function (AUC HMbCF)

1 evidences

In non-diabetic individuals with hypomagnesemia, oral MgCl2 improved beta-cell compensatory function versus placebo over 3 months.

Trust comment: Randomized double-blind clinical trial with objective metabolic outcome but limited to hypomagnesemic, non-diabetic subjects.

Study Details

PMID:21241290
Participants:97
Impact:MgCl2 group AUC increased from 7.591 to 18.855 cm^2 (change ≈ +11.264 cm^2); placebo showed no change
Trust score:4/5

QTc dispersion (QTcd)

1 evidences

Compared normal vs low dialysate magnesium in hemodialysis; changing dialysate Mg did not significantly alter QTc dispersion.

Trust comment: Small within-subject dialysis study (n=22) with appropriate measurements but limited power to detect small QTcd differences.

Study Details

PMID:22299661
Participants:22
Impact:no significant change pre- vs post-dialysis (mean change ≈+9 ms; p>0.05)
Trust score:3/5

depression severity (Beck score)

1 evidences

500 mg magnesium oxide daily for 8 weeks in depressed patients improved depression scores and serum magnesium but did not change BDNF.

Trust comment: Double-blind randomized clinical trial with clear outcomes but small sample (n=46) limits generalizability.

Study Details

PMID:33745609
Participants:46
Impact:improved (significant, P = 0.01)
Trust score:4/5

minimum plaque pH

1 evidences

In children, hydroxyapatite toothpastes (containing magnesium‑substituted HAp among other components) increased plaque pH and reduced cariogenic bacteria over the trial.

Trust comment: Large, triple-blind randomized trial (n=610) with meaningful clinical endpoints though COVID-related adherence and follow-up delays are limitations.

Study Details

PMID:38453554
Participants:610
Impact:increased (HAF1000: 5.32 ± 0.41 → 5.72 ± 0.22 at 2 years; P ≈ 0.01)
Trust score:4/5

Streptococcus mutans (primary cariogenic bacteria)

1 evidences

In children, hydroxyapatite toothpastes (containing magnesium‑substituted HAp among other components) increased plaque pH and reduced cariogenic bacteria over the trial.

Trust comment: Large, triple-blind randomized trial (n=610) with meaningful clinical endpoints though COVID-related adherence and follow-up delays are limitations.

Study Details

PMID:38453554
Participants:610
Impact:decreased (HAF1000 score 3.11 ± 1.13 → 2.00 ± 0.54 at 2 years; P = 0.03)
Trust score:4/5

magnesium deficiency frequency

1 evidences

Magnesium deficiency frequency in paediatric coeliac patients without malabsorption was similar to controls and appeared diet-related.

Trust comment: Observational cross-sectional assessment with moderate sample size and standard biochemical measures, but not interventional.

Study Details

PMID:15380898
Participants:77
Impact:19.6% (treated) vs 21.4% (untreated) vs 25% (controls)
Trust score:3/5

serum magnesium concentration decreased

1 evidences

Magnesium deficiency frequency in paediatric coeliac patients without malabsorption was similar to controls and appeared diet-related.

Trust comment: Observational cross-sectional assessment with moderate sample size and standard biochemical measures, but not interventional.

Study Details

PMID:15380898
Participants:77
Impact:7.3% (treated) vs 3.6% (untreated) vs 0% (controls)
Trust score:3/5

erythrocyte magnesium concentration decreased

1 evidences

Magnesium deficiency frequency in paediatric coeliac patients without malabsorption was similar to controls and appeared diet-related.

Trust comment: Observational cross-sectional assessment with moderate sample size and standard biochemical measures, but not interventional.

Study Details

PMID:15380898
Participants:77
Impact:14.6% (treated) vs 25% (untreated) vs 12.5% (controls)
Trust score:3/5

Diastolic blood pressure

7 evidences

In type 2 diabetics, combined minerals + vitamins (including Mg+Zn) for 3 months lowered systolic, diastolic and mean blood pressure; Mg+Zn alone did not.

Trust comment: Randomized double-blind placebo-controlled design but small group sizes limit precision and subgroup inference for magnesium-specific effects.

Study Details

PMID:15190052
Participants:69
Impact:-6 mmHg (83 ± 11 to 77 ± 9 mmHg) in MV group
Trust score:3/5

Replacing regular salt in processed foods with a mineral salt high in potassium and magnesium reduced sodium intake and lowered blood pressure over 8 weeks.

Trust comment: Randomized, double-blind, placebo-controlled trial with objective biochemical measures and good adherence, though sample size is modest.

Study Details

PMID:21888642
Participants:45
Impact:-2.7 mmHg (mean decrease in Smart Salt group)
Trust score:4/5

Cross-sectional study of 90 healthy adults found higher drinking-water magnesium and serum Mg associated with lower diastolic BP and relationships with lipids and glucose indices.

Trust comment: Observational cross-sectional design with modest sample size; associations reported but not causal.

Study Details

PMID:22361711
Participants:90
Impact:lower in area with higher water Mg (association)
Trust score:3/5

Combination mineral supplementation (including magnesium) produced small and generally non-significant changes in blood pressure in patients with mild/borderline hypertension.

Trust comment: Randomized trial with modest sample size and directly measured clinic BP; effects small and not statistically significant.

Study Details

PMID:7490154
Participants:125
Impact:no significant change (e.g., K+Mg: +0.4 mmHg; 95% CI -2.5 to +3.3)
Trust score:4/5

In hypertensive type II diabetics, replacing salt with a substitute containing potassium and magnesium significantly reduced systolic blood pressure after 3 months versus regular salt.

Trust comment: Randomized blinded controlled trial but small sample (n=40) and intervention combined K and Mg making Mg-specific effects uncertain.

Study Details

PMID:8895035
Participants:40
Impact:no significant change
Trust score:3/5

In normotensive women with low habitual mineral intake, magnesium supplementation (336 mg/d) did not produce significant reductions in 24-hour ambulatory systolic or diastolic blood pressure compared with placebo.

Trust comment: Large randomized placebo-controlled trial (n=300) showing no significant BP effect of magnesium in normotensive women.

Study Details

PMID:9449404
Participants:300
Impact:-0.7 mmHg (95% CI -2.2 to 0.8; not significant)
Trust score:4/5

Magnesium treatment lowered systolic and diastolic blood pressure more than methyldopa in pregnancy-induced hypertension.

Trust comment: Small randomized trial with clinically relevant blood pressure outcomes but limited sample size.

Study Details

PMID:10828704
Participants:33
Impact:92 ± 10 vs 94 ± 10 mmHg (magnesium vs methyldopa); small but significant reduction (p < 0.05)
Trust score:3/5

urinary sodium excretion (dU-Na)

1 evidences

Replacing regular salt in processed foods with a mineral salt high in potassium and magnesium reduced sodium intake and lowered blood pressure over 8 weeks.

Trust comment: Randomized, double-blind, placebo-controlled trial with objective biochemical measures and good adherence, though sample size is modest.

Study Details

PMID:21888642
Participants:45
Impact:-29.8 mmol (change 0 vs +8 wk in Smart Salt group)
Trust score:4/5

CRP (log)

1 evidences

In heart failure patients, oral magnesium raised serum and intracellular Mg and substantially lowered CRP after 5 weeks compared with untreated patients.

Trust comment: Small, non-blinded treatment comparison with limited sample size for the intervention (17 treated, 18 controls); biologic endpoints reported.

Study Details

PMID:17479208
Participants:35
Impact:decrease from 1.4±0.4 to 0.8±0.3 with Mg treatment (P<0.001)
Trust score:3/5

Intracellular water (ICW)

1 evidences

Two weeks of magnesium-creatine supplementation increased intracellular water and improved quadriceps peak torque and power in humans.

Trust comment: Randomized, blinded study but small sample (35) and short duration (2 weeks).

Study Details

PMID:14506619
Participants:35
Impact:increase (MgC-Cre 26.29 → 28.01 L, P<0.05)
Trust score:3/5

peak torque (knee extension)

1 evidences

Two weeks of magnesium-creatine supplementation increased intracellular water and improved quadriceps peak torque and power in humans.

Trust comment: Randomized, blinded study but small sample (35) and short duration (2 weeks).

Study Details

PMID:14506619
Participants:35
Impact:increase (MgC-Cre 124.5 → 135.8 Nm, P<0.05)
Trust score:3/5

power

1 evidences

Two weeks of magnesium-creatine supplementation increased intracellular water and improved quadriceps peak torque and power in humans.

Trust comment: Randomized, blinded study but small sample (35) and short duration (2 weeks).

Study Details

PMID:14506619
Participants:35
Impact:increase in both treatment groups (P<0.05)
Trust score:3/5

ionized serum calcium

1 evidences

In SAH patients randomized to magnesium vs placebo, magnesium was associated with lower ionized calcium but calcitriol/PTH were not affected; PTH linked to poor outcome in a subgroup.

Trust comment: Large RCT dataset analyzed with appropriate models; results are specific to SAH patient population.

Study Details

PMID:18317951
Participants:167
Impact:inversely related to serum magnesium (B = -0.1; 95% CI -0.12 to -0.06) — hypocalcemia observed
Trust score:4/5

delayed cerebral ischemia (DCI) and poor outcome

1 evidences

In SAH patients randomized to magnesium vs placebo, magnesium was associated with lower ionized calcium but calcitriol/PTH were not affected; PTH linked to poor outcome in a subgroup.

Trust comment: Large RCT dataset analyzed with appropriate models; results are specific to SAH patient population.

Study Details

PMID:18317951
Participants:167
Impact:no increased risk associated with hypocalcemia or magnesium treatment (no significant effect)
Trust score:4/5

parathyroid hormone (PTH) association

1 evidences

In SAH patients randomized to magnesium vs placebo, magnesium was associated with lower ionized calcium but calcitriol/PTH were not affected; PTH linked to poor outcome in a subgroup.

Trust comment: Large RCT dataset analyzed with appropriate models; results are specific to SAH patient population.

Study Details

PMID:18317951
Participants:167
Impact:high PTH associated with poor outcome in subgroup with known PTH (OR 5.4; 1.6–18.9), independent of magnesium
Trust score:4/5

urinary calcium excretion

1 evidences

Different potassium- and magnesium-containing supplements were given to kidney stone patients for one month and urine markers of stone risk were measured.

Trust comment: Human controlled supplementation with clear urinary outcomes but small sample, short duration, and mixed multi-nutrient arms limit attribution to magnesium alone.

Study Details

PMID:15117041
Participants:61
Impact:decrease (with K Na citrate and K Mg citrate); no change (with Mg glycine)
Trust score:3/5

hs-CRP (inflammation)

2 evidences

Patients with diabetic foot ulcers received magnesium plus vitamin E or placebo for 12 weeks; ulcer size and many metabolic/inflammatory markers improved with supplementation.

Trust comment: Randomized placebo-controlled design is strong, but co-supplementation with vitamin E prevents attribution of effects to magnesium alone and sample is modest.

Study Details

PMID:30693609
Participants:57
Impact:decrease -3.42 mg/L (β -3.42; p<0.001)
Trust score:3/5

Magnesium plus vitamin E for 12 weeks reduced hirsutism and inflammation markers and increased nitric oxide and antioxidant capacity in women with PCOS.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate reporting of effect sizes.

Study Details

PMID:30565017
Participants:60
Impact:reduced (β −0.67 mg/L; 95% CI −1.20, −0.14; P=0.01)
Trust score:5/5

ulcer size (length/width/depth)

1 evidences

Twelve-week magnesium supplementation in patients with diabetic foot ulcers increased serum magnesium and improved ulcer size, glycemic control, inflammation, and antioxidant capacity compared with placebo.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial with clear magnesium-specific supplementation and clinically meaningful metabolic and wound outcomes.

Study Details

PMID:28540570
Participants:70
Impact:greater reductions (length -1.8 vs -0.9 cm; width -1.6 vs -0.8 cm; depth -0.8 vs -0.3 cm; P≤0.02)
Trust score:4/5

glycemic control (FPG, insulin, HbA1c)

1 evidences

Twelve-week magnesium supplementation in patients with diabetic foot ulcers increased serum magnesium and improved ulcer size, glycemic control, inflammation, and antioxidant capacity compared with placebo.

Trust comment: Well-conducted randomized double-blind placebo-controlled trial with clear magnesium-specific supplementation and clinically meaningful metabolic and wound outcomes.

Study Details

PMID:28540570
Participants:70
Impact:improvements (FPG -45.4 vs -10.6 mg/dL; insulin -2.4 vs +1.5 μIU/mL; HbA1c -0.7 vs -0.1%; P≤0.04)
Trust score:4/5

hyperdense red blood cells

1 evidences

In patients with haemoglobin SC disease, oral magnesium showed no measurable hematologic benefit over placebo in this small phase II trial.

Trust comment: Randomized double-blind multicenter trial but terminated early with only 36 evaluable subjects, limiting power.

Study Details

PMID:21275961
Participants:36
Impact:no effect after 8 weeks
Trust score:3/5

vaso-occlusive events

1 evidences

In patients with haemoglobin SC disease, oral magnesium showed no measurable hematologic benefit over placebo in this small phase II trial.

Trust comment: Randomized double-blind multicenter trial but terminated early with only 36 evaluable subjects, limiting power.

Study Details

PMID:21275961
Participants:36
Impact:no effect
Trust score:3/5

mean cell volume / HbF

1 evidences

In patients with haemoglobin SC disease, oral magnesium showed no measurable hematologic benefit over placebo in this small phase II trial.

Trust comment: Randomized double-blind multicenter trial but terminated early with only 36 evaluable subjects, limiting power.

Study Details

PMID:21275961
Participants:36
Impact:no change attributable to magnesium (HC groups showed increases)
Trust score:3/5

leukocyte TRPM6 mRNA expression

1 evidences

Four months of oral magnesium (360 mg elemental) increased leukocyte TRPM6 mRNA expression in adults with new pre-hypertension; TRPM7 and SLC41A1 were unchanged.

Trust comment: Randomized double-blind trial but small sample and molecular leukocyte endpoint limits clinical generalizability.

Study Details

PMID:29256407
Participants:36
Impact:increased (2.1 ± 1.37 vs 0.8 ± 0.4; p<0.05)
Trust score:3/5

leukocyte TRPM7 transcription

1 evidences

Four months of oral magnesium (360 mg elemental) increased leukocyte TRPM6 mRNA expression in adults with new pre-hypertension; TRPM7 and SLC41A1 were unchanged.

Trust comment: Randomized double-blind trial but small sample and molecular leukocyte endpoint limits clinical generalizability.

Study Details

PMID:29256407
Participants:36
Impact:no significant change
Trust score:3/5

leukocyte SLC41A1 transcription

1 evidences

Four months of oral magnesium (360 mg elemental) increased leukocyte TRPM6 mRNA expression in adults with new pre-hypertension; TRPM7 and SLC41A1 were unchanged.

Trust comment: Randomized double-blind trial but small sample and molecular leukocyte endpoint limits clinical generalizability.

Study Details

PMID:29256407
Participants:36
Impact:no significant change
Trust score:3/5

body fat mass change

1 evidences

An open-label randomized trial of a supplement containing calcium, magnesium, and lactulose produced a small but statistically significant reduction in whole-body fat mass at 12 months (difference −0.8 kg), though contribution of magnesium alone was unclear.

Trust comment: Randomized but open-label trial with small sample and a combined intervention (Ca+Mg+lactulose) so magnesium-specific effects cannot be isolated.

Study Details

PMID:24231016
Participants:76
Impact:intake −0.8 kg vs control over 12 months (between-group difference −0.8 kg; 95% CI −1.5 to 0.0; P=0.046)
Trust score:3/5

body fat percentage

1 evidences

An open-label randomized trial of a supplement containing calcium, magnesium, and lactulose produced a small but statistically significant reduction in whole-body fat mass at 12 months (difference −0.8 kg), though contribution of magnesium alone was unclear.

Trust comment: Randomized but open-label trial with small sample and a combined intervention (Ca+Mg+lactulose) so magnesium-specific effects cannot be isolated.

Study Details

PMID:24231016
Participants:76
Impact:trend toward lower in intake group at 12 months (P=0.09)
Trust score:3/5

CSF magnesium concentration

1 evidences

Spinal anaesthesia reduced CSF total and ionized magnesium by ~10%; intravenous magnesium infusion raised serum magnesium but did not alter CSF magnesium concentrations.

Trust comment: Prospective randomized controlled study with clear biochemical measures though moderate sample (35 completers); findings robust for CSF vs serum differences.

Study Details

PMID:22661752
Participants:35
Impact:total and ionized CSF Mg decreased by ~10% after spinal anaesthesia
Trust score:4/5

effect of IV magnesium on CSF magnesium

1 evidences

Spinal anaesthesia reduced CSF total and ionized magnesium by ~10%; intravenous magnesium infusion raised serum magnesium but did not alter CSF magnesium concentrations.

Trust comment: Prospective randomized controlled study with clear biochemical measures though moderate sample (35 completers); findings robust for CSF vs serum differences.

Study Details

PMID:22661752
Participants:35
Impact:peripheral IV Mg increased serum Mg (>80% increase) but produced no change in CSF Mg (no central effect observed)
Trust score:4/5

Hirsutism score

1 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind trial but magnesium was given with other supplements, so effects cannot be attributed to magnesium alone.

Study Details

PMID:28668998
Participants:60
Impact:-2.4 ±1.2 vs -0.1 ±0.4 (P<0.001) vs placebo
Trust score:3/5

high-sensitivity C-reactive protein (hs-CRP)

1 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind trial but magnesium was given with other supplements, so effects cannot be attributed to magnesium alone.

Study Details

PMID:28668998
Participants:60
Impact:-0.7 ±0.8 vs +0.2 ±1.8 mg/L (P<0.001) vs placebo
Trust score:3/5

total antioxidant capacity

1 evidences

Twelve weeks of magnesium-zinc-calcium-vitamin D co-supplementation in women with PCOS reduced hirsutism and some inflammation/oxidative stress markers and increased antioxidant capacity.

Trust comment: Randomized double-blind trial but magnesium was given with other supplements, so effects cannot be attributed to magnesium alone.

Study Details

PMID:28668998
Participants:60
Impact:+46.6 ±66.5 vs -7.7 ±130.1 mmol/L (P=0.04) vs placebo
Trust score:3/5

Plasma lactate normalization

1 evidences

Randomized trial in patients with alcohol withdrawal: IV magnesium (alone or with thiamine) raised serum Mg, led to more consistent plasma lactate normalization and faster initial resolution of withdrawal scores compared with thiamine alone; ETKA did not improve overall.

Trust comment: Randomized trial (n=115) with comprehensive biochemical and clinical measures; subgroup analyses support biochemical plausibility though not all endpoints changed.

Study Details

PMID:35484175
Participants:115
Impact:greater normalization in magnesium-containing arms (e.g., combined thiamine+Mg showed significant normalization; higher % normalized vs thiamine alone)
Trust score:4/5

Time to AWS resolution (GMAWS=0)

1 evidences

Randomized trial in patients with alcohol withdrawal: IV magnesium (alone or with thiamine) raised serum Mg, led to more consistent plasma lactate normalization and faster initial resolution of withdrawal scores compared with thiamine alone; ETKA did not improve overall.

Trust comment: Randomized trial (n=115) with comprehensive biochemical and clinical measures; subgroup analyses support biochemical plausibility though not all endpoints changed.

Study Details

PMID:35484175
Participants:115
Impact:decreased (median ~5.5–6 h in magnesium arms vs 10 h with thiamine alone)
Trust score:4/5

Oxaliplatin-induced cumulative sensory neurotoxicity

1 evidences

In a large phase III RCT, peri-infusion intravenous calcium and magnesium did not reduce cumulative oxaliplatin-induced sensory neurotoxicity or acute neuropathy compared with placebo.

Trust comment: Large, well-conducted phase III randomized double-blind trial with robust endpoints failing to show benefit.

Study Details

PMID:24297951
Participants:353
Impact:No significant reduction with calcium/magnesium infusion vs placebo
Trust score:5/5

Time to grade 2 neuropathy / clinician measures

1 evidences

In a large phase III RCT, peri-infusion intravenous calcium and magnesium did not reduce cumulative oxaliplatin-induced sensory neurotoxicity or acute neuropathy compared with placebo.

Trust comment: Large, well-conducted phase III randomized double-blind trial with robust endpoints failing to show benefit.

Study Details

PMID:24297951
Participants:353
Impact:No significant difference between arms
Trust score:5/5

hypotension incidence

1 evidences

In hypertensive patients, IV magnesium (with or without lidocaine) was tested to reduce the blood-pressure spike from intubation.

Trust comment: Randomized, double-blind trial in 96 patients with clear clinical endpoints though limited to peri-intubation setting.

Study Details

PMID:36857471
Participants:96
Impact:5 patients developed hypotension in 40 mg/kg MgSO4 group
Trust score:4/5

incidence of hypocalcemia at 72 h

1 evidences

Infants of diabetic mothers with low cord magnesium received IM magnesium at birth; magnesium did not significantly reduce hypocalcemia incidence at 72 hours.

Trust comment: Randomized trial with small sample and some missing data; primary endpoint not significantly different, but secondary calcium drop was reduced.

Study Details

PMID:9766410
Participants:49
Impact:0% (0/23) treated vs 12.5% (2/16) untreated; p=0.16 (no significant reduction)
Trust score:3/5

mean serum calcium at 72 h

1 evidences

Infants of diabetic mothers with low cord magnesium received IM magnesium at birth; magnesium did not significantly reduce hypocalcemia incidence at 72 hours.

Trust comment: Randomized trial with small sample and some missing data; primary endpoint not significantly different, but secondary calcium drop was reduced.

Study Details

PMID:9766410
Participants:49
Impact:no significant difference (2.28 vs 2.22 mM; p=0.39)
Trust score:3/5

drop in serum calcium from birth to 72 h

1 evidences

Infants of diabetic mothers with low cord magnesium received IM magnesium at birth; magnesium did not significantly reduce hypocalcemia incidence at 72 hours.

Trust comment: Randomized trial with small sample and some missing data; primary endpoint not significantly different, but secondary calcium drop was reduced.

Study Details

PMID:9766410
Participants:49
Impact:less decline in treated group (0.30 ± 0.05 mM) vs untreated (0.45 ± 0.05 mM); p=0.04
Trust score:3/5

neurologic abnormalities at discharge

1 evidences

Postnatal magnesium sulfate given to term neonates with severe asphyxia improved short-term neurologic outcomes at discharge compared with placebo.

Trust comment: Checklist: confirm human Mg effect; extract key clinical outcomes; verify n=40. Randomized placebo-controlled trial with clear outcome improvements at discharge but modest sample size limits long-term conclusions.

Study Details

PMID:19349375
Participants:40
Impact:22% in treatment vs 56% in placebo
Trust score:4/5

neuroimaging abnormalities (head CT day 14)

1 evidences

Postnatal magnesium sulfate given to term neonates with severe asphyxia improved short-term neurologic outcomes at discharge compared with placebo.

Trust comment: Checklist: confirm human Mg effect; extract key clinical outcomes; verify n=40. Randomized placebo-controlled trial with clear outcome improvements at discharge but modest sample size limits long-term conclusions.

Study Details

PMID:19349375
Participants:40
Impact:16% in treatment vs 44% in placebo
Trust score:4/5

oral feeding (sucking) at discharge

1 evidences

Postnatal magnesium sulfate given to term neonates with severe asphyxia improved short-term neurologic outcomes at discharge compared with placebo.

Trust comment: Checklist: confirm human Mg effect; extract key clinical outcomes; verify n=40. Randomized placebo-controlled trial with clear outcome improvements at discharge but modest sample size limits long-term conclusions.

Study Details

PMID:19349375
Participants:40
Impact:77% in treatment vs 37% in placebo
Trust score:4/5

postoperative pain (PACU FLACC AUC up to 90 min)

1 evidences

Systemic magnesium infusion did not reduce immediate post-tonsillectomy pain or PACU opioid use in children, though treated children had higher serum magnesium levels at surgery end.

Trust comment: Checklist: confirm human Mg infusion; extract pain/opioid and serum outcomes; verify n=60. Well-designed double-blind RCT with adequate sample for immediate outcomes showing no clinical analgesic benefit despite raised serum Mg.

Study Details

PMID:26501831
Participants:60
Impact:no significant difference between magnesium and control
Trust score:4/5

opioid (morphine) consumption in PACU

1 evidences

Systemic magnesium infusion did not reduce immediate post-tonsillectomy pain or PACU opioid use in children, though treated children had higher serum magnesium levels at surgery end.

Trust comment: Checklist: confirm human Mg infusion; extract pain/opioid and serum outcomes; verify n=60. Well-designed double-blind RCT with adequate sample for immediate outcomes showing no clinical analgesic benefit despite raised serum Mg.

Study Details

PMID:26501831
Participants:60
Impact:no clinically significant difference
Trust score:4/5

POST incidence at 4 h

1 evidences

A preoperative magnesium lozenge reduced incidence and severity of immediate postoperative sore throat compared with placebo.

Trust comment: Randomized, placebo-controlled trial with clear, clinically relevant endpoints though modest sample size.

Study Details

PMID:22797283
Participants:70
Impact:absolute reduction ~26% (P=0.032)
Trust score:4/5

POST incidence at 2 h

1 evidences

A preoperative magnesium lozenge reduced incidence and severity of immediate postoperative sore throat compared with placebo.

Trust comment: Randomized, placebo-controlled trial with clear, clinically relevant endpoints though modest sample size.

Study Details

PMID:22797283
Participants:70
Impact:magnesium 23% vs control 57% (absolute reduction ~34%, P=0.007)
Trust score:4/5

POST severity (immediate/2 h)

1 evidences

A preoperative magnesium lozenge reduced incidence and severity of immediate postoperative sore throat compared with placebo.

Trust comment: Randomized, placebo-controlled trial with clear, clinically relevant endpoints though modest sample size.

Study Details

PMID:22797283
Participants:70
Impact:severity significantly lower at 0 and 2 h (P=0.007 and P=0.002)
Trust score:4/5

postoperative pain (VAS)

1 evidences

Perioperative IV magnesium infusion reduced postoperative pain and improved quality of recovery scores after septorhinoplasty.

Trust comment: Randomized controlled design with adequate sample size and well-defined recovery measures, though single-center.

Study Details

PMID:38108626
Participants:120
Impact:significantly reduced at multiple early postoperative timepoints (p<0.001)
Trust score:4/5

quality of recovery (QoR-40)

3 evidences

Perioperative IV magnesium infusion reduced postoperative pain and improved quality of recovery scores after septorhinoplasty.

Trust comment: Randomized controlled design with adequate sample size and well-defined recovery measures, though single-center.

Study Details

PMID:38108626
Participants:120
Impact:higher QoR-40 scores in magnesium group (p<0.001)
Trust score:4/5

IV magnesium during thyroidectomy at the studied dose did not significantly improve overall postoperative recovery (QoR-40).

Trust comment: Prospective double-blind randomized trial with adequate sample size; magnesium showed no benefit at the administered dose.

Study Details

PMID:29324495
Participants:135
Impact:no significant improvement with magnesium (mean 184.3 vs control 179.4)
Trust score:4/5

Perioperative IV magnesium improved 24‑hour quality of recovery and reduced post-discharge oral opioid use after outpatient segmental mastectomy.

Trust comment: Prospective double-blind RCT with clinically meaningful endpoints and objective opioid use data, although sample is modest.

Study Details

PMID:24491463
Participants:46
Impact:increase (median difference +24 points at 24 h; 99% CI 3 to 33; P<0.001)
Trust score:4/5

Neuropathic pain severity (NPSI, numeric scale)

1 evidences

One-month oral magnesium versus placebo in neuropathic pain: no significant difference vs placebo on pain scores or quality of life, though some within-group improvements were seen.

Trust comment: Randomized double-blind trial but small sample (n=45) and short duration (4 weeks) with large placebo response limits confidence in negative result.

Study Details

PMID:21659058
Participants:45
Impact:no significant difference vs placebo after 4 weeks
Trust score:3/5

Frequency of pain paroxysms

1 evidences

One-month oral magnesium versus placebo in neuropathic pain: no significant difference vs placebo on pain scores or quality of life, though some within-group improvements were seen.

Trust comment: Randomized double-blind trial but small sample (n=45) and short duration (4 weeks) with large placebo response limits confidence in negative result.

Study Details

PMID:21659058
Participants:45
Impact:decreased vs baseline within magnesium group (between-group difference not significant)
Trust score:3/5

Quality of life (QoL / emotional component)

1 evidences

One-month oral magnesium versus placebo in neuropathic pain: no significant difference vs placebo on pain scores or quality of life, though some within-group improvements were seen.

Trust comment: Randomized double-blind trial but small sample (n=45) and short duration (4 weeks) with large placebo response limits confidence in negative result.

Study Details

PMID:21659058
Participants:45
Impact:no between-group difference; some within-group emotional improvement
Trust score:3/5

muscle magnesium content

2 evidences

In healthy male volunteers, magnesium supplementation during prolonged reduced movement (hypokinesia) was associated with larger decreases in muscle magnesium and increased plasma and excreted magnesium compared with controls.

Trust comment: Controlled human study but small sample, long duration and specific conditions (hypokinesia) limit generalizability.

Study Details

PMID:20363596
Participants:40
Impact:decreased (P<0.05), greater decrease with supplementation during hypokinesia
Trust score:3/5

Six weeks of magnesium supplementation did not change muscle magnesium content, strength, or mass compared with placebo; overall improvements were likely due to general care.

Trust comment: Randomized placebo-controlled trial with moderate sample size; outcomes measured objectively but short duration.

Study Details

PMID:16173138
Participants:59
Impact:no increase with magnesium supplementation (no between-group change)
Trust score:4/5

functional outcome (mRS 3–6 at 90 days)

1 evidences

Ancillary analysis of FAST-MAG found intravenous magnesium sulfate given early after stroke did not reduce hematoma expansion or improve 90-day functional outcomes in patients with intracerebral hemorrhage.

Trust comment: Ancillary analysis of a large randomized prehospital trial with prospectively collected data; retrospective subanalysis but adequate sample for the question.

Study Details

PMID:35380053
Participants:268
Impact:59% (magnesium) vs 50% (placebo); P=0.5 (no significant difference)
Trust score:4/5

umbilical venous ionized magnesium concentration

1 evidences

Magnesium sulfate given during labor raised fetal blood magnesium but did not change fetal inflammatory cytokine levels at delivery.

Trust comment: Randomized, double-blind placebo-controlled trial but small pilot sample (n=22) limits precision.

Study Details

PMID:11408847
Participants:22
Impact:+1.09 mg/dL (2.32 vs 1.23 mg/dL; P < .001)
Trust score:4/5

interleukin-1beta (umbilical)

1 evidences

Magnesium sulfate given during labor raised fetal blood magnesium but did not change fetal inflammatory cytokine levels at delivery.

Trust comment: Randomized, double-blind placebo-controlled trial but small pilot sample (n=22) limits precision.

Study Details

PMID:11408847
Participants:22
Impact:no significant change
Trust score:4/5

interleukin-6 (umbilical)

1 evidences

Magnesium sulfate given during labor raised fetal blood magnesium but did not change fetal inflammatory cytokine levels at delivery.

Trust comment: Randomized, double-blind placebo-controlled trial but small pilot sample (n=22) limits precision.

Study Details

PMID:11408847
Participants:22
Impact:no significant change
Trust score:4/5

tumor necrosis factor-alpha (umbilical)

1 evidences

Magnesium sulfate given during labor raised fetal blood magnesium but did not change fetal inflammatory cytokine levels at delivery.

Trust comment: Randomized, double-blind placebo-controlled trial but small pilot sample (n=22) limits precision.

Study Details

PMID:11408847
Participants:22
Impact:no significant change
Trust score:4/5

insomnia severity index (ISI)

1 evidences

A two-week randomized trial of a multi-ingredient supplement (contains magnesium) did not improve overall sleep quality versus placebo; small transient improvements in some secondary measures were observed.

Trust comment: Well-conducted, randomized double-blind trial with adequate size, but magnesium is one component of a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:28218661
Participants:160
Impact:improved at day 3 favoring active (between-group difference reported)
Trust score:3/5

state anxiety (STAI-S, pre- to post-administration)

1 evidences

A two-week randomized trial of a multi-ingredient supplement (contains magnesium) did not improve overall sleep quality versus placebo; small transient improvements in some secondary measures were observed.

Trust comment: Well-conducted, randomized double-blind trial with adequate size, but magnesium is one component of a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:28218661
Participants:160
Impact:small treatment effect pre- to post-administration (significant)
Trust score:3/5

fasting glucose

2 evidences

In type 2 diabetics with normal magnesium, 360 mg Mg daily for 3 months raised urinary Mg but did not improve blood sugar or insulin sensitivity.

Trust comment: Randomized, crossover, double-blind placebo-controlled trial with moderate completion (56 completers) — good internal validity.

Study Details

PMID:25204013
Participants:56
Impact:no significant change
Trust score:4/5

Oral magnesium (382 mg elemental/day) for 16 weeks reduced metabolic syndrome prevalence and improved blood pressure and fasting glucose in people with MetS and low magnesium.

Trust comment: Randomized double-blind placebo-controlled trial with large sample (198) and significant, clinically relevant metabolic outcomes.

Study Details

PMID:29793665
Participants:198
Impact:−12.4 ± 3.6 mg/dL (Mg vs placebo), P<0.005
Trust score:4/5

migraine attack frequency

2 evidences

Daily 600 mg oral magnesium for 12 weeks reduced migraine attack frequency and decreased migraine days and symptomatic medication use.

Trust comment: Prospective, multi-center, double-blind randomized trial with clear clinically relevant endpoints — moderate sample size.

Study Details

PMID:8792038
Participants:81
Impact:-41.6% (magnesium) vs -15.8% (placebo) in weeks 9–12
Trust score:4/5

Double-blind randomized placebo-controlled trial (30 magnesium, 10 placebo) in migraine without aura showing reduced attack frequency, severity, and electrophysiologic measures after 3 months of oral magnesium citrate 600 mg/day.

Trust comment: Randomized placebo-controlled trial showing clinically relevant reductions, but small sample size and imbalance between arms (30 vs 10) limit precision.

Study Details

PMID:18705538
Participants:40
Impact:significant decrease with magnesium vs placebo (post/pre ratio difference; P=0.005)
Trust score:3/5

days with migraine

1 evidences

Daily 600 mg oral magnesium for 12 weeks reduced migraine attack frequency and decreased migraine days and symptomatic medication use.

Trust comment: Prospective, multi-center, double-blind randomized trial with clear clinically relevant endpoints — moderate sample size.

Study Details

PMID:8792038
Participants:81
Impact:decreased (significant)
Trust score:4/5

symptomatic medication consumption per patient

1 evidences

Daily 600 mg oral magnesium for 12 weeks reduced migraine attack frequency and decreased migraine days and symptomatic medication use.

Trust comment: Prospective, multi-center, double-blind randomized trial with clear clinically relevant endpoints — moderate sample size.

Study Details

PMID:8792038
Participants:81
Impact:decreased (significant)
Trust score:4/5

Metabolic syndrome prevalence

1 evidences

Oral magnesium (382 mg elemental/day) for 16 weeks reduced metabolic syndrome prevalence and improved blood pressure and fasting glucose in people with MetS and low magnesium.

Trust comment: Randomized double-blind placebo-controlled trial with large sample (198) and significant, clinically relevant metabolic outcomes.

Study Details

PMID:29793665
Participants:198
Impact:48% (Mg) vs 77.5% (placebo) at 16 weeks (P=0.01) — lower in Mg group
Trust score:4/5

Systolic blood pressure

7 evidences

In type 2 diabetics, combined minerals + vitamins (including Mg+Zn) for 3 months lowered systolic, diastolic and mean blood pressure; Mg+Zn alone did not.

Trust comment: Randomized double-blind placebo-controlled design but small group sizes limit precision and subgroup inference for magnesium-specific effects.

Study Details

PMID:15190052
Participants:69
Impact:-8 mmHg (130 ± 19 to 122 ± 16 mmHg) in MV group
Trust score:3/5

Oral magnesium (382 mg elemental/day) for 16 weeks reduced metabolic syndrome prevalence and improved blood pressure and fasting glucose in people with MetS and low magnesium.

Trust comment: Randomized double-blind placebo-controlled trial with large sample (198) and significant, clinically relevant metabolic outcomes.

Study Details

PMID:29793665
Participants:198
Impact:−3.6 ± 3.3 mmHg (Mg vs placebo), P=0.001
Trust score:4/5

Replacing regular salt in processed foods with a mineral salt high in potassium and magnesium reduced sodium intake and lowered blood pressure over 8 weeks.

Trust comment: Randomized, double-blind, placebo-controlled trial with objective biochemical measures and good adherence, though sample size is modest.

Study Details

PMID:21888642
Participants:45
Impact:-7.5 mmHg (mean decrease in Smart Salt group)
Trust score:4/5

Combination mineral supplementation (including magnesium) produced small and generally non-significant changes in blood pressure in patients with mild/borderline hypertension.

Trust comment: Randomized trial with modest sample size and directly measured clinic BP; effects small and not statistically significant.

Study Details

PMID:7490154
Participants:125
Impact:no significant change (e.g., K+Mg: -1.3 mmHg; 95% CI -4.4 to +1.8)
Trust score:4/5

In hypertensive type II diabetics, replacing salt with a substitute containing potassium and magnesium significantly reduced systolic blood pressure after 3 months versus regular salt.

Trust comment: Randomized blinded controlled trial but small sample (n=40) and intervention combined K and Mg making Mg-specific effects uncertain.

Study Details

PMID:8895035
Participants:40
Impact:decrease ≈9.6 mmHg (163.2 to 153.6 mmHg after 3 months)
Trust score:3/5

In normotensive women with low habitual mineral intake, magnesium supplementation (336 mg/d) did not produce significant reductions in 24-hour ambulatory systolic or diastolic blood pressure compared with placebo.

Trust comment: Large randomized placebo-controlled trial (n=300) showing no significant BP effect of magnesium in normotensive women.

Study Details

PMID:9449404
Participants:300
Impact:-0.9 mmHg (95% CI -2.6 to 0.8; not significant)
Trust score:4/5

Magnesium treatment lowered systolic and diastolic blood pressure more than methyldopa in pregnancy-induced hypertension.

Trust comment: Small randomized trial with clinically relevant blood pressure outcomes but limited sample size.

Study Details

PMID:10828704
Participants:33
Impact:138 ± 13 vs 148 ± 15 mmHg (magnesium vs methyldopa); ~-10 mmHg (p < 0.0001)
Trust score:3/5

Urine magnesium excretion

1 evidences

In 62 healthy adults, high phosphorus (1000 mg/day) with differing calcium (0, 500, 1000 mg/day) altered mineral handling: fasting plasma phosphate unchanged, high P without Ca reduced renal calcium excretion and disturbed calcium balance, while calcium supplementation mitigated negative effects; transient FGF23 rise at 4 weeks and modest decreases in some bone turnover markers with Ca supplementation.

Trust comment: Randomized, double-blind, placebo-controlled human intervention (62 completers) measuring Mg outcomes though Mg was not the intervention target.

Study Details

PMID:26786148
Participants:62
Impact:Decreased in P1000/Ca0 group from 113 ±41 mg/d (placebo) to 84 ±32 mg/d at 8 weeks (≈−29 mg/d; P≤0.001)
Trust score:4/5

postoperative atrial fibrillation incidence

2 evidences

Perioperative magnesium administration (1.5 g daily starting before bypass) significantly reduced postoperative atrial fibrillation incidence compared with control.

Trust comment: Randomized controlled trial with 207 patients showing significant reductions in postoperative AF with magnesium; clear, clinically relevant outcome.

Study Details

PMID:14618045
Participants:207
Impact:Control 38% vs magnesium 14.8% (8/54) — absolute −23.2 percentage points; P=0.007
Trust score:4/5

In 100 CABG patients, postoperative prophylaxis with bisoprolol plus magnesium reduced atrial fibrillation incidence and shortened hospital stay versus control.

Trust comment: Randomized controlled trial with 100 patients and clinically meaningful, statistically significant outcomes; combination therapy includes bisoprolol so effect not attributable to magnesium alone.

Study Details

PMID:16870070
Participants:100
Impact:reduction from 42% to 20% (absolute ARR 22 percentage points; p=0.030)
Trust score:4/5

Combination benefit (sotalol + magnesium)

1 evidences

Perioperative magnesium administration (1.5 g daily starting before bypass) significantly reduced postoperative atrial fibrillation incidence compared with control.

Trust comment: Randomized controlled trial with 207 patients showing significant reductions in postoperative AF with magnesium; clear, clinically relevant outcome.

Study Details

PMID:14618045
Participants:207
Impact:Sotalol+Mg group had 1.9% AF vs higher rates with single agents and control (further reduction)
Trust score:4/5

device-oriented composite endpoint (DoCE)

1 evidences

In STEMI patients, magnesium-based bioresorbable scaffolds had higher device-related event rates, mainly more target lesion revascularisations within the first year, compared with metallic sirolimus-eluting stents.

Trust comment: Randomized, multicentre trial with independent event adjudication but modest sample size and single-blind design limit it slightly.

Study Details

PMID:35225793
Participants:142
Impact:+11.0% absolute (17.6% vs 6.6%)
Trust score:4/5

target lesion revascularisation (TLR)

1 evidences

In STEMI patients, magnesium-based bioresorbable scaffolds had higher device-related event rates, mainly more target lesion revascularisations within the first year, compared with metallic sirolimus-eluting stents.

Trust comment: Randomized, multicentre trial with independent event adjudication but modest sample size and single-blind design limit it slightly.

Study Details

PMID:35225793
Participants:142
Impact:+10.9% absolute (16.2% vs 5.3%)
Trust score:4/5

inhaled corticosteroid dose reduction

1 evidences

In adults with asthma undergoing a corticosteroid-reduction protocol, oral magnesium supplementation (450 mg/day) did not meaningfully reduce the inhaled corticosteroid dose required to maintain control compared with placebo.

Trust comment: Randomized, placebo-controlled trial but modest sample and small effect size yield low confidence in a benefit for magnesium.

Study Details

PMID:16338599
Participants:92
Impact:-13 µg geometric mean reduction in magnesium group (vs -11 µg placebo); no significant corticosteroid-sparing effect
Trust score:3/5

intraoperative opioid requirement (remifentanil)

1 evidences

Randomized controlled trial where IV magnesium during robotic prostatectomy reduced perioperative blood pressure rises, lowered cortisol, decreased opioid use, and reduced early postoperative pain.

Trust comment: Randomized, double-blind clinical trial with objective hemodynamic and hormonal measures and moderate sample size (n=52) supporting physiologic effects.

Study Details

PMID:33611742
Participants:52
Impact:-35% (magnesium vs control); P=0.011
Trust score:4/5

inflammation markers

1 evidences

In patients with type 2 diabetes, combined choline+magnesium supplementation improved markers of inflammation and endothelial dysfunction more than either alone or placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clinically relevant endpoints.

Study Details

PMID:31012803
Participants:96
Impact:improved with choline+magnesium co-supplementation versus single supplements or placebo (statistical significance reported)
Trust score:4/5

endothelial dysfunction

1 evidences

In patients with type 2 diabetes, combined choline+magnesium supplementation improved markers of inflammation and endothelial dysfunction more than either alone or placebo.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample size and clinically relevant endpoints.

Study Details

PMID:31012803
Participants:96
Impact:improved with choline+magnesium co-supplementation versus single supplements or placebo (statistical significance reported)
Trust score:4/5

postoperative pain at rest (24 h)

1 evidences

Oral magnesium added to ibuprofen reduced pain at rest at 24 hours after wisdom-tooth surgery compared with placebo.

Trust comment: Triple-blinded randomized split-mouth RCT with appropriate analysis but small sample and limited clinical significance of effect size.

Study Details

PMID:39949727
Participants:25
Impact:HP-VAS mean 30.80 vs 46.04; treatment difference −15.08 points (95% CI −29.01 to −1.14), P = 0.044
Trust score:4/5

rescue analgesic use

1 evidences

Oral magnesium added to ibuprofen reduced pain at rest at 24 hours after wisdom-tooth surgery compared with placebo.

Trust comment: Triple-blinded randomized split-mouth RCT with appropriate analysis but small sample and limited clinical significance of effect size.

Study Details

PMID:39949727
Participants:25
Impact:40% in magnesium group vs 56% in placebo group (absolute difference −16 percentage points)
Trust score:4/5

Serum BDNF

1 evidences

500 mg magnesium oxide daily for 8 weeks in depressed patients improved depression scores and serum magnesium but did not change BDNF.

Trust comment: Double-blind randomized clinical trial with clear outcomes but small sample (n=46) limits generalizability.

Study Details

PMID:33745609
Participants:46
Impact:no significant change (P = 0.507)
Trust score:4/5

PPAR-γ expression (PBMC)

1 evidences

250 mg/day magnesium oxide for 6 weeks in women with GDM decreased fasting glucose and modulated insulin/lipid‑related gene expression in PBMCs.

Trust comment: Randomized double-blind placebo-controlled trial with biologically plausible molecular and glucose changes but small sample (n=40).

Study Details

PMID:29256406
Participants:40
Impact:upregulated (P = 0.003)
Trust score:4/5

GLUT-1 expression (PBMC)

1 evidences

250 mg/day magnesium oxide for 6 weeks in women with GDM decreased fasting glucose and modulated insulin/lipid‑related gene expression in PBMCs.

Trust comment: Randomized double-blind placebo-controlled trial with biologically plausible molecular and glucose changes but small sample (n=40).

Study Details

PMID:29256406
Participants:40
Impact:upregulated (P = 0.004)
Trust score:4/5

LDLR expression (PBMC)

1 evidences

250 mg/day magnesium oxide for 6 weeks in women with GDM decreased fasting glucose and modulated insulin/lipid‑related gene expression in PBMCs.

Trust comment: Randomized double-blind placebo-controlled trial with biologically plausible molecular and glucose changes but small sample (n=40).

Study Details

PMID:29256406
Participants:40
Impact:downregulated (P = 0.001)
Trust score:4/5

incidence of vasopressor (pressor) support required

1 evidences

Randomized double-blind trial in carotid endarterectomy patients: high‑dose IV magnesium raised serum Mg but did not increase need for vasopressor support.

Trust comment: Well-designed randomized, double-blind, placebo-controlled trial with adequate sample (n=80); outcomes directly measured and clinically relevant.

Study Details

PMID:16385331
Participants:80
Impact:no significant change (magnesium vs placebo)
Trust score:4/5

amount and duration of phenylephrine support

1 evidences

Randomized double-blind trial in carotid endarterectomy patients: high‑dose IV magnesium raised serum Mg but did not increase need for vasopressor support.

Trust comment: Well-designed randomized, double-blind, placebo-controlled trial with adequate sample (n=80); outcomes directly measured and clinically relevant.

Study Details

PMID:16385331
Participants:80
Impact:no significant difference (magnesium vs placebo)
Trust score:4/5

anxiety

2 evidences

Double-blind RCT of a multivitamin/mineral (includes magnesium) in healthy men found reduced anxiety and perceived stress versus placebo.

Trust comment: Randomized double-blind RCT but tested a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:10907676
Participants:80
Impact:↓ (statistically significant reduction vs placebo)
Trust score:3/5

Pilot randomized trial testing hawthorn and magnesium (600 mg) found declines in blood pressure across groups but no significant difference for magnesium versus placebo.

Trust comment: Small randomized pilot study with limited power and mixed interventions, so negative result for magnesium is inconclusive.

Study Details

PMID:11807965
Participants:36
Impact:trend toward reduction seen with hawthorn, not magnesium (no significant magnesium effect)
Trust score:3/5

perceived stress

1 evidences

Double-blind RCT of a multivitamin/mineral (includes magnesium) in healthy men found reduced anxiety and perceived stress versus placebo.

Trust comment: Randomized double-blind RCT but tested a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:10907676
Participants:80
Impact:↓ (statistically significant reduction vs placebo)
Trust score:3/5

fatigue / tiredness

1 evidences

Double-blind RCT of a multivitamin/mineral (includes magnesium) in healthy men found reduced anxiety and perceived stress versus placebo.

Trust comment: Randomized double-blind RCT but tested a multi-ingredient product so effects cannot be attributed to magnesium alone.

Study Details

PMID:10907676
Participants:80
Impact:trend ↓ (participants tended to feel less tired)
Trust score:3/5

magnesium absorption (26Mg/24Mg percentage excess)

1 evidences

In a randomized crossover trial, 2 weeks of 15 g/day wheat dextrin did not affect measured calcium or magnesium absorption in women.

Trust comment: Randomized crossover with direct isotope-based absorption measurements and reasonable sample (n=40); well controlled for the question asked.

Study Details

PMID:22117983
Participants:40
Impact:no significant change (7.8% vs 7.9% for wheat dextrin vs placebo)
Trust score:4/5

calcium absorption (45Ca AUC 0–9 h)

1 evidences

In a randomized crossover trial, 2 weeks of 15 g/day wheat dextrin did not affect measured calcium or magnesium absorption in women.

Trust comment: Randomized crossover with direct isotope-based absorption measurements and reasonable sample (n=40); well controlled for the question asked.

Study Details

PMID:22117983
Participants:40
Impact:no significant change
Trust score:4/5

postoperative blood magnesium level

1 evidences

Perioperative IV magnesium sulfate did not reduce postoperative pain scores or morphine consumption after total knee arthroplasty compared with saline.

Trust comment: Randomized clinical trial with clear outcomes and 40 patients, but limited sample size for detecting small analgesic effects.

Study Details

PMID:25616206
Participants:40
Impact:+0.40 mmol/L (1.25 vs 0.85 mmol/L)
Trust score:4/5

morphine consumption

1 evidences

Perioperative IV magnesium sulfate did not reduce postoperative pain scores or morphine consumption after total knee arthroplasty compared with saline.

Trust comment: Randomized clinical trial with clear outcomes and 40 patients, but limited sample size for detecting small analgesic effects.

Study Details

PMID:25616206
Participants:40
Impact:no significant change
Trust score:4/5

postoperative pain score

2 evidences

Perioperative IV magnesium sulfate did not reduce postoperative pain scores or morphine consumption after total knee arthroplasty compared with saline.

Trust comment: Randomized clinical trial with clear outcomes and 40 patients, but limited sample size for detecting small analgesic effects.

Study Details

PMID:25616206
Participants:40
Impact:no significant change
Trust score:4/5

In abdominal hysterectomy patients, single-dose IV magnesium given before surgery reduced postoperative pain scores, opioid (tramadol) consumption, and periincisional hyperalgesia compared with saline.

Trust comment: Randomized controlled design with clear clinical endpoints; limited to single surgery type and reported without detailed numeric values in abstract.

Study Details

PMID:22399124
Participants:60
Impact:Significantly lower in magnesium group (p<0.05)
Trust score:4/5

leg cramp distress

1 evidences

Oral magnesium reduced distress from pregnancy-related leg cramps compared with placebo over 3 weeks.

Trust comment: Prospective, double-blind randomized trial with clear patient-reported outcome and supporting lab data, moderate sample size.

Study Details

PMID:7631676
Participants:73
Impact:decreased (p < 0.05 vs placebo; p < 0.001 vs baseline)
Trust score:4/5

intracellular magnesium

3 evidences

In heart failure patients, oral magnesium raised serum and intracellular Mg and substantially lowered CRP after 5 weeks compared with untreated patients.

Trust comment: Small, non-blinded treatment comparison with limited sample size for the intervention (17 treated, 18 controls); biologic endpoints reported.

Study Details

PMID:17479208
Participants:35
Impact:increase with Mg treatment (P=0.01)
Trust score:3/5

Six months of oral magnesium in patients with coronary artery disease raised intracellular Mg, increased exercise duration, reduced exercise-induced chest pain, and improved quality of life.

Trust comment: Multicenter randomized double-blind placebo-controlled trial (n=187) with clinically meaningful, statistically significant endpoints.

Study Details

PMID:12615252
Participants:187
Impact:+2.9 mEq/L (35.5 vs 32.6 mEq/L, p=0.0151)
Trust score:4/5

In coronary artery disease patients, lower intracellular magnesium was associated with higher platelet-dependent thrombosis; apolipoprotein B also correlated positively with thrombosis.

Trust comment: Prospective observational study with modest sample size; shows associations but cannot prove causation.

Study Details

PMID:10754344
Participants:42
Impact:Inverse correlation with platelet-dependent thrombosis (r = -0.46, p = 0.003)
Trust score:3/5

cardioversion success rate

1 evidences

Pretreatment with intravenous potassium/magnesium solution increased cardioversion success rates and lowered the energy required to restore sinus rhythm in patients with persistent AF.

Trust comment: Randomized trial with moderate sample size showing significant improvements, though blinding and other design details are less clear.

Study Details

PMID:21815963
Participants:170
Impact:increase (96.4% with K/Mg pretreatment vs 86.0% control, P=0.005)
Trust score:4/5

effective energy required

1 evidences

Pretreatment with intravenous potassium/magnesium solution increased cardioversion success rates and lowered the energy required to restore sinus rhythm in patients with persistent AF.

Trust comment: Randomized trial with moderate sample size showing significant improvements, though blinding and other design details are less clear.

Study Details

PMID:21815963
Participants:170
Impact:decrease (140.8±26.9 J vs 182.5±52.2 J, P=0.02)
Trust score:4/5

implant stability (ISQ, PTV)

1 evidences

Magnesium-incorporated implant surfaces performed similarly to blasted magnesium-incorporated surfaces for stability and bone loss over 15 months.

Trust comment: Randomized double-blind clinical trial with 15-month follow-up but relatively small patient number.

Study Details

PMID:23278670
Participants:40
Impact:high stability (>71) and no significant difference between surfaces (ISQ P=0.988, PTV P=0.935)
Trust score:4/5

marginal bone loss

1 evidences

Magnesium-incorporated implant surfaces performed similarly to blasted magnesium-incorporated surfaces for stability and bone loss over 15 months.

Trust comment: Randomized double-blind clinical trial with 15-month follow-up but relatively small patient number.

Study Details

PMID:23278670
Participants:40
Impact:0.71 ±0.65 mm vs 0.75 ±0.73 mm at 15 months; no significant difference (P=0.807)
Trust score:4/5

Implant success rate

1 evidences

Magnesium-incorporated implant surfaces performed similarly to blasted magnesium-incorporated surfaces for stability and bone loss over 15 months.

Trust comment: Randomized double-blind clinical trial with 15-month follow-up but relatively small patient number.

Study Details

PMID:23278670
Participants:40
Impact:100% at 1 year for both surfaces
Trust score:4/5

muscle strength

1 evidences

Six weeks of magnesium supplementation did not change muscle magnesium content, strength, or mass compared with placebo; overall improvements were likely due to general care.

Trust comment: Randomized placebo-controlled trial with moderate sample size; outcomes measured objectively but short duration.

Study Details

PMID:16173138
Participants:59
Impact:+14% during trial overall (p<0.001) but no difference between magnesium and placebo
Trust score:4/5

muscle mass

1 evidences

Six weeks of magnesium supplementation did not change muscle magnesium content, strength, or mass compared with placebo; overall improvements were likely due to general care.

Trust comment: Randomized placebo-controlled trial with moderate sample size; outcomes measured objectively but short duration.

Study Details

PMID:16173138
Participants:59
Impact:+11% during trial (p=0.05) but no difference between magnesium and placebo
Trust score:4/5

incidence of catheter-related bladder discomfort (CRBD)

1 evidences

Perioperative IV magnesium sulfate reduced catheter-related bladder discomfort and decreased some opioid requirements in male patients after laparoscopic GI cancer surgery.

Trust comment: Well-designed single-center double-blind RCT with pre-specified outcomes and meaningful effect sizes, though moderate sample size.

Study Details

PMID:38042781
Participants:88
Impact:reduced — 67.4%→40.0% at 0 h; 69.8%→37.8% at 1 h; 51.2%→17.8% at 2 h; 32.6%→8.9% at 6 h (p≤0.01)
Trust score:4/5

moderate-to-severe CRBD incidence

1 evidences

Perioperative IV magnesium sulfate reduced catheter-related bladder discomfort and decreased some opioid requirements in male patients after laparoscopic GI cancer surgery.

Trust comment: Well-designed single-center double-blind RCT with pre-specified outcomes and meaningful effect sizes, though moderate sample size.

Study Details

PMID:38042781
Participants:88
Impact:reduced at 0 h (62.1%→16.7%, p=0.002) and 1 h (56.7%→23.5%, p=0.028)
Trust score:4/5

intraoperative remifentanil requirement

1 evidences

Perioperative IV magnesium sulfate reduced catheter-related bladder discomfort and decreased some opioid requirements in male patients after laparoscopic GI cancer surgery.

Trust comment: Well-designed single-center double-blind RCT with pre-specified outcomes and meaningful effect sizes, though moderate sample size.

Study Details

PMID:38042781
Participants:88
Impact:reduced 0.9±0.3 mg → 0.7±0.2 mg (p<0.001); also lower 24-h sufentanil 54→50 μg (p<0.001)
Trust score:4/5

Harris hip score improvement

1 evidences

In this small randomized surgical trial, fixation with biodegradable magnesium screws produced greater functional (Harris) score improvement and better radiologic/ perfusion findings at 6 months than titanium screws or direct embedding.

Trust comment: Randomized surgical study with objective imaging and clinical scores but small sample, single-blind design, and short (6-month) follow-up.

Study Details

PMID:37481538
Participants:36
Impact:mean increase 15.78 points (Mg screw) vs 10.94 (titanium) and 8.74 (embed) at 6 months; Mg group superior (p<0.01)
Trust score:3/5

excellent + good rate (Harris)

1 evidences

In this small randomized surgical trial, fixation with biodegradable magnesium screws produced greater functional (Harris) score improvement and better radiologic/ perfusion findings at 6 months than titanium screws or direct embedding.

Trust comment: Randomized surgical study with objective imaging and clinical scores but small sample, single-blind design, and short (6-month) follow-up.

Study Details

PMID:37481538
Participants:36
Impact:66.7% (Mg) vs 46.2% (titanium) vs 33.3% (embed)
Trust score:3/5

microcirculation by DCE-MRI

1 evidences

In this small randomized surgical trial, fixation with biodegradable magnesium screws produced greater functional (Harris) score improvement and better radiologic/ perfusion findings at 6 months than titanium screws or direct embedding.

Trust comment: Randomized surgical study with objective imaging and clinical scores but small sample, single-blind design, and short (6-month) follow-up.

Study Details

PMID:37481538
Participants:36
Impact:greater improvement in necrotic-area perfusion in Mg screw group vs controls at 6 months
Trust score:3/5

need for oxygen therapy

1 evidences

Oral magnesium (300 mg/day) in hospitalized moderate COVID-19 patients increased serum magnesium, improved oxygenation, reduced need for oxygen therapy, and improved quality of life and depression scores compared with placebo.

Trust comment: Double-blind randomized trial with appropriate outcomes but single-center and modest sample (n=60) limits generalizability.

Study Details

PMID:38654355
Participants:60
Impact:magnesium 30% (9/30) vs placebo 46.7% (14/30); absolute -16.7 percentage points (P<0.001)
Trust score:4/5

magnesium-mediated indirect effect on systolic blood pressure

1 evidences

In a repeated-measures cohort, higher ambient temperature lowered blood pressure mainly via a direct effect; urinary calcium contributed a very small indirect (mediated) increase in BP per 5°C rise.

Trust comment: Large longitudinal dataset with repeated 24‑h urine measures and causal mediation methods, but mediation estimates sensitive to unmeasured confounding as acknowledged by authors.

Study Details

PMID:39705978
Participants:1175
Impact:−0.004 mmHg per 5°C increase (95% CI: −0.03, 0.02) — essentially negligible
Trust score:4/5

magnesium-mediated indirect effect on diastolic blood pressure

1 evidences

In a repeated-measures cohort, higher ambient temperature lowered blood pressure mainly via a direct effect; urinary calcium contributed a very small indirect (mediated) increase in BP per 5°C rise.

Trust comment: Large longitudinal dataset with repeated 24‑h urine measures and causal mediation methods, but mediation estimates sensitive to unmeasured confounding as acknowledged by authors.

Study Details

PMID:39705978
Participants:1175
Impact:~0.04 mmHg per 5°C increase (95% CI crosses zero) — negligible/uncertain
Trust score:4/5

magnesium-mediated indirect effect on mean arterial pressure

1 evidences

In a repeated-measures cohort, higher ambient temperature lowered blood pressure mainly via a direct effect; urinary calcium contributed a very small indirect (mediated) increase in BP per 5°C rise.

Trust comment: Large longitudinal dataset with repeated 24‑h urine measures and causal mediation methods, but mediation estimates sensitive to unmeasured confounding as acknowledged by authors.

Study Details

PMID:39705978
Participants:1175
Impact:−0.00 mmHg per 5°C increase (95% CI: −0.01, 0.02) — negligible
Trust score:4/5

vital signs (HR, RR, SpO2, MAP)

1 evidences

Newborns with severe birth asphyxia received IV magnesium sulphate; serum Mg rose into a neuroprotective range with no significant adverse effects on vital signs.

Trust comment: Randomized clinical trial in neonates with clear, significant biochemical effects and safety monitoring though sample size was modest.

Study Details

PMID:16567913
Participants:40
Impact:no significant alterations after magnesium infusion
Trust score:4/5

myocardial autoresuscitation

1 evidences

27 CABG patients randomized to cardioplegia with different magnesium concentrations; the 8–10 mmol/L magnesium solution showed better myocardial protection.

Trust comment: Randomized clinical setting with objective biomarkers but small group sizes (n≈9 per arm).

Study Details

PMID:12139118
Participants:27
Impact:higher in 8–10 mmol/L Mg group (100% vs 77.8% and 66.7%)
Trust score:3/5

cardiac injury biomarkers (cTnI, CK-MB)

1 evidences

27 CABG patients randomized to cardioplegia with different magnesium concentrations; the 8–10 mmol/L magnesium solution showed better myocardial protection.

Trust comment: Randomized clinical setting with objective biomarkers but small group sizes (n≈9 per arm).

Study Details

PMID:12139118
Participants:27
Impact:lower at 6–72 h in 8–10 mmol/L Mg group (p<0.01 vs lower and higher Mg groups)
Trust score:3/5

postoperative ventilation and ICU stay

1 evidences

27 CABG patients randomized to cardioplegia with different magnesium concentrations; the 8–10 mmol/L magnesium solution showed better myocardial protection.

Trust comment: Randomized clinical setting with objective biomarkers but small group sizes (n≈9 per arm).

Study Details

PMID:12139118
Participants:27
Impact:shorter in 8–10 mmol/L Mg group versus other groups
Trust score:3/5

muscle strength / functional mobility

1 evidences

74 overweight middle-aged women received 250 mg Mg/day or placebo for 8 weeks; small within-group changes occurred but no significant benefits versus placebo.

Trust comment: Double-blind randomized placebo-controlled trial of moderate size; outcomes largely not significant between groups.

Study Details

PMID:23619906
Participants:74
Impact:handgrip and TGUG improved vs baseline but not significantly different from placebo
Trust score:4/5

urinary albumin excretion

1 evidences

12-month randomized double-blind trial in 28 type 1 diabetics found no group differences in kidney function or most lipids; three treated patients had triglyceride increases.

Trust comment: Small randomized double-blind placebo-controlled trial but low sample size limits power to detect modest effects.

Study Details

PMID:10423707
Participants:28
Impact:no significant difference vs placebo
Trust score:3/5

glomerular filtration (Cr-EDTA clearance)

1 evidences

12-month randomized double-blind trial in 28 type 1 diabetics found no group differences in kidney function or most lipids; three treated patients had triglyceride increases.

Trust comment: Small randomized double-blind placebo-controlled trial but low sample size limits power to detect modest effects.

Study Details

PMID:10423707
Participants:28
Impact:no significant difference vs placebo
Trust score:3/5

IL-6 (inflammatory marker)

1 evidences

In 44 men with moderate-to-severe COPD, an 8-week fortified whey beverage containing 275 mg elemental magnesium improved inflammation, fat-free mass, muscle strength, and respiratory-quality-of-life measures versus control.

Trust comment: Randomized single-blind RCT with objective measures and reported between-group statistics, but small sample and multi-ingredient intervention (magnesium combined with whey and vitamin C) limit attribution solely to magnesium.

Study Details

PMID:32807165
Participants:44
Impact:decrease −3.33 ± 6.41 pg/ml in intervention; between-group p=0.034
Trust score:4/5

fat-free mass

1 evidences

In 44 men with moderate-to-severe COPD, an 8-week fortified whey beverage containing 275 mg elemental magnesium improved inflammation, fat-free mass, muscle strength, and respiratory-quality-of-life measures versus control.

Trust comment: Randomized single-blind RCT with objective measures and reported between-group statistics, but small sample and multi-ingredient intervention (magnesium combined with whey and vitamin C) limit attribution solely to magnesium.

Study Details

PMID:32807165
Participants:44
Impact:increase +2.85 ± 4.65 kg in intervention vs control; between-group p=0.025
Trust score:4/5

handgrip strength

2 evidences

In 44 men with moderate-to-severe COPD, an 8-week fortified whey beverage containing 275 mg elemental magnesium improved inflammation, fat-free mass, muscle strength, and respiratory-quality-of-life measures versus control.

Trust comment: Randomized single-blind RCT with objective measures and reported between-group statistics, but small sample and multi-ingredient intervention (magnesium combined with whey and vitamin C) limit attribution solely to magnesium.

Study Details

PMID:32807165
Participants:44
Impact:right +2.76 ± 3.81 kg (p=0.023); left +3.34 ± 5.65 kg (p=0.045) vs control
Trust score:4/5

In vitamin D–deficient middle-aged women, 8 weeks of weekly 50,000 IU vitamin D plus daily magnesium improved muscle strength and function and raised serum vitamin D.

Trust comment: Randomized trial with adequate reporting, but because vitamin D and magnesium were co-administered, effects cannot be attributed to magnesium alone.

Study Details

PMID:32955720
Participants:83
Impact:increased (significant vs placebo)
Trust score:4/5

Hospital length of stay

1 evidences

In 100 CABG patients, postoperative prophylaxis with bisoprolol plus magnesium reduced atrial fibrillation incidence and shortened hospital stay versus control.

Trust comment: Randomized controlled trial with 100 patients and clinically meaningful, statistically significant outcomes; combination therapy includes bisoprolol so effect not attributable to magnesium alone.

Study Details

PMID:16870070
Participants:100
Impact:median reduction 2 days (7 vs 9 days; p=0.022)
Trust score:4/5

>=50% migraine reduction (responder rate)

1 evidences

Randomized double-blind trial comparing a combined riboflavin/magnesium/feverfew compound to placebo (containing low-dose riboflavin) for 3 months in migraine prevention.

Trust comment: Randomized design but small completed sample and placebo contained riboflavin (possible active comparator) reduce interpretability.

Study Details

PMID:15447697
Participants:49
Impact:no difference active vs placebo (42% vs 44%; P=0.87)
Trust score:3/5

migraine days / migraine index

1 evidences

Randomized double-blind trial comparing a combined riboflavin/magnesium/feverfew compound to placebo (containing low-dose riboflavin) for 3 months in migraine prevention.

Trust comment: Randomized design but small completed sample and placebo contained riboflavin (possible active comparator) reduce interpretability.

Study Details

PMID:15447697
Participants:49
Impact:both groups improved vs baseline; no difference between groups
Trust score:3/5

low back pain (VAS)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up trial with clear patient-reported outcomes, moderate sample size (105).

Study Details

PMID:29322254
Participants:105
Impact:significant decrease vs baseline and control (p < 0.001)
Trust score:4/5

back-specific disability (Oswestry)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up trial with clear patient-reported outcomes, moderate sample size (105).

Study Details

PMID:29322254
Participants:105
Impact:significant improvement vs baseline and control (p < 0.001)
Trust score:4/5

quality of life (EuroQol-5D)

1 evidences

Thermal mineral water baths (high in calcium-magnesium-bicarbonate) plus usual care improved pain, disability and quality of life in chronic low back pain patients, with effects persisting at follow-up.

Trust comment: Randomized controlled follow-up trial with clear patient-reported outcomes, moderate sample size (105).

Study Details

PMID:29322254
Participants:105
Impact:significant improvement vs baseline and control (p < 0.001)
Trust score:4/5

atrial fibrillation incidence

1 evidences

Perioperative magnesium infusion raised serum magnesium and reduced post-CABG atrial fibrillation incidence in non-diabetic patients.

Trust comment: Large randomized clinical trial in CABG patients; clinically relevant endpoints though subgroup effect by diabetes.

Study Details

PMID:17694684
Participants:345
Impact:reduced incidence among non-diabetics receiving magnesium (significant)
Trust score:4/5

creatinine clearance

1 evidences

Hypomagnesemic patients experienced greater decline in kidney function after high-osmolality contrast; magnesium appears protective against contrast-induced nephrotoxicity.

Trust comment: Randomized design but small sample (n=39) and subgroup comparisons limit precision.

Study Details

PMID:9669426
Participants:39
Impact:greater decrease in hypomagnesemic placebo patients (≈79% vs 35% decrease; P < 0.01)
Trust score:3/5

contrast nephrotoxicity

1 evidences

Hypomagnesemic patients experienced greater decline in kidney function after high-osmolality contrast; magnesium appears protective against contrast-induced nephrotoxicity.

Trust comment: Randomized design but small sample (n=39) and subgroup comparisons limit precision.

Study Details

PMID:9669426
Participants:39
Impact:attenuated by normal/higher magnesium status
Trust score:3/5

cramp frequency

1 evidences

Oral magnesium (300 mg/day) for 4 weeks reduced frequency and intensity of pregnancy-related leg cramps compared with placebo.

Trust comment: Double-blind RCT with good completion rate (80/86) and clinically meaningful patient-reported outcomes with significant differences.

Study Details

PMID:22909270
Participants:80
Impact:50% reduction achieved in 86.0% (magnesium) vs 60.5% (placebo) (P = 0.007)
Trust score:4/5

cramp intensity

1 evidences

Oral magnesium (300 mg/day) for 4 weeks reduced frequency and intensity of pregnancy-related leg cramps compared with placebo.

Trust comment: Double-blind RCT with good completion rate (80/86) and clinically meaningful patient-reported outcomes with significant differences.

Study Details

PMID:22909270
Participants:80
Impact:50% reduction achieved in 69.8% (magnesium) vs 48.8% (placebo) (P = 0.048)
Trust score:4/5

ionic magnesium (iMg)

1 evidences

Four weeks of 212 mg/day magnesium oxide raised ionic magnesium but did not change performance or recovery measures in physically active women.

Trust comment: Double-blind crossover with measured biochemical and performance endpoints; modest sample size (32) limits precision but design is strong.

Study Details

PMID:11252079
Participants:32
Impact:increased with magnesium treatment versus placebo (P < 0.05)
Trust score:4/5

exercise performance

1 evidences

Four weeks of 212 mg/day magnesium oxide raised ionic magnesium but did not change performance or recovery measures in physically active women.

Trust comment: Double-blind crossover with measured biochemical and performance endpoints; modest sample size (32) limits precision but design is strong.

Study Details

PMID:11252079
Participants:32
Impact:no significant effect after 4 weeks (no change)
Trust score:4/5

recovery indices

1 evidences

Four weeks of 212 mg/day magnesium oxide raised ionic magnesium but did not change performance or recovery measures in physically active women.

Trust comment: Double-blind crossover with measured biochemical and performance endpoints; modest sample size (32) limits precision but design is strong.

Study Details

PMID:11252079
Participants:32
Impact:no significant effect after 4 weeks (no change)
Trust score:4/5

urine potassium excretion

1 evidences

In hypertensive type II diabetics, replacing salt with a substitute containing potassium and magnesium significantly reduced systolic blood pressure after 3 months versus regular salt.

Trust comment: Randomized blinded controlled trial but small sample (n=40) and intervention combined K and Mg making Mg-specific effects uncertain.

Study Details

PMID:8895035
Participants:40
Impact:increase (58.8 to 77.3 mmol/24 h, p<0.05)
Trust score:3/5

opioid requirement (remifentanil consumption)

1 evidences

In postoperative cardiac surgery patients, IV magnesium reduced cumulative remifentanil requirements and was associated with lower pain scores at some time points without prolonging extubation time.

Trust comment: Randomized small RCT (n=40) with opioid-sparing findings but limited sample size and incomplete numeric reporting in the snippet.

Study Details

PMID:16490760
Participants:40
Impact:reduced cumulative requirement (statistically significant; exact amount not reported in snippet)
Trust score:3/5

pain scores (VAS/PIS)

1 evidences

In postoperative cardiac surgery patients, IV magnesium reduced cumulative remifentanil requirements and was associated with lower pain scores at some time points without prolonging extubation time.

Trust comment: Randomized small RCT (n=40) with opioid-sparing findings but limited sample size and incomplete numeric reporting in the snippet.

Study Details

PMID:16490760
Participants:40
Impact:lower VAS at 8h and 9h (2 vs 8 and 2 vs 7); fewer high PIS events
Trust score:3/5

ventilation-related dose reductions

1 evidences

In postoperative cardiac surgery patients, IV magnesium reduced cumulative remifentanil requirements and was associated with lower pain scores at some time points without prolonging extubation time.

Trust comment: Randomized small RCT (n=40) with opioid-sparing findings but limited sample size and incomplete numeric reporting in the snippet.

Study Details

PMID:16490760
Participants:40
Impact:more dose reductions for low ventilatory frequency in magnesium group (17 vs 6)
Trust score:3/5

24-h ambulatory and office blood pressure

1 evidences

Daily magnesium (350 mg) for 24 weeks reduced arterial stiffness (pulse-wave velocity) in overweight/obese adults without changing blood pressure.

Trust comment: Well-conducted randomized double-blind trial with objective vascular outcome but small sample size (n=52).

Study Details

PMID:27053384
Participants:52
Impact:no change
Trust score:4/5

fasting plasma glucose

2 evidences

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind design but co-supplementation (multiple nutrients) prevents attribution of effects to magnesium alone.

Study Details

PMID:29316405
Participants:60
Impact:decreased −0.37 ± 0.09 mmol/L vs +0.01 ± 0.09 (placebo); P=0.003
Trust score:3/5

Patients with diabetic foot ulcers received magnesium plus vitamin E or placebo for 12 weeks; ulcer size and many metabolic/inflammatory markers improved with supplementation.

Trust comment: Randomized placebo-controlled design is strong, but co-supplementation with vitamin E prevents attribution of effects to magnesium alone and sample is modest.

Study Details

PMID:30693609
Participants:57
Impact:decrease -13.41 mg/dL (β -13.41; p=0.001)
Trust score:3/5

serum insulin / HOMA-IR

1 evidences

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind design but co-supplementation (multiple nutrients) prevents attribution of effects to magnesium alone.

Study Details

PMID:29316405
Participants:60
Impact:insulin −21.0 ± 4.8 pmol/L and HOMA-IR −1.0 ± 1.1 vs increases in placebo; P<0.001
Trust score:3/5

triglycerides and VLDL

1 evidences

Six weeks of magnesium-zinc-calcium-vitamin D co-supplementation in gestational diabetes improved fasting glucose, insulin-related markers and some lipid markers versus placebo.

Trust comment: Randomized, double-blind design but co-supplementation (multiple nutrients) prevents attribution of effects to magnesium alone.

Study Details

PMID:29316405
Participants:60
Impact:triglycerides −0.25 ± 0.10 mmol/L and VLDL −0.11 ± 0.04 mmol/L vs increases in placebo; P=0.001
Trust score:3/5

serum magnesium level

2 evidences

Measured serum magnesium in malnourished and healthy children and found lower Mg in more severe malnutrition and growth retardation.

Trust comment: Human observational study with clear measurements and moderate sample size but cross-sectional design limits causal inference.

Study Details

PMID:9604603
Participants:58
Impact:decreased in moderate and severe malnutrition; ~50% of marasmic children hypomagnesemic (<1.56 mg/dL)
Trust score:3/5

Preoperative oral magnesium (1,600 mg) was as effective as IV magnesium (2 g) in preventing post-CABG hypomagnesemia and arrhythmia up to 48 hours.

Trust comment: Randomized, blinded clinical study with clear endpoints and moderate sample size; some exclusions and short follow-up limit generalizability.

Study Details

PMID:30517252
Participants:67
Impact:no significant difference between oral (1,600 mg) and IV (2 g) up to 48 h
Trust score:4/5

serum magnesium (all subjects)

1 evidences

A 2-week application of 56 mg/day transdermal magnesium cream produced a non-significant serum Mg rise overall and a significant serum Mg increase in non-athlete subgroup.

Trust comment: Checklist: confirm human Mg effect; focus on serum/urine markers; verify completions n=24. Randomized single-blind pilot with small sample and low topical dose—signals seen in non-athletes but limited power and external validity.

Study Details

PMID:28403154
Participants:24
Impact:increase +8.54% (0.82 to 0.89 mmol/L), not statistically significant (p=0.29)
Trust score:3/5

serum magnesium (non-athletes)

1 evidences

A 2-week application of 56 mg/day transdermal magnesium cream produced a non-significant serum Mg rise overall and a significant serum Mg increase in non-athlete subgroup.

Trust comment: Checklist: confirm human Mg effect; focus on serum/urine markers; verify completions n=24. Randomized single-blind pilot with small sample and low topical dose—signals seen in non-athletes but limited power and external validity.

Study Details

PMID:28403154
Participants:24
Impact:increase +22.7% (0.75 to 0.92 mmol/L), statistically significant (p=0.02)
Trust score:3/5

bronchial reactivity (PC20)

1 evidences

Two months of oral magnesium (300 mg/day) in children with moderate persistent asthma improved bronchial reactivity, reduced skin allergen responses, and improved symptom control versus placebo.

Trust comment: Checklist: confirm human Mg supplementation; identify clinical respiratory outcomes; verify n=37. Double-blind randomized placebo-controlled trial with objective bronchial reactivity improvements and clinical benefit signals, though modest sample size.

Study Details

PMID:16788707
Participants:37
Impact:significant improvement (PC20 increased) in magnesium group
Trust score:4/5

allergen-induced skin responses

1 evidences

Two months of oral magnesium (300 mg/day) in children with moderate persistent asthma improved bronchial reactivity, reduced skin allergen responses, and improved symptom control versus placebo.

Trust comment: Checklist: confirm human Mg supplementation; identify clinical respiratory outcomes; verify n=37. Double-blind randomized placebo-controlled trial with objective bronchial reactivity improvements and clinical benefit signals, though modest sample size.

Study Details

PMID:16788707
Participants:37
Impact:decreased in magnesium group
Trust score:4/5

asthma exacerbations and rescue inhaler use

1 evidences

Two months of oral magnesium (300 mg/day) in children with moderate persistent asthma improved bronchial reactivity, reduced skin allergen responses, and improved symptom control versus placebo.

Trust comment: Checklist: confirm human Mg supplementation; identify clinical respiratory outcomes; verify n=37. Double-blind randomized placebo-controlled trial with objective bronchial reactivity improvements and clinical benefit signals, though modest sample size.

Study Details

PMID:16788707
Participants:37
Impact:fewer exacerbations and reduced salbutamol use in magnesium group
Trust score:4/5

mean pain score

1 evidences

Magnesium-based trigger point injections reduced pain versus waitlist and produced similar pain improvement to lidocaine injections.

Trust comment: Randomized double-blind RCT but small and underpowered; results show benefit versus waitlist but no advantage over lidocaine.

Study Details

PMID:35339694
Participants:44
Impact:-2.6/10 (magnesium group, mean change); lidocaine -2.9/10; waitlist -0.5/10
Trust score:3/5

pain with function and quality of life

1 evidences

Magnesium-based trigger point injections reduced pain versus waitlist and produced similar pain improvement to lidocaine injections.

Trust comment: Randomized double-blind RCT but small and underpowered; results show benefit versus waitlist but no advantage over lidocaine.

Study Details

PMID:35339694
Participants:44
Impact:improved in both magnesium and lidocaine groups (no superiority of magnesium)
Trust score:3/5

pain (VAS) at day 4

1 evidences

Adding oral magnesium to NSAID treatment gave greater short-term (day 4) pain and function improvement but no difference at day 10 (final outcome).

Trust comment: Large randomized trial but open-label and short follow-up for final outcomes, limiting robustness of long-term benefit claims.

Study Details

PMID:33812327
Participants:209
Impact:greater improvement in NSAID + magnesium group versus other groups (significant at day 4)
Trust score:3/5

functional outcome (RMDQ) at day 4

1 evidences

Adding oral magnesium to NSAID treatment gave greater short-term (day 4) pain and function improvement but no difference at day 10 (final outcome).

Trust comment: Large randomized trial but open-label and short follow-up for final outcomes, limiting robustness of long-term benefit claims.

Study Details

PMID:33812327
Participants:209
Impact:greater improvement in NSAID + magnesium group versus other groups (significant at day 4)
Trust score:3/5

pain and function at day 10

1 evidences

Adding oral magnesium to NSAID treatment gave greater short-term (day 4) pain and function improvement but no difference at day 10 (final outcome).

Trust comment: Large randomized trial but open-label and short follow-up for final outcomes, limiting robustness of long-term benefit claims.

Study Details

PMID:33812327
Participants:209
Impact:no significant difference between groups (final outcome)
Trust score:3/5

PAI-1 (plasminogen activator inhibitor-1)

1 evidences

In people with type 2 diabetes, 2 months of choline and/or magnesium supplementation; combined choline+magnesium improved coagulation markers more than either alone.

Trust comment: Randomized, double-blind, placebo-controlled pilot RCT with 96 participants; moderate sample and appropriate design, but pilot size limits precision.

Study Details

PMID:31385202
Participants:96
Impact:decreased (p<0.05)
Trust score:4/5

Coagulation (overall)

1 evidences

In people with type 2 diabetes, 2 months of choline and/or magnesium supplementation; combined choline+magnesium improved coagulation markers more than either alone.

Trust comment: Randomized, double-blind, placebo-controlled pilot RCT with 96 participants; moderate sample and appropriate design, but pilot size limits precision.

Study Details

PMID:31385202
Participants:96
Impact:improved with combined choline+magnesium vs single supplements (p<0.05)
Trust score:4/5

lipid profile

1 evidences

In people with type 2 diabetes, 2 months of choline and/or magnesium supplementation; combined choline+magnesium improved coagulation markers more than either alone.

Trust comment: Randomized, double-blind, placebo-controlled pilot RCT with 96 participants; moderate sample and appropriate design, but pilot size limits precision.

Study Details

PMID:31385202
Participants:96
Impact:no clear significant change reported
Trust score:4/5

febrile neutropenia episodes

1 evidences

Oral magnesium (250 mg/day) given per chemotherapy cycle reduced febrile neutropenia episodes and delayed their onset in pediatric solid-tumor patients receiving cisplatin-based chemotherapy.

Trust comment: Randomized clinical trial with intention-to-treat analysis and clear clinical endpoints, but single-center and cycle-level randomization considerations exist.

Study Details

PMID:33030582
Participants:101
Impact:RR 0.53 (95% CI 0.32–0.89); NNT = 4
Trust score:4/5

septic shock secondary to FN

1 evidences

Oral magnesium (250 mg/day) given per chemotherapy cycle reduced febrile neutropenia episodes and delayed their onset in pediatric solid-tumor patients receiving cisplatin-based chemotherapy.

Trust comment: Randomized clinical trial with intention-to-treat analysis and clear clinical endpoints, but single-center and cycle-level randomization considerations exist.

Study Details

PMID:33030582
Participants:101
Impact:RR 0.43 (95% CI 0.02–0.94); NNT = 6
Trust score:4/5

time to FN

1 evidences

Oral magnesium (250 mg/day) given per chemotherapy cycle reduced febrile neutropenia episodes and delayed their onset in pediatric solid-tumor patients receiving cisplatin-based chemotherapy.

Trust comment: Randomized clinical trial with intention-to-treat analysis and clear clinical endpoints, but single-center and cycle-level randomization considerations exist.

Study Details

PMID:33030582
Participants:101
Impact:+5 days delay on average (p=0.031)
Trust score:4/5

urinary and fecal magnesium loss

1 evidences

In healthy male volunteers, magnesium supplementation during prolonged reduced movement (hypokinesia) was associated with larger decreases in muscle magnesium and increased plasma and excreted magnesium compared with controls.

Trust comment: Controlled human study but small sample, long duration and specific conditions (hypokinesia) limit generalizability.

Study Details

PMID:20363596
Participants:40
Impact:increased (P<0.05) with hypokinesia, more so with supplementation
Trust score:3/5

24-h urinary cortisol excretion

1 evidences

Daily oral magnesium (350 mg) for 24 weeks lowered 24‑h urinary cortisol and altered cortisol/cortisone and metabolite ratios consistent with increased cortisol inactivation (increased 11β‑HSD2 activity).

Trust comment: Randomized double-blind placebo-controlled trial with objective urinary measures and good compliance, but this is a post-hoc/exploratory analysis and not adjusted for multiple comparisons.

Study Details

PMID:33030273
Participants:49
Impact:−32 nmol/24-h (95% CI −59; −5; p = .021)
Trust score:4/5

cortisol/cortisone ratio (index of 11β‑HSD2)

1 evidences

Daily oral magnesium (350 mg) for 24 weeks lowered 24‑h urinary cortisol and altered cortisol/cortisone and metabolite ratios consistent with increased cortisol inactivation (increased 11β‑HSD2 activity).

Trust comment: Randomized double-blind placebo-controlled trial with objective urinary measures and good compliance, but this is a post-hoc/exploratory analysis and not adjusted for multiple comparisons.

Study Details

PMID:33030273
Participants:49
Impact:−0.10 nmol/nmol (95% CI −0.17; −0.03; p = .005)
Trust score:4/5

THFs/THE (overall 11β‑HSD activity)

1 evidences

Daily oral magnesium (350 mg) for 24 weeks lowered 24‑h urinary cortisol and altered cortisol/cortisone and metabolite ratios consistent with increased cortisol inactivation (increased 11β‑HSD2 activity).

Trust comment: Randomized double-blind placebo-controlled trial with objective urinary measures and good compliance, but this is a post-hoc/exploratory analysis and not adjusted for multiple comparisons.

Study Details

PMID:33030273
Participants:49
Impact:−0.09 μmol/μmol (95% CI −0.17; −0.02; p = .018)
Trust score:4/5

serum potassium

3 evidences

Potassium‑magnesium citrate corrected thiazide-induced low potassium; higher doses modestly increased serum magnesium and urinary magnesium and dose-dependently raised urinary pH and citrate.

Trust comment: Randomized study with clear biochemical endpoints and dose-response data in humans; moderate sample size but appropriate design.

Study Details

PMID:10423646
Participants:61
Impact:increased; >80% of subjects regained normal values despite continued thiazide therapy
Trust score:4/5

In healthy volunteers on thiazides, potassium-magnesium citrate formulations corrected hypokalemia; two formulations modestly raised serum magnesium and urinary pH/citrate more than the third.

Trust comment: Randomized comparison in 62 healthy volunteers with objective biochemical endpoints; tolerability differences noted.

Study Details

PMID:9824785
Participants:62
Impact:corrected by all three K-Mg citrate formulations
Trust score:4/5

In volunteers on thiazide, potassium-magnesium-citrate prevented magnesium depletion and maintained potassium better than potassium chloride.

Trust comment: Double-blind randomized trial but small sample (n=22) with physiologic and biochemical endpoints reported.

Study Details

PMID:16645424
Participants:22
Impact:maintained (no significant decline with K-Mg-citrate over 6 months)
Trust score:4/5

ionized magnesium concentration

1 evidences

Adding EDTA to propofol did not alter ionized magnesium or calcium levels, haemodynamics, or other measured safety labs in cardiac surgery patients.

Trust comment: Large, randomized, double-blind multicenter trial but not primarily an intervention testing magnesium supplementation — measured Mg as a safety parameter.

Study Details

PMID:11310907
Participants:102
Impact:no significant change between groups
Trust score:3/5

ionized calcium concentration

1 evidences

Adding EDTA to propofol did not alter ionized magnesium or calcium levels, haemodynamics, or other measured safety labs in cardiac surgery patients.

Trust comment: Large, randomized, double-blind multicenter trial but not primarily an intervention testing magnesium supplementation — measured Mg as a safety parameter.

Study Details

PMID:11310907
Participants:102
Impact:no significant change between groups
Trust score:3/5

haemodynamic variables

1 evidences

Adding EDTA to propofol did not alter ionized magnesium or calcium levels, haemodynamics, or other measured safety labs in cardiac surgery patients.

Trust comment: Large, randomized, double-blind multicenter trial but not primarily an intervention testing magnesium supplementation — measured Mg as a safety parameter.

Study Details

PMID:11310907
Participants:102
Impact:no significant change between groups
Trust score:3/5

neurotoxicity incidence

1 evidences

In metastatic colorectal cancer patients receiving mFOLFOX6, peri-infusion calcium/magnesium did not significantly change oxaliplatin-related neurotoxicity, blood/platinum levels, or tumor response compared with placebo.

Trust comment: Double-blind randomized design is strong but small sample likely underpowered to detect modest neuroprotective effects.

Study Details

PMID:20108160
Participants:33
Impact:No significant difference after six cycles (Ca/Mg n=17 vs placebo n=16)
Trust score:3/5

blood platinum concentration/AUC

1 evidences

In metastatic colorectal cancer patients receiving mFOLFOX6, peri-infusion calcium/magnesium did not significantly change oxaliplatin-related neurotoxicity, blood/platinum levels, or tumor response compared with placebo.

Trust comment: Double-blind randomized design is strong but small sample likely underpowered to detect modest neuroprotective effects.

Study Details

PMID:20108160
Participants:33
Impact:No significant difference between groups
Trust score:3/5

tumor response / progression-free survival

1 evidences

In metastatic colorectal cancer patients receiving mFOLFOX6, peri-infusion calcium/magnesium did not significantly change oxaliplatin-related neurotoxicity, blood/platinum levels, or tumor response compared with placebo.

Trust comment: Double-blind randomized design is strong but small sample likely underpowered to detect modest neuroprotective effects.

Study Details

PMID:20108160
Participants:33
Impact:No significant difference (RR and DCR similar; median PFS 9.2 vs 8.1 months)
Trust score:3/5

5-mC methylation at cg16371860 (TMPRSS2 promoter)

1 evidences

Personalized magnesium supplementation (reducing Ca:Mg ratio) changed TMPRSS2 DNA methylation at specific CpG sites in participants <65 years, suggesting potential downregulation of TMPRSS2 expression.

Trust comment: Double-blind RCT with good sample handling and QC (224 samples analyzed); effects are site-specific and strongest in the <65 subgroup.

Study Details

PMID:34116393
Participants:224
Impact:+7.2% (increase vs placebo) in ages <65 y
Trust score:4/5

5-hmC modification at cg26337277 (TMPRSS2 promoter)

1 evidences

Personalized magnesium supplementation (reducing Ca:Mg ratio) changed TMPRSS2 DNA methylation at specific CpG sites in participants <65 years, suggesting potential downregulation of TMPRSS2 expression.

Trust comment: Double-blind RCT with good sample handling and QC (224 samples analyzed); effects are site-specific and strongest in the <65 subgroup.

Study Details

PMID:34116393
Participants:224
Impact:-2.3% (decrease vs placebo) in ages <65 y
Trust score:4/5

mean arterial pressure (MAP)

1 evidences

In hemodialysis patients, low dialysate magnesium (with certain calcium levels) caused marked drops in blood pressure and cardiac performance; increasing dialysate magnesium improved intradialytic stability.

Trust comment: Small, mechanistic crossover and short-term clinical study with clear physiological measures but limited sample size.

Study Details

PMID:15327421
Participants:22
Impact:decrease of 15.2% in group IV (0.25 mmol/L Mg, 1.25 mmol/L Ca) vs others (P < 0.05)
Trust score:3/5

cardiac index / stroke index

1 evidences

In hemodialysis patients, low dialysate magnesium (with certain calcium levels) caused marked drops in blood pressure and cardiac performance; increasing dialysate magnesium improved intradialytic stability.

Trust comment: Small, mechanistic crossover and short-term clinical study with clear physiological measures but limited sample size.

Study Details

PMID:15327421
Participants:22
Impact:cardiac index −12.1% and stroke index −17% in group IV (reported alongside MAP drop)
Trust score:3/5

intradialytic morbidity / hypotension

1 evidences

In hemodialysis patients, low dialysate magnesium (with certain calcium levels) caused marked drops in blood pressure and cardiac performance; increasing dialysate magnesium improved intradialytic stability.

Trust comment: Small, mechanistic crossover and short-term clinical study with clear physiological measures but limited sample size.

Study Details

PMID:15327421
Participants:22
Impact:treatment with 0.75 mmol/L dMg reduced intradialytic morbidity and improved BP stability (P < 0.001 and P < 0.05)
Trust score:3/5

correction of hypomagnesemia

1 evidences

In pooled T2D trial patients, dapagliflozin increased serum magnesium modestly and a higher proportion of patients corrected baseline hypomagnesemia versus placebo over 24 weeks.

Trust comment: Large pooled post hoc analysis of randomized trials yielding precise estimates, but analysis is post hoc and not designed primarily to test magnesium outcomes.

Study Details

PMID:31375422
Participants:4398
Impact:proportion achieving Mg ≥0.74 mmol/L increased by +47.8 percentage points vs placebo (95% CI 41.4, 53.9)
Trust score:4/5

office systolic blood pressure (SBP)

1 evidences

Randomized trial in women with metabolic syndrome: oral magnesium L‑lactate reduced systolic blood pressure and ambulatory heart rate but did not change QTc.

Trust comment: Randomized interventional trial with modest sample size; results suggest BP/HR benefits but would benefit from larger confirmatory studies.

Study Details

PMID:37010174
Participants:58
Impact:↓ (significant reduction vs baseline/placebo)
Trust score:3/5

ambulatory heart rate (HR)

1 evidences

Randomized trial in women with metabolic syndrome: oral magnesium L‑lactate reduced systolic blood pressure and ambulatory heart rate but did not change QTc.

Trust comment: Randomized interventional trial with modest sample size; results suggest BP/HR benefits but would benefit from larger confirmatory studies.

Study Details

PMID:37010174
Participants:58
Impact:↓ (significant reduction on magnesium)
Trust score:3/5

Corrected QT interval (QTc)

1 evidences

Randomized trial in women with metabolic syndrome: oral magnesium L‑lactate reduced systolic blood pressure and ambulatory heart rate but did not change QTc.

Trust comment: Randomized interventional trial with modest sample size; results suggest BP/HR benefits but would benefit from larger confirmatory studies.

Study Details

PMID:37010174
Participants:58
Impact:no significant change
Trust score:3/5

muscle flexibility (ankle dorsiflexion)

1 evidences

Topical MagPro™ cream did not improve muscle flexibility or endurance compared with placebo in active adults.

Trust comment: Double-blind randomized controlled design but small sample and topical application limits systemic magnesium exposure.

Study Details

PMID:22067254
Participants:38
Impact:no significant change
Trust score:3/5

muscle endurance (cycling bouts)

1 evidences

Topical MagPro™ cream did not improve muscle flexibility or endurance compared with placebo in active adults.

Trust comment: Double-blind randomized controlled design but small sample and topical application limits systemic magnesium exposure.

Study Details

PMID:22067254
Participants:38
Impact:no significant change
Trust score:3/5

small arterial compliance

1 evidences

Chronic oral magnesium (800 mg/day) for 3 months improved small arterial compliance in symptomatic heart failure patients.

Trust comment: Randomized trial with objective vascular measures but small sample size limits generalizability.

Study Details

PMID:16470086
Participants:22
Impact:improved at 3 months (vs placebo)
Trust score:3/5

exercise capacity

1 evidences

Chronic oral magnesium (800 mg/day) for 3 months improved small arterial compliance in symptomatic heart failure patients.

Trust comment: Randomized trial with objective vascular measures but small sample size limits generalizability.

Study Details

PMID:16470086
Participants:22
Impact:no clear improvement reported
Trust score:3/5

quality of life score

1 evidences

Chronic oral magnesium (800 mg/day) for 3 months improved small arterial compliance in symptomatic heart failure patients.

Trust comment: Randomized trial with objective vascular measures but small sample size limits generalizability.

Study Details

PMID:16470086
Participants:22
Impact:no clear improvement reported
Trust score:3/5

serum ionized magnesium

1 evidences

In healthy donors undergoing leukapheresis, IV magnesium prevented drops in ionized magnesium but did not reduce citrate-related symptoms.

Trust comment: Randomized, double-blind placebo-controlled trial in humans but small sample size (30 donors).

Study Details

PMID:15934992
Participants:30
Impact:maintained with Mg (vs 39%±11% decrease with placebo, p<1e-10)
Trust score:4/5

parathyroid hormone response

1 evidences

In healthy donors undergoing leukapheresis, IV magnesium prevented drops in ionized magnesium but did not reduce citrate-related symptoms.

Trust comment: Randomized, double-blind placebo-controlled trial in humans but small sample size (30 donors).

Study Details

PMID:15934992
Participants:30
Impact:greater/more vigorous with Mg supplementation
Trust score:4/5

glucose

1 evidences

In healthy donors undergoing leukapheresis, IV magnesium prevented drops in ionized magnesium but did not reduce citrate-related symptoms.

Trust comment: Randomized, double-blind placebo-controlled trial in humans but small sample size (30 donors).

Study Details

PMID:15934992
Participants:30
Impact:higher with Mg supplementation
Trust score:4/5

successful cardioversion rate

1 evidences

In a large randomized double-blind trial, IV magnesium before electric cardioversion did not improve success rates or reduce energy/shocks required.

Trust comment: Large randomized, double-blind, placebo-controlled trial with clear endpoints and adequate sample size.

Study Details

PMID:27586232
Participants:261
Impact:no difference (86.4% Mg vs 86.0% placebo, P=0.94)
Trust score:5/5

energy required for cardioversion

1 evidences

In a large randomized double-blind trial, IV magnesium before electric cardioversion did not improve success rates or reduce energy/shocks required.

Trust comment: Large randomized, double-blind, placebo-controlled trial with clear endpoints and adequate sample size.

Study Details

PMID:27586232
Participants:261
Impact:no difference (123.3±55.5 J vs 129.5±52.6 J, P=0.40)
Trust score:5/5

number of shocks required

1 evidences

In a large randomized double-blind trial, IV magnesium before electric cardioversion did not improve success rates or reduce energy/shocks required.

Trust comment: Large randomized, double-blind, placebo-controlled trial with clear endpoints and adequate sample size.

Study Details

PMID:27586232
Participants:261
Impact:no difference (2.25±1.24 vs 2.41±1.22, P=0.31)
Trust score:5/5

pain score (Numeric Rating Scale)

1 evidences

Erector spinae plane block reduced pain and pain medication use in post-herpetic neuralgia; adding magnesium to the block did not provide extra benefit.

Trust comment: Randomized double-blind RCT with clear outcomes but single-center and modest sample size.

Study Details

PMID:35901476
Participants:75
Impact:decreased (P<0.05) with ESPB
Trust score:4/5

analgesic consumption (pregabalin and acetaminophen)

1 evidences

Erector spinae plane block reduced pain and pain medication use in post-herpetic neuralgia; adding magnesium to the block did not provide extra benefit.

Trust comment: Randomized double-blind RCT with clear outcomes but single-center and modest sample size.

Study Details

PMID:35901476
Participants:75
Impact:decreased from weeks 3–12 (P<0.05) with ESPB
Trust score:4/5

additional effect of magnesium sulphate in ESPB

1 evidences

Erector spinae plane block reduced pain and pain medication use in post-herpetic neuralgia; adding magnesium to the block did not provide extra benefit.

Trust comment: Randomized double-blind RCT with clear outcomes but single-center and modest sample size.

Study Details

PMID:35901476
Participants:75
Impact:no significant additional benefit (P>0.05)
Trust score:4/5

correlation with disease severity

1 evidences

Case–control study comparing serum minerals between newly diagnosed hemifacial spasm patients and healthy volunteers; reported significant differences in serum calcium, phosphate and magnesium between groups.

Trust comment: Prospective case-control comparison with modest sample size; labeling as randomized appears inconsistent with design.

Study Details

PMID:30417857
Participants:86
Impact:no significant correlation between serum Mg and severity or quality of life
Trust score:3/5

Urinary pH

1 evidences

Different potassium- and magnesium-containing supplements were given to kidney stone patients for one month and urine markers of stone risk were measured.

Trust comment: Human controlled supplementation with clear urinary outcomes but small sample, short duration, and mixed multi-nutrient arms limit attribution to magnesium alone.

Study Details

PMID:15117041
Participants:61
Impact:increase (with K Na citrate and K Mg citrate); decrease (with Mg glycine)
Trust score:3/5

systolic blood pressure (insulin-dependent diabetes)

1 evidences

In a randomized double-blind crossover trial, diabetics received magnesium or vitamin C to assess effects on blood pressure, glucose and lipids.

Trust comment: Randomized double-blind crossover design is strong, but modest sample size and subgroup-specific effects limit broad generalizability.

Study Details

PMID:8546437
Participants:56
Impact:decrease ≈ -6 mmHg (138 → 132 mmHg; p<0.05)
Trust score:4/5

diastolic blood pressure (insulin-dependent diabetes)

1 evidences

In a randomized double-blind crossover trial, diabetics received magnesium or vitamin C to assess effects on blood pressure, glucose and lipids.

Trust comment: Randomized double-blind crossover design is strong, but modest sample size and subgroup-specific effects limit broad generalizability.

Study Details

PMID:8546437
Participants:56
Impact:decrease ≈ -5 mmHg (82 → 77 mmHg; p<0.05)
Trust score:4/5

glycemic control (non-insulin-dependent diabetes)

1 evidences

In a randomized double-blind crossover trial, diabetics received magnesium or vitamin C to assess effects on blood pressure, glucose and lipids.

Trust comment: Randomized double-blind crossover design is strong, but modest sample size and subgroup-specific effects limit broad generalizability.

Study Details

PMID:8546437
Participants:56
Impact:no benefit from magnesium supplementation
Trust score:4/5

Calcium absorption

1 evidences

Healthy men ingested lactulose with calcium and magnesium tracers; urinary isotope ratios showed increased mineral absorption with lactulose.

Trust comment: Double-blind randomized crossover with objective isotope measures is high quality despite small n and short-term measurement.

Study Details

PMID:17484373
Participants:24
Impact:increase (significant for high-dose vs placebo)
Trust score:4/5

bone resorption markers

1 evidences

Healthy men ingested lactulose with calcium and magnesium tracers; urinary isotope ratios showed increased mineral absorption with lactulose.

Trust comment: Double-blind randomized crossover with objective isotope measures is high quality despite small n and short-term measurement.

Study Details

PMID:17484373
Participants:24
Impact:no change
Trust score:4/5

ulcer length

1 evidences

Patients with diabetic foot ulcers received magnesium plus vitamin E or placebo for 12 weeks; ulcer size and many metabolic/inflammatory markers improved with supplementation.

Trust comment: Randomized placebo-controlled design is strong, but co-supplementation with vitamin E prevents attribution of effects to magnesium alone and sample is modest.

Study Details

PMID:30693609
Participants:57
Impact:decrease -0.56 cm (β -0.56; p=0.003)
Trust score:3/5

new-onset postoperative atrial fibrillation incidence

1 evidences

High-dose intraoperative magnesium did not reduce the incidence of new-onset postoperative atrial fibrillation after cardiac surgery.

Trust comment: Large, double-blind, placebo-controlled randomized trial with appropriate adjustments and a null result.

Study Details

PMID:26237622
Participants:363
Impact:42.5% (Mg) vs 37.9% (placebo); absolute +4.6%, not significant (p=0.40)
Trust score:4/5

time to onset of POAF

1 evidences

High-dose intraoperative magnesium did not reduce the incidence of new-onset postoperative atrial fibrillation after cardiac surgery.

Trust comment: Large, double-blind, placebo-controlled randomized trial with appropriate adjustments and a null result.

Study Details

PMID:26237622
Participants:363
Impact:no difference between groups
Trust score:4/5

adjusted odds of POAF

1 evidences

High-dose intraoperative magnesium did not reduce the incidence of new-onset postoperative atrial fibrillation after cardiac surgery.

Trust comment: Large, double-blind, placebo-controlled randomized trial with appropriate adjustments and a null result.

Study Details

PMID:26237622
Participants:363
Impact:OR 1.09 (95% CI 0.69–1.72); not significant
Trust score:4/5

whole blood ionized magnesium (iMg2+)

1 evidences

In this small repeated-measures secondary analysis, short-term self-reported dietary magnesium intake did not correlate with whole blood ionized or serum magnesium concentrations.

Trust comment: Secondary analysis of a small pilot crossover study with limited sample size and reliance on self-reported dietary intake.

Study Details

PMID:37036758
Participants:23
Impact:no association with short-term self-reported dietary Mg (beta −125.4 ± 176.95; p=0.49)
Trust score:3/5

serum magnesium (s-Mg)

1 evidences

In this small repeated-measures secondary analysis, short-term self-reported dietary magnesium intake did not correlate with whole blood ionized or serum magnesium concentrations.

Trust comment: Secondary analysis of a small pilot crossover study with limited sample size and reliance on self-reported dietary intake.

Study Details

PMID:37036758
Participants:23
Impact:no association with short-term dietary Mg (beta −9.33 ± 5.04; p=0.08)
Trust score:3/5

magnesium retention

1 evidences

In controlled metabolic-balance studies of adolescent girls, blacks excreted less urinary magnesium than whites and magnesium retention was higher on a low-sodium diet.

Trust comment: Controlled metabolic-balance crossover study with objective intake/excretion measures in a reasonably sized cohort, supporting internal validity.

Study Details

PMID:23553157
Participants:67
Impact:higher with low-sodium diet (50.1 ± 44.0 mg/d) vs high-sodium (39.3 ± 49.8 mg/d); p<0.05
Trust score:4/5

fecal magnesium excretion

1 evidences

In controlled metabolic-balance studies of adolescent girls, blacks excreted less urinary magnesium than whites and magnesium retention was higher on a low-sodium diet.

Trust comment: Controlled metabolic-balance crossover study with objective intake/excretion measures in a reasonably sized cohort, supporting internal validity.

Study Details

PMID:23553157
Participants:67
Impact:no significant effect of salt or calcium intake
Trust score:4/5

ionized magnesium level

1 evidences

Giving magnesium sulfate during cardiopulmonary bypass in children raised ionized magnesium and reduced hypomagnesemia and postoperative junctional ectopic tachycardia, with a dose-related effect.

Trust comment: Randomized double-blind pediatric RCT with clear outcome measures and dose-response, moderate sample size (n=99).

Study Details

PMID:19819469
Participants:99
Impact:+0.06 (group2 vs placebo), +0.08 (group3 vs placebo) (0.51 → 0.57 and 0.59)
Trust score:4/5

hypomagnesemia incidence

1 evidences

Giving magnesium sulfate during cardiopulmonary bypass in children raised ionized magnesium and reduced hypomagnesemia and postoperative junctional ectopic tachycardia, with a dose-related effect.

Trust comment: Randomized double-blind pediatric RCT with clear outcome measures and dose-response, moderate sample size (n=99).

Study Details

PMID:19819469
Participants:99
Impact:placebo 77.8% → group2 63% (-14.8 percentage points), group3 47.4% (-30.4 percentage points)
Trust score:4/5

junctional ectopic tachycardia incidence

1 evidences

Giving magnesium sulfate during cardiopulmonary bypass in children raised ionized magnesium and reduced hypomagnesemia and postoperative junctional ectopic tachycardia, with a dose-related effect.

Trust comment: Randomized double-blind pediatric RCT with clear outcome measures and dose-response, moderate sample size (n=99).

Study Details

PMID:19819469
Participants:99
Impact:placebo 17.9% → group2 6.7% (-11.2 pp), group3 0% (-17.9 pp)
Trust score:4/5

arterial oxygen saturation (SaO2) change

1 evidences

Oral magnesium (300 mg/day) in hospitalized moderate COVID-19 patients increased serum magnesium, improved oxygenation, reduced need for oxygen therapy, and improved quality of life and depression scores compared with placebo.

Trust comment: Double-blind randomized trial with appropriate outcomes but single-center and modest sample (n=60) limits generalizability.

Study Details

PMID:38654355
Participants:60
Impact:magnesium +4.55 ±2.35 vs placebo +1.80 ±1.67 (between-group P<0.001)
Trust score:4/5

dietary magnesium intake

1 evidences

A low-sodium diet in pregnancy reduced magnesium intake but maternal magnesium homeostasis was maintained via reduced urinary excretion.

Trust comment: Randomized dietary trial with modest sample size and biochemical measures, but indirect assessment of magnesium effects and limited numeric detail in excerpt.

Study Details

PMID:9175991
Participants:94
Impact:significant decrease (low-Na group vs control; exact amounts not reported in excerpt)
Trust score:3/5

serum phosphorus

1 evidences

Infants fed an amino-acid formula maintained normal blood phosphorus, calcium, and magnesium after 16 weeks, including those on acid-suppressive drugs.

Trust comment: Data from a randomized double-blind trial's subgroup (retrospective subgroup analysis, not randomized by acid-suppressive use) with measured serum values.

Study Details

PMID:31425366
Participants:66
Impact:maintained (within reference at 16 weeks)
Trust score:4/5

pain score (VAS)

1 evidences

Adding 200 mg epidural magnesium to local anaesthetic+steroid reduced leg radicular pain and improved function up to 3 months.

Trust comment: Randomized, double-blind, controlled trial with 100 patients showing consistent between-group differences (p-values reported).

Study Details

PMID:33559245
Participants:100
Impact:greater decrease vs control at all time points (p<0.001)
Trust score:4/5

functional ability (Modified Oswestry Disability Questionnaire)

1 evidences

Adding 200 mg epidural magnesium to local anaesthetic+steroid reduced leg radicular pain and improved function up to 3 months.

Trust comment: Randomized, double-blind, controlled trial with 100 patients showing consistent between-group differences (p-values reported).

Study Details

PMID:33559245
Participants:100
Impact:greater improvement vs control at all time points (p<0.001)
Trust score:4/5

RASS score (sedation/agitation)

1 evidences

Double-blind RCT in older adults undergoing EVAR testing intraoperative magnesium infusion versus saline for effects on postoperative sedation, delirium and pain.

Trust comment: Well-conducted double-blind RCT with clear biochemical effects but limited by single center and lower-than-expected delirium incidence.

Study Details

PMID:36749742
Participants:63
Impact:no significant difference at ICU admission or during 24 h (primary outcome)
Trust score:4/5

pain (NRS)

1 evidences

Double-blind RCT in older adults undergoing EVAR testing intraoperative magnesium infusion versus saline for effects on postoperative sedation, delirium and pain.

Trust comment: Well-conducted double-blind RCT with clear biochemical effects but limited by single center and lower-than-expected delirium incidence.

Study Details

PMID:36749742
Participants:63
Impact:lower pain at 1 h in magnesium group (median 0 vs 3; p=0.048); other time points no difference
Trust score:4/5

ionized/total plasma magnesium

1 evidences

Double-blind RCT in older adults undergoing EVAR testing intraoperative magnesium infusion versus saline for effects on postoperative sedation, delirium and pain.

Trust comment: Well-conducted double-blind RCT with clear biochemical effects but limited by single center and lower-than-expected delirium incidence.

Study Details

PMID:36749742
Participants:63
Impact:increased significantly in magnesium group (ionized 0.66 vs 0.50 mmol/L at ICU admission; p<0.0001)
Trust score:4/5

dietary calcium and potassium intake

1 evidences

Adding dried figs increased dietary mineral intake (by recall) but did not change blood mineral concentrations, including magnesium.

Trust comment: Crossover dietary trial with objective blood measures but modest sample and reliance on self-reported intake for dietary changes.

Study Details

PMID:25156424
Participants:88
Impact:increased during fig-supplemented period (24 h recall; P < 0.05)
Trust score:3/5

blood mineral levels (including magnesium)

1 evidences

Adding dried figs increased dietary mineral intake (by recall) but did not change blood mineral concentrations, including magnesium.

Trust comment: Crossover dietary trial with objective blood measures but modest sample and reliance on self-reported intake for dietary changes.

Study Details

PMID:25156424
Participants:88
Impact:no significant change in biochemical blood mineral measurements
Trust score:3/5

overall atrial fibrillation incidence

1 evidences

Perioperative magnesium raised serum magnesium and modestly reduced early (day 1) postoperative atrial fibrillation but did not significantly reduce overall AF incidence.

Trust comment: Randomized study with adequate sample size and clear endpoints; effect limited to early postoperative day and overall AF reduction was not statistically significant.

Study Details

PMID:14992881
Participants:202
Impact:no significant reduction (30.5% vs 42.3%, p = 0.08)
Trust score:4/5

atrial fibrillation on postoperative day 1

1 evidences

Perioperative magnesium raised serum magnesium and modestly reduced early (day 1) postoperative atrial fibrillation but did not significantly reduce overall AF incidence.

Trust comment: Randomized study with adequate sample size and clear endpoints; effect limited to early postoperative day and overall AF reduction was not statistically significant.

Study Details

PMID:14992881
Participants:202
Impact:reduced (3/105 [2.9%] vs 9/97 [9.3%], p = 0.05)
Trust score:4/5

serum magnesium (post-bolus)

1 evidences

Perioperative magnesium raised serum magnesium and modestly reduced early (day 1) postoperative atrial fibrillation but did not significantly reduce overall AF incidence.

Trust comment: Randomized study with adequate sample size and clear endpoints; effect limited to early postoperative day and overall AF reduction was not statistically significant.

Study Details

PMID:14992881
Participants:202
Impact:increased (4.75 mg/dL vs 1.91 mg/dL, p < 0.001)
Trust score:4/5

depression score (Yasavage and Brink)

1 evidences

In elderly type 2 diabetics with hypomagnesemia, oral magnesium chloride was as effective as imipramine for depression score improvement and raised serum magnesium markedly.

Trust comment: Randomized trial but small, specific population (elderly diabetics with hypomagnesemia) limits broad applicability.

Study Details

PMID:19271419
Participants:23
Impact:no significant difference between Mg and imipramine at 12 weeks (11.4 vs 10.9, p = 0.27)
Trust score:3/5

magnesium adherence to stent

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind clinical trial with clear outcomes and adequate reporting; single-center and moderate sample size are limitations.

Study Details

PMID:40148554
Participants:61
Impact:higher in Hydroplus (group1 median 0.20 mg/dL) vs Tria 0.07 and InLay 0.05 mg/dL (p < 0.01)
Trust score:4/5

calcium adherence to stent

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind clinical trial with clear outcomes and adequate reporting; single-center and moderate sample size are limitations.

Study Details

PMID:40148554
Participants:61
Impact:higher in Hydroplus (median 5.42 mg/dL) vs Tria 1.92 and InLay 1.98 mg/dL (p = 0.02)
Trust score:4/5

urinary symptom score (USSQ at removal)

1 evidences

After 4 weeks indwelling, stents with Hydroplus coating (Percuflex) accumulated more calcium and magnesium and caused worse urinary symptoms compared with Percushield (Tria) and pHreeCoat (InLay Optima) coated stents.

Trust comment: Randomized single-blind clinical trial with clear outcomes and adequate reporting; single-center and moderate sample size are limitations.

Study Details

PMID:40148554
Participants:61
Impact:worse in Hydroplus group (31.5) vs Tria (25.0) and InLay (22.0), p < 0.01
Trust score:4/5

maximal inspiratory pressure (MIP)

1 evidences

Oral magnesium (300 mg/day) for 8 weeks improved respiratory muscle strength and clinical score in children/adolescents with cystic fibrosis.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial with objective physiologic endpoints and clear statistically significant effects.

Study Details

PMID:22648717
Participants:44
Impact:+11% predicted after magnesium vs +0.5% after placebo (P < 0.001)
Trust score:4/5

maximal expiratory pressure (MEP)

1 evidences

Oral magnesium (300 mg/day) for 8 weeks improved respiratory muscle strength and clinical score in children/adolescents with cystic fibrosis.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial with objective physiologic endpoints and clear statistically significant effects.

Study Details

PMID:22648717
Participants:44
Impact:+11.9% predicted after magnesium vs +0.8% after placebo (P < 0.001)
Trust score:4/5

Shwachman–Kulczycki (SK) clinical score

1 evidences

Oral magnesium (300 mg/day) for 8 weeks improved respiratory muscle strength and clinical score in children/adolescents with cystic fibrosis.

Trust comment: Randomized, double-blind, placebo-controlled crossover trial with objective physiologic endpoints and clear statistically significant effects.

Study Details

PMID:22648717
Participants:44
Impact:+4.48 points after magnesium vs −1.30 after placebo (P < 0.001)
Trust score:4/5

overall cognitive z-score

1 evidences

In patients after aneurysmal subarachnoid hemorrhage, magnesium treatment had no effect on cognitive outcomes at ~12 weeks.

Trust comment: Large randomized trial (derived from MASH‑2) with standardized cognitive assessments but found no effect of magnesium on cognition.

Study Details

PMID:30048027
Participants:209
Impact:no significant difference (magnesium mean z = 0.05 vs placebo mean z = −0.04; RR ~0.99; B non-significant)
Trust score:4/5

pain score change at 30 min

1 evidences

In an ED randomized trial, IV magnesium reduced migraine pain similarly to metoclopramide and prochlorperazine at 30 minutes (non-inferior) but patients more often needed rescue analgesia.

Trust comment: Randomized, double-blind controlled trial with moderate sample size but prematurely terminated and with confounding adjunctive treatments.

Study Details

PMID:33041146
Participants:157
Impact:median −3 points (magnesium), similar to comparators; magnesium non-inferior
Trust score:4/5

need for rescue analgesia (magnesium group)

1 evidences

In an ED randomized trial, IV magnesium reduced migraine pain similarly to metoclopramide and prochlorperazine at 30 minutes (non-inferior) but patients more often needed rescue analgesia.

Trust comment: Randomized, double-blind controlled trial with moderate sample size but prematurely terminated and with confounding adjunctive treatments.

Study Details

PMID:33041146
Participants:157
Impact:43% required rescue analgesia (vs 34% metoclopramide, 33% prochlorperazine)
Trust score:4/5

adverse events (magnesium group)

1 evidences

In an ED randomized trial, IV magnesium reduced migraine pain similarly to metoclopramide and prochlorperazine at 30 minutes (non-inferior) but patients more often needed rescue analgesia.

Trust comment: Randomized, double-blind controlled trial with moderate sample size but prematurely terminated and with confounding adjunctive treatments.

Study Details

PMID:33041146
Participants:157
Impact:reported in 5% of patients (similar/lower than comparators)
Trust score:4/5

constipation score

1 evidences

Oral magnesium sulfate for 1 month improved constipation symptoms and reduced painful bowel evacuation in children with spastic cerebral palsy.

Trust comment: Randomized double-blind RCT with 100 children and clear significant outcomes, though full group-by-group denominators not reported in the excerpt.

Study Details

PMID:33481179
Participants:100
Impact:improved (P < 0.001)
Trust score:4/5

stool frequency

1 evidences

Oral magnesium sulfate for 1 month improved constipation symptoms and reduced painful bowel evacuation in children with spastic cerebral palsy.

Trust comment: Randomized double-blind RCT with 100 children and clear significant outcomes, though full group-by-group denominators not reported in the excerpt.

Study Details

PMID:33481179
Participants:100
Impact:increased (P < 0.001)
Trust score:4/5

painful bowel evacuation attempts

1 evidences

Oral magnesium sulfate for 1 month improved constipation symptoms and reduced painful bowel evacuation in children with spastic cerebral palsy.

Trust comment: Randomized double-blind RCT with 100 children and clear significant outcomes, though full group-by-group denominators not reported in the excerpt.

Study Details

PMID:33481179
Participants:100
Impact:decreased from 55.6% to 22% (−33.6 percentage points; P = 0.001)
Trust score:4/5

serum magnesium normalization

1 evidences

Daily 500 mg magnesium oxide for 8 weeks improved serum magnesium normalization rates and produced greater reductions in depression scores than placebo in hypomagnesemic depressed patients.

Trust comment: Randomized double-blind placebo-controlled trial with clear biochemical and clinical endpoints; reasonable sample but limited to hypomagnesemic depressed patients.

Study Details

PMID:28241991
Participants:60
Impact:normalized in 88.5% (MG) vs 48.1% (PG) (P = 0.002)
Trust score:4/5

depression severity (Beck Depression Inventory-II)

1 evidences

Daily 500 mg magnesium oxide for 8 weeks improved serum magnesium normalization rates and produced greater reductions in depression scores than placebo in hypomagnesemic depressed patients.

Trust comment: Randomized double-blind placebo-controlled trial with clear biochemical and clinical endpoints; reasonable sample but limited to hypomagnesemic depressed patients.

Study Details

PMID:28241991
Participants:60
Impact:greater mean reduction in magnesium group: −15.65 ± 8.9 vs −10.40 ± 7.9 in placebo (P = 0.02)
Trust score:4/5

postoperative atrial tachyarrhythmias (POAT) incidence

1 evidences

In CABG patients, postoperative magnesium (given alone or with digoxin/propranolol) did not reduce atrial tachyarrhythmias, whereas propranolol did.

Trust comment: Large randomized clinical trial (n=400) with clear primary outcome showing no benefit of magnesium for POAT.

Study Details

PMID:11312480
Participants:400
Impact:no effect (38% in magnesium-only vs 38% control)
Trust score:4/5

serum calcification propensity (T50)

1 evidences

Randomized double-blind trial in hemodialysis patients: increasing dialysate magnesium from 1.0 to 2.0 mEq/L for 28 days increased T50 (reduced calcification propensity).

Trust comment: Single-center randomized double-blind controlled trial with 57 completers and a clear, significant primary outcome.

Study Details

PMID:30131425
Participants:57
Impact:+73 minutes (between-group difference at follow-up; P=0.001)
Trust score:4/5

height-for-age (linear growth)

1 evidences

Measured serum magnesium in malnourished and healthy children and found lower Mg in more severe malnutrition and growth retardation.

Trust comment: Human observational study with clear measurements and moderate sample size but cross-sectional design limits causal inference.

Study Details

PMID:9604603
Participants:58
Impact:positively correlated with serum magnesium (lower height-for-age associated with lower Mg)
Trust score:3/5

serum albumin

1 evidences

Measured serum magnesium in malnourished and healthy children and found lower Mg in more severe malnutrition and growth retardation.

Trust comment: Human observational study with clear measurements and moderate sample size but cross-sectional design limits causal inference.

Study Details

PMID:9604603
Participants:58
Impact:significant correlation with serum magnesium (lower albumin associated with lower Mg)
Trust score:3/5

hearing loss at 500 Hz (3 months)

1 evidences

Randomized double-blind trial of vitamins A, C, E plus magnesium (ACEMg) vs placebo in cochlear implant patients; a non-significant tendency toward less hearing loss with ACEMg was observed but trial was prematurely discontinued and underpowered.

Trust comment: Well-designed randomized double-blind trial but prematurely discontinued and underpowered, so efficacy conclusions are tentative.

Study Details

PMID:32665006
Participants:51
Impact:placebo mean loss 30.21 dB vs ACEMg 26.00 dB; difference −4.15 dB (95% CI −12.95, 4.65), p=0.3468 (not significant)
Trust score:3/5

hearing loss at 500 Hz (per-protocol)

1 evidences

Randomized double-blind trial of vitamins A, C, E plus magnesium (ACEMg) vs placebo in cochlear implant patients; a non-significant tendency toward less hearing loss with ACEMg was observed but trial was prematurely discontinued and underpowered.

Trust comment: Well-designed randomized double-blind trial but prematurely discontinued and underpowered, so efficacy conclusions are tentative.

Study Details

PMID:32665006
Participants:51
Impact:placebo mean 29.17 dB vs ACEMg 23.64 dB; estimated difference −8.01 dB (not significant)
Trust score:3/5

adverse events / safety

1 evidences

Randomized double-blind trial of vitamins A, C, E plus magnesium (ACEMg) vs placebo in cochlear implant patients; a non-significant tendency toward less hearing loss with ACEMg was observed but trial was prematurely discontinued and underpowered.

Trust comment: Well-designed randomized double-blind trial but prematurely discontinued and underpowered, so efficacy conclusions are tentative.

Study Details

PMID:32665006
Participants:51
Impact:ACEMg generally well tolerated; fewer AEs/SAEs numerically versus placebo
Trust score:3/5

Time Get Up and Go (TGUG) time

1 evidences

In vitamin D–deficient middle-aged women, 8 weeks of weekly 50,000 IU vitamin D plus daily magnesium improved muscle strength and function and raised serum vitamin D.

Trust comment: Randomized trial with adequate reporting, but because vitamin D and magnesium were co-administered, effects cannot be attributed to magnesium alone.

Study Details

PMID:32955720
Participants:83
Impact:decreased (improved; significant vs placebo)
Trust score:4/5

Serum 25(OH)D

1 evidences

In vitamin D–deficient middle-aged women, 8 weeks of weekly 50,000 IU vitamin D plus daily magnesium improved muscle strength and function and raised serum vitamin D.

Trust comment: Randomized trial with adequate reporting, but because vitamin D and magnesium were co-administered, effects cannot be attributed to magnesium alone.

Study Details

PMID:32955720
Participants:83
Impact:increased (significant)
Trust score:4/5

Overall tolerability

1 evidences

Open-label randomized multicenter study in women with premature labor found IV magnesium sulfate generally well tolerated with mostly mild local and systemic adverse events.

Trust comment: Multicenter randomized safety study but open-label with modest sample size and no efficacy endpoints.

Study Details

PMID:12648863
Participants:47
Impact:generally good; 72.5% rated very good or good
Trust score:3/5

local adverse events

1 evidences

Open-label randomized multicenter study in women with premature labor found IV magnesium sulfate generally well tolerated with mostly mild local and systemic adverse events.

Trust comment: Multicenter randomized safety study but open-label with modest sample size and no efficacy endpoints.

Study Details

PMID:12648863
Participants:47
Impact:injection site pain, itching, erythema, swelling common
Trust score:3/5

Toxic serum magnesium (>2.5 mmol/L)

1 evidences

Open-label randomized multicenter study in women with premature labor found IV magnesium sulfate generally well tolerated with mostly mild local and systemic adverse events.

Trust comment: Multicenter randomized safety study but open-label with modest sample size and no efficacy endpoints.

Study Details

PMID:12648863
Participants:47
Impact:not observed
Trust score:3/5

physical comfort / physical independence

1 evidences

An IV magnesium infusion before anesthesia improved early postoperative recovery scores and physical comfort after laparoscopic cholecystectomy.

Trust comment: Prospective randomized double-blind trial with a reasonable sample size and clinically relevant recovery endpoints.

Study Details

PMID:33074940
Participants:114
Impact:improved in magnesium group vs control
Trust score:4/5

plasma parathormone (iPTH)

1 evidences

In hemodialysis patients, 12 weeks of magnesium carbonate reduced phosphate and parathormone and improved calcium-phosphate balance.

Trust comment: Human clinical treatment with randomized groups but small and uneven group sizes and some non-random allocation reduce confidence.

Study Details

PMID:21812357
Participants:64
Impact:-82.9 pg/mL (~-15.8%)
Trust score:3/5

calcium-phosphate product (Ca x P)

1 evidences

In hemodialysis patients, 12 weeks of magnesium carbonate reduced phosphate and parathormone and improved calcium-phosphate balance.

Trust comment: Human clinical treatment with randomized groups but small and uneven group sizes and some non-random allocation reduce confidence.

Study Details

PMID:21812357
Participants:64
Impact:-1.1 mmol2/L2 (~-23.9%)
Trust score:3/5

lean body mass

1 evidences

74 overweight middle-aged women received 250 mg Mg/day or placebo for 8 weeks; small within-group changes occurred but no significant benefits versus placebo.

Trust comment: Double-blind randomized placebo-controlled trial of moderate size; outcomes largely not significant between groups.

Study Details

PMID:23619906
Participants:74
Impact:increase vs baseline (P=0.05) but not significant versus placebo
Trust score:4/5

systolic blood pressure (SBP)

1 evidences

In this birth cohort, higher dairy and higher magnesium (dietary) intakes in early life were associated with modestly lower blood pressure at age 8.

Trust comment: Observational cohort with moderate sample size showing associations but not causal evidence.

Study Details

PMID:22234043
Participants:335
Impact:-2.5 mm Hg (highest vs lowest dairy quintile at 18 months); negative linear trend with magnesium intake
Trust score:3/5

diastolic blood pressure (DBP)

1 evidences

In this birth cohort, higher dairy and higher magnesium (dietary) intakes in early life were associated with modestly lower blood pressure at age 8.

Trust comment: Observational cohort with moderate sample size showing associations but not causal evidence.

Study Details

PMID:22234043
Participants:335
Impact:-1.9 mm Hg (highest vs lowest dairy quintile); 56.5 vs 59.3 mm Hg in consistent high dairy consumers (P=0.006)
Trust score:3/5

serum Ca/Mg ratio

1 evidences

Cross-sectional study of 90 healthy adults found higher drinking-water magnesium and serum Mg associated with lower diastolic BP and relationships with lipids and glucose indices.

Trust comment: Observational cross-sectional design with modest sample size; associations reported but not causal.

Study Details

PMID:22361711
Participants:90
Impact:predicted glucose levels (association)
Trust score:3/5

duration of spinal analgesia

1 evidences

In 52 laboring patients, adding 50 mg intrathecal magnesium to fentanyl prolonged median spinal analgesia duration from 60 to 75 minutes without increased side effects.

Trust comment: Prospective randomized controlled trial with clear clinical endpoint and reported median difference; sample moderate but appropriate for the setting.

Study Details

PMID:12198056
Participants:52
Impact:median increase +15 min (75 vs 60 min)
Trust score:4/5

total cardiovascular disease risk

1 evidences

In this large prospective cohort of women, higher dietary magnesium intake was not significantly associated with lower risk of total cardiovascular disease or coronary heart disease.

Trust comment: Large prospective cohort with long follow-up and many events, but observational design limits causal inference.

Study Details

PMID:16214452
Participants:39876
Impact:no significant association (highest vs lowest quintile RR 0.87, 95% CI 0.72–1.05; p for trend=0.24)
Trust score:4/5

stroke and MI

1 evidences

In this large prospective cohort of women, higher dietary magnesium intake was not significantly associated with lower risk of total cardiovascular disease or coronary heart disease.

Trust comment: Large prospective cohort with long follow-up and many events, but observational design limits causal inference.

Study Details

PMID:16214452
Participants:39876
Impact:no significant associations observed for nonfatal MI or total stroke
Trust score:4/5

MVP symptom count

1 evidences

Many symptomatic mitral valve prolapse patients had low serum magnesium; magnesium supplementation markedly reduced symptom count and catecholamine excretion in treated patients.

Trust comment: Large cohort assessment and double-blind crossover supplementation in hypomagnesemic patients support moderate–high internal validity though exact supplement sample size unclear.

Study Details

PMID:9070556
Participants:141
Impact:decreased from 10.4 to 5.6 symptoms per patient after 5 weeks (−4.8 symptoms, p < 0.0001)
Trust score:4/5

noradrenaline excretion

1 evidences

Many symptomatic mitral valve prolapse patients had low serum magnesium; magnesium supplementation markedly reduced symptom count and catecholamine excretion in treated patients.

Trust comment: Large cohort assessment and double-blind crossover supplementation in hypomagnesemic patients support moderate–high internal validity though exact supplement sample size unclear.

Study Details

PMID:9070556
Participants:141
Impact:reduced (patients with high excretion fell from 63% to 17%, p < 0.01)
Trust score:4/5

adrenaline excretion

1 evidences

Many symptomatic mitral valve prolapse patients had low serum magnesium; magnesium supplementation markedly reduced symptom count and catecholamine excretion in treated patients.

Trust comment: Large cohort assessment and double-blind crossover supplementation in hypomagnesemic patients support moderate–high internal validity though exact supplement sample size unclear.

Study Details

PMID:9070556
Participants:141
Impact:mean daily excretion significantly decreased after magnesium (p < 0.01)
Trust score:4/5

forced expiratory rate

1 evidences

Inhaled magnesium showed no meaningful bronchodilator benefit versus placebo in patients with mild to severe asthma.

Trust comment: Small (n=39) double-blind, placebo-controlled crossover trial but reported only modest/insignificant effects for magnesium.

Study Details

PMID:16369066
Participants:39
Impact:no significant improvement vs placebo
Trust score:3/5

respiratory rate

1 evidences

Inhaled magnesium showed no meaningful bronchodilator benefit versus placebo in patients with mild to severe asthma.

Trust comment: Small (n=39) double-blind, placebo-controlled crossover trial but reported only modest/insignificant effects for magnesium.

Study Details

PMID:16369066
Participants:39
Impact:no significant change vs placebo
Trust score:3/5

Heart rate

1 evidences

Inhaled magnesium showed no meaningful bronchodilator benefit versus placebo in patients with mild to severe asthma.

Trust comment: Small (n=39) double-blind, placebo-controlled crossover trial but reported only modest/insignificant effects for magnesium.

Study Details

PMID:16369066
Participants:39
Impact:no significant change vs placebo
Trust score:3/5

plasma magnesium

3 evidences

High‑dose oral magnesium for 3 months corrected hypomagnesemia in type II diabetic patients but did not change glycemic control (HbA1c).

Trust comment: Randomized double-blind placebo-controlled trial but small sample and limited metabolic impact despite biochemical correction.

Study Details

PMID:7729296
Participants:40
Impact:increased from ~0.73 to ~0.81 mmol/L after 3 months (significant)
Trust score:3/5

28-day magnesium supplementation was associated with reduced nicotine dependence scores and cigarette consumption and raised plasma magnesium in psychiatric smokers.

Trust comment: Small clinical cohort with measurable biomarker and behavioral changes but potential confounding (concomitant benzodiazepines) and limited control details.

Study Details

PMID:15724865
Participants:53
Impact:increased from 17.2 ± 1.2 mg/L to 26.1 ± 1.6 mg/L (P < 0.01)
Trust score:3/5

In 52 men after CABG, daily small-dose beer raised plasma magnesium without obvious liver harm over 30 days.

Trust comment: Randomized trial in clinically stable post-CABG men; small sample and short duration limit generalizability.

Study Details

PMID:10730110
Participants:52
Impact:+0.09 mmol/L (from 0.89 to 0.98 mmol/L; ≈+10%)
Trust score:4/5

glycemic control (HbA1c)

1 evidences

High‑dose oral magnesium for 3 months corrected hypomagnesemia in type II diabetic patients but did not change glycemic control (HbA1c).

Trust comment: Randomized double-blind placebo-controlled trial but small sample and limited metabolic impact despite biochemical correction.

Study Details

PMID:7729296
Participants:40
Impact:no meaningful change (≈7.4% before vs ≈7.2% after; not altered)
Trust score:3/5

implant stability (ISQ)

1 evidences

Oral magnesium citrate after immediate dental implant placement improved implant stability, peri-implant radiodensity, reduced horizontal and vertical bone gaps and reduced postoperative pain.

Trust comment: Randomized trial with objective radiographic and stability measures but small sample (n=54) and single-center dental setting limits generalizability.

Study Details

PMID:38820086
Participants:54
Impact:significant improvement at 12 weeks in magnesium group (intergroup and intragroup)
Trust score:3/5

peri-implant radiodensity

1 evidences

Oral magnesium citrate after immediate dental implant placement improved implant stability, peri-implant radiodensity, reduced horizontal and vertical bone gaps and reduced postoperative pain.

Trust comment: Randomized trial with objective radiographic and stability measures but small sample (n=54) and single-center dental setting limits generalizability.

Study Details

PMID:38820086
Participants:54
Impact:significant increase at 6 and 12 weeks in magnesium group (intergroup and intragroup)
Trust score:3/5

horizontal and vertical bone gap (HBG/VBG)

1 evidences

Oral magnesium citrate after immediate dental implant placement improved implant stability, peri-implant radiodensity, reduced horizontal and vertical bone gaps and reduced postoperative pain.

Trust comment: Randomized trial with objective radiographic and stability measures but small sample (n=54) and single-center dental setting limits generalizability.

Study Details

PMID:38820086
Participants:54
Impact:significant reductions at 12 weeks in magnesium group (HBG 12-week change significant intergroup; VBG 12 significant intergroup)
Trust score:3/5

Serum alkaline phosphatase (ALP)

1 evidences

Oral magnesium citrate after immediate dental implant placement improved implant stability, peri-implant radiodensity, reduced horizontal and vertical bone gaps and reduced postoperative pain.

Trust comment: Randomized trial with objective radiographic and stability measures but small sample (n=54) and single-center dental setting limits generalizability.

Study Details

PMID:38820086
Participants:54
Impact:postoperative ALP significantly increased in intervention (P = 0.013)
Trust score:3/5

postoperative pain (NRS)

2 evidences

Oral magnesium citrate after immediate dental implant placement improved implant stability, peri-implant radiodensity, reduced horizontal and vertical bone gaps and reduced postoperative pain.

Trust comment: Randomized trial with objective radiographic and stability measures but small sample (n=54) and single-center dental setting limits generalizability.

Study Details

PMID:38820086
Participants:54
Impact:significant decrease overall and on days 5 and 7 (P = .017 and P = .002)
Trust score:3/5

An IV magnesium infusion before anesthesia improved early postoperative recovery scores and physical comfort after laparoscopic cholecystectomy.

Trust comment: Prospective randomized double-blind trial with a reasonable sample size and clinically relevant recovery endpoints.

Study Details

PMID:33074940
Participants:114
Impact:lower in magnesium group vs control on POD1 (control NRS reported ~3; adjP<0.05)
Trust score:4/5

red blood cell magnesium

1 evidences

Mothers with idiopathic preterm delivery had much lower intracellular (red blood cell) magnesium levels than mothers with term deliveries.

Trust comment: Case-control observational study with reasonable sample size but potential confounding and association only.

Study Details

PMID:23444748
Participants:141
Impact:markedly decreased in preterm delivery group (below physiological values)
Trust score:3/5

systolic blood pressure (water C)

1 evidences

In middle-aged adults with low urinary magnesium, mineral water high in magnesium (and other minerals) increased urinary magnesium excretion and reduced blood pressure (notably with multi-mineral water C).

Trust comment: Randomized intervention with physiological and clinical outcomes but small sample, subgroup exclusions, and exploratory analyses limit certainty.

Study Details

PMID:15571635
Participants:70
Impact:decreased from 156.8 to 150.1 mm Hg at 2 weeks (p = 0.034) and to 150.4 at 4 weeks (p = 0.017)
Trust score:3/5

diastolic blood pressure (water C)

1 evidences

In middle-aged adults with low urinary magnesium, mineral water high in magnesium (and other minerals) increased urinary magnesium excretion and reduced blood pressure (notably with multi-mineral water C).

Trust comment: Randomized intervention with physiological and clinical outcomes but small sample, subgroup exclusions, and exploratory analyses limit certainty.

Study Details

PMID:15571635
Participants:70
Impact:decreased from 91.7 to 88.0 mm Hg at 2 weeks (p = 0.014) and to 89.1 at 4 weeks (p = 0.020)
Trust score:3/5

TNF-α gene expression

1 evidences

Six weeks of 250 mg/day magnesium oxide in women with gestational diabetes reduced pro-inflammatory gene expression and lowered certain neonatal complications.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear molecular and clinical outcomes but small sample (n=36) limits generalizability.

Study Details

PMID:31099333
Participants:36
Impact:downregulated (P = 0.006)
Trust score:4/5

IL-8 gene expression

1 evidences

Six weeks of 250 mg/day magnesium oxide in women with gestational diabetes reduced pro-inflammatory gene expression and lowered certain neonatal complications.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear molecular and clinical outcomes but small sample (n=36) limits generalizability.

Study Details

PMID:31099333
Participants:36
Impact:downregulated (P = 0.03)
Trust score:4/5

TGF-β gene expression

1 evidences

Six weeks of 250 mg/day magnesium oxide in women with gestational diabetes reduced pro-inflammatory gene expression and lowered certain neonatal complications.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear molecular and clinical outcomes but small sample (n=36) limits generalizability.

Study Details

PMID:31099333
Participants:36
Impact:upregulated (P = 0.03)
Trust score:4/5

newborn hyperbilirubinemia

1 evidences

Six weeks of 250 mg/day magnesium oxide in women with gestational diabetes reduced pro-inflammatory gene expression and lowered certain neonatal complications.

Trust comment: Randomized, double-blind, placebo-controlled trial with clear molecular and clinical outcomes but small sample (n=36) limits generalizability.

Study Details

PMID:31099333
Participants:36
Impact:reduced (11.1% vs 44.4%; P = 0.02)
Trust score:4/5

morning systolic and diastolic blood pressure

1 evidences

In a 16-week randomized double-blind pilot trial, a nutraceutical mix containing magnesium produced significant reductions in several morning blood pressure measures and evening systolic BP versus placebo.

Trust comment: Randomized double-blind placebo-controlled pilot but very small sample (n=36), limiting generalizability.

Study Details

PMID:30471072
Participants:36
Impact:decrease (significant vs baseline and placebo)
Trust score:3/5

evening systolic blood pressure

1 evidences

In a 16-week randomized double-blind pilot trial, a nutraceutical mix containing magnesium produced significant reductions in several morning blood pressure measures and evening systolic BP versus placebo.

Trust comment: Randomized double-blind placebo-controlled pilot but very small sample (n=36), limiting generalizability.

Study Details

PMID:30471072
Participants:36
Impact:decrease (significant vs baseline and placebo)
Trust score:3/5

estimated cardiovascular risk

1 evidences

In a 16-week randomized double-blind pilot trial, a nutraceutical mix containing magnesium produced significant reductions in several morning blood pressure measures and evening systolic BP versus placebo.

Trust comment: Randomized double-blind placebo-controlled pilot but very small sample (n=36), limiting generalizability.

Study Details

PMID:30471072
Participants:36
Impact:reduced (significant vs baseline and placebo)
Trust score:3/5

exercise duration

1 evidences

Six months of oral magnesium in patients with coronary artery disease raised intracellular Mg, increased exercise duration, reduced exercise-induced chest pain, and improved quality of life.

Trust comment: Multicenter randomized double-blind placebo-controlled trial (n=187) with clinically meaningful, statistically significant endpoints.

Study Details

PMID:12615252
Participants:187
Impact:+0.9 minutes (8.7 vs 7.8 min, p=0.0075)
Trust score:4/5

exercise-induced chest pain

1 evidences

Six months of oral magnesium in patients with coronary artery disease raised intracellular Mg, increased exercise duration, reduced exercise-induced chest pain, and improved quality of life.

Trust comment: Multicenter randomized double-blind placebo-controlled trial (n=187) with clinically meaningful, statistically significant endpoints.

Study Details

PMID:12615252
Participants:187
Impact:reduced absolute 13% (8% vs 21%, p=0.0237)
Trust score:4/5

pediatric mortality

1 evidences

In a secondary analysis of samples from a tocolytic trial, higher umbilical cord ionized magnesium levels were associated with increased pediatric mortality (7 deaths among 82 with Mg levels measured).

Trust comment: Observational analysis within a trial with small sample (n=82) and few events (n=7); association significant but limited by wide CI.

Study Details

PMID:11430960
Participants:82
Impact:increased association with higher cord ionized Mg (adjusted OR 7.7, 95% CI 1.2–47.6, p=0.03)
Trust score:3/5

cord ionized magnesium level

1 evidences

In a secondary analysis of samples from a tocolytic trial, higher umbilical cord ionized magnesium levels were associated with increased pediatric mortality (7 deaths among 82 with Mg levels measured).

Trust comment: Observational analysis within a trial with small sample (n=82) and few events (n=7); association significant but limited by wide CI.

Study Details

PMID:11430960
Participants:82
Impact:higher median in deaths (0.76 vs 0.55 mmol/L, p=0.03)
Trust score:3/5

blood pressure

1 evidences

In 698 adults with high-normal diastolic BP, daily magnesium supplementation (360 mg) did not significantly change blood pressure at 3 or 6 months overall.

Trust comment: Large randomized, double‑blind, placebo‑controlled trial with high compliance and objective endpoints.

Study Details

PMID:7795837
Participants:698
Impact:no significant change at 3 and 6 months (overall)
Trust score:5/5

perioperative ischemia (ECG changes)

1 evidences

In coronary artery bypass patients, adding magnesium to cardioplegia raised postoperative serum magnesium and reduced perioperative ischemic ECG changes and ventricular ectopy.

Trust comment: Randomized controlled trial but small (n=50); results suggest benefit but limited power.

Study Details

PMID:8857989
Participants:50
Impact:fewer ischemic ECG changes with magnesium (p < 0.03)
Trust score:3/5

ventricular arrhythmia / ventricular ectopy

1 evidences

In coronary artery bypass patients, adding magnesium to cardioplegia raised postoperative serum magnesium and reduced perioperative ischemic ECG changes and ventricular ectopy.

Trust comment: Randomized controlled trial but small (n=50); results suggest benefit but limited power.

Study Details

PMID:8857989
Participants:50
Impact:significantly less ventricular ectopy in magnesium group (p < 0.01)
Trust score:3/5

atrial fibrillation

1 evidences

In coronary artery bypass patients, adding magnesium to cardioplegia raised postoperative serum magnesium and reduced perioperative ischemic ECG changes and ventricular ectopy.

Trust comment: Randomized controlled trial but small (n=50); results suggest benefit but limited power.

Study Details

PMID:8857989
Participants:50
Impact:8 vs 5 cases (control vs magnesium)
Trust score:3/5

Body mass index (BMI)

1 evidences

Randomized trial where adults with metabolic risk drank Mg-enriched water vs placebo for 4 weeks; MEW showed improvements in metabolic markers and gut microbiome diversity.

Trust comment: Randomized clinical trial but small sample (N=30) and short duration (4 weeks), limiting generalizability and long-term conclusions.

Study Details

PMID:39947040
Participants:30
Impact:improved (decreased) with MEW intake
Trust score:3/5

insulin and triglycerides

1 evidences

Randomized trial where adults with metabolic risk drank Mg-enriched water vs placebo for 4 weeks; MEW showed improvements in metabolic markers and gut microbiome diversity.

Trust comment: Randomized clinical trial but small sample (N=30) and short duration (4 weeks), limiting generalizability and long-term conclusions.

Study Details

PMID:39947040
Participants:30
Impact:improvements reported (lowered insulin and triglycerides) with MEW
Trust score:3/5

gut microbiome diversity

1 evidences

Randomized trial where adults with metabolic risk drank Mg-enriched water vs placebo for 4 weeks; MEW showed improvements in metabolic markers and gut microbiome diversity.

Trust comment: Randomized clinical trial but small sample (N=30) and short duration (4 weeks), limiting generalizability and long-term conclusions.

Study Details

PMID:39947040
Participants:30
Impact:greater diversity in MEW group vs placebo
Trust score:3/5

serum C-telopeptides (CTX)

1 evidences

Randomized controlled study where high-calcium milk with added magnesium reduced a marker of bone resorption (serum CTX) in postmenopausal women over 4 weeks without changing serum PTH.

Trust comment: Randomized controlled trial with clear biochemical endpoints and significant CTX changes, but short duration (4 weeks) and modest sample size limit long-term interpretation.

Study Details

PMID:12495258
Participants:50
Impact:decreased in milk group from 0.43 ± 0.04 ng/mL to 0.32 ± 0.02 at 2 weeks and 0.28 ± 0.02 at 4 weeks (p < 0.0001)
Trust score:4/5

serum parathyroid hormone (PTH)

1 evidences

Randomized controlled study where high-calcium milk with added magnesium reduced a marker of bone resorption (serum CTX) in postmenopausal women over 4 weeks without changing serum PTH.

Trust comment: Randomized controlled trial with clear biochemical endpoints and significant CTX changes, but short duration (4 weeks) and modest sample size limit long-term interpretation.

Study Details

PMID:12495258
Participants:50
Impact:no change with time or drink
Trust score:4/5

urinary calcium and magnesium (night)

1 evidences

Randomized controlled study where high-calcium milk with added magnesium reduced a marker of bone resorption (serum CTX) in postmenopausal women over 4 weeks without changing serum PTH.

Trust comment: Randomized controlled trial with clear biochemical endpoints and significant CTX changes, but short duration (4 weeks) and modest sample size limit long-term interpretation.

Study Details

PMID:12495258
Participants:50
Impact:increased during the night in the milk group
Trust score:4/5

EEG resting state theta

1 evidences

Double-blind RCT in 100 moderately stressed adults testing a multi-ingredient supplement containing magnesium; the combined treatment increased EEG resting-state theta after acute social stress.

Trust comment: Well-designed double-blind RCT with 100 participants, but the intervention is a multi-ingredient combination so effects cannot be attributed to magnesium alone.

Study Details

PMID:33896388
Participants:100
Impact:increased (p<.05)
Trust score:4/5

Peripheral blood mononuclear cell magnesium per cell

1 evidences

Study of 28 patients receiving IL-2 therapy showing serum and urinary magnesium fell while lymphocyte magnesium per cell increased during treatment.

Trust comment: Clear biochemical measurements in a small clinical cohort; not a magnesium intervention study, so findings describe Mg dynamics during IL-2 therapy.

Study Details

PMID:11873239
Participants:28
Impact:increased within 24 hours (p<.005)
Trust score:3/5

hsCRP (between-group at end)

1 evidences

Pilot randomized study in 26 prediabetic subjects given oral magnesium (382 mg/day) for 3 months showed no clear anti-inflammatory benefit overall.

Trust comment: Pilot RCT with small sample and limited power; objective measures but mixed and largely non-significant results.

Study Details

PMID:23073360
Participants:26
Impact:lower in magnesium vs control (3.3±2.5 vs 8.0±5.9 mg/L; p=0.03)
Trust score:3/5

hsCRP (within magnesium group)

1 evidences

Pilot randomized study in 26 prediabetic subjects given oral magnesium (382 mg/day) for 3 months showed no clear anti-inflammatory benefit overall.

Trust comment: Pilot RCT with small sample and limited power; objective measures but mixed and largely non-significant results.

Study Details

PMID:23073360
Participants:26
Impact:no significant change from baseline (4.1±3.0 → 3.3±2.5; p=0.45)
Trust score:3/5

TNF-alpha, IL-6, IL-10

1 evidences

Pilot randomized study in 26 prediabetic subjects given oral magnesium (382 mg/day) for 3 months showed no clear anti-inflammatory benefit overall.

Trust comment: Pilot RCT with small sample and limited power; objective measures but mixed and largely non-significant results.

Study Details

PMID:23073360
Participants:26
Impact:no significant differences between groups
Trust score:3/5

urinary potassium concentration (potassium loss)

1 evidences

Adding magnesium to the bypass prime kept magnesium levels during surgery and reduced potassium loss after surgery in children.

Trust comment: Randomized pediatric RCT with clear biochemical outcomes but modest sample size (n=40).

Study Details

PMID:12760983
Participants:40
Impact:decreased at 24 h after CPB (44.2 vs 60.9 mmol/L; −27.5%)
Trust score:4/5

lung function (FEV1)

1 evidences

In this randomized placebo-controlled trial of oral magnesium in stable COPD, magnesium supplementation was associated with lower CRP at 6 months but no clear respiratory or functional benefits.

Trust comment: Randomized double-blind RCT with robust methods but underpowered due to incomplete enrollment, limiting conclusions.

Study Details

PMID:34260036
Participants:49
Impact:no significant improvement in respiratory parameters over time
Trust score:4/5

delayed cerebral ischemia

1 evidences

Magnesium treatment did not reduce the risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Trust comment: Large randomized placebo-controlled phase III trial substudy with clear hazard ratio reporting and adequate sample size.

Study Details

PMID:26502971
Participants:616
Impact:no effect (hazard ratio 1.0; 95% CI 0.7–1.4)
Trust score:5/5

interaction with blood glucose

1 evidences

Magnesium treatment did not reduce the risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Trust comment: Large randomized placebo-controlled phase III trial substudy with clear hazard ratio reporting and adequate sample size.

Study Details

PMID:26502971
Participants:616
Impact:no interaction detected (no modification of magnesium effect by fasting or daily glucose)
Trust score:5/5

clinical outcome (overall)

1 evidences

Magnesium treatment did not reduce the risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Trust comment: Large randomized placebo-controlled phase III trial substudy with clear hazard ratio reporting and adequate sample size.

Study Details

PMID:26502971
Participants:616
Impact:no improvement with magnesium treatment (consistent with main trial findings)
Trust score:5/5

percentage retention of magnesium load (%Ret)

1 evidences

A short (1-h) magnesium-loading test performs like the 8-h standard; magnesium treatment reduced percentage retention and correlated with bone magnesium.

Trust comment: Prospective, randomized-controlled elements and objective biochemical and bone measures across three cohorts (total n=99).

Study Details

PMID:10583708
Participants:99
Impact:decreased with Mg medication (47 ± 43 → 16 ± 26 in transplant patients)
Trust score:4/5

femur (bone) magnesium concentration correlation

1 evidences

A short (1-h) magnesium-loading test performs like the 8-h standard; magnesium treatment reduced percentage retention and correlated with bone magnesium.

Trust comment: Prospective, randomized-controlled elements and objective biochemical and bone measures across three cohorts (total n=99).

Study Details

PMID:10583708
Participants:99
Impact:inverse correlation with %Ret (r = -0.7093)
Trust score:4/5

short MLT vs standard MLT

1 evidences

A short (1-h) magnesium-loading test performs like the 8-h standard; magnesium treatment reduced percentage retention and correlated with bone magnesium.

Trust comment: Prospective, randomized-controlled elements and objective biochemical and bone measures across three cohorts (total n=99).

Study Details

PMID:10583708
Participants:99
Impact:1-h test equivalent to 8-h standard (performance comparable)
Trust score:4/5

new postoperative atrial fibrillation (urgent CABG subgroup)

1 evidences

In 400 CABG patients randomized to cardioplegia with or without magnesium, magnesium reduced intra- and postoperative arrhythmias, notably lowering new postoperative atrial fibrillation in urgent cases.

Trust comment: Large randomized trial (n=400) with clinically important endpoints; subgroup effects noted for urgent CABG patients.

Study Details

PMID:11833996
Participants:400
Impact:reduced (34% → 19%; p = 0.03)
Trust score:4/5

requirement for internal defibrillation and temporary epicardial pacing

1 evidences

In 400 CABG patients randomized to cardioplegia with or without magnesium, magnesium reduced intra- and postoperative arrhythmias, notably lowering new postoperative atrial fibrillation in urgent cases.

Trust comment: Large randomized trial (n=400) with clinically important endpoints; subgroup effects noted for urgent CABG patients.

Study Details

PMID:11833996
Participants:400
Impact:reduced in magnesium-supplemented group (significant in urgent CABG subgroup)
Trust score:4/5

calcium/magnesium ratio (Ca/Mg)

1 evidences

In 96 hypertensive patients, changes in serum magnesium and the Ca/Mg ratio during ACE inhibitor therapy were associated with changes in insulin sensitivity and triglycerides.

Trust comment: Analysis of 96 patients from double-blind ACE inhibitor studies showing correlations but not direct magnesium intervention causality.

Study Details

PMID:9037321
Participants:96
Impact:inverse correlation with insulin sensitivity change (r = -0.27, p < 0.008)
Trust score:3/5

proportion with hearing improvement (>10 dB)

1 evidences

In a randomized double‑blind trial of 28 patients with sudden sensorineural hearing loss, adding oral magnesium to steroids increased the rate and magnitude of hearing improvement, especially at low frequencies.

Trust comment: Randomized, double‑blind, placebo‑controlled trial but small sample (n=28) limiting precision.

Study Details

PMID:15330150
Participants:28
Impact:significantly higher in magnesium group
Trust score:4/5

mean hearing threshold improvement

1 evidences

In a randomized double‑blind trial of 28 patients with sudden sensorineural hearing loss, adding oral magnesium to steroids increased the rate and magnitude of hearing improvement, especially at low frequencies.

Trust comment: Randomized, double‑blind, placebo‑controlled trial but small sample (n=28) limiting precision.

Study Details

PMID:15330150
Participants:28
Impact:significantly greater mean improvement across frequencies (notably low-tone range)
Trust score:4/5

maximum clot firmness (ROTEM)

1 evidences

Intraoperative IV magnesium raised serum magnesium and reduced clot firmness on ROTEM, indicating reduced postoperative hypercoagulability.

Trust comment: Randomized clinical trial with objective coagulation measures and moderate sample size.

Study Details

PMID:25132158
Participants:44
Impact:decreased on postoperative day 3 (p<0.05)
Trust score:4/5

cancer mortality

1 evidences

Higher dietary magnesium intake was associated with lower all-cause, cardiovascular, and cancer mortality in adults at high cardiovascular risk.

Trust comment: Large, well-characterized Mediterranean cohort from a randomized trial (PREDIMED) with multivariable adjustment and robust follow-up.

Study Details

PMID:24259558
Participants:7216
Impact:inversely associated with magnesium intake
Trust score:5/5

anxiety-related premenstrual symptoms

2 evidences

Daily 200 mg magnesium (as MgO) plus 50 mg vitamin B6 for one menstrual cycle produced a small reduction in anxiety-related premenstrual symptoms in women.

Trust comment: Randomized double-blind crossover RCT with clear outcome but small sample and modest effect size; limited by short duration and poor MgO absorption.

Study Details

PMID:10746516
Participants:44
Impact:decrease (significant vs placebo in Mg+B6 group; p=0.040)
Trust score:4/5

Randomized double-blind crossover trial in 85 women testing magnesium vs sorbitol placebo for premenstrual symptoms; sorbitol unexpectedly reduced symptoms.

Trust comment: Well-designed randomized double-blind crossover with 85 participants and significant p-values, but an active placebo complicates interpretation of magnesium's effect.

Study Details

PMID:12018972
Participants:85
Impact:reduced by sorbitol vs magnesium (P<0.001)
Trust score:4/5

urinary magnesium output

1 evidences

Daily 200 mg magnesium (as MgO) plus 50 mg vitamin B6 for one menstrual cycle produced a small reduction in anxiety-related premenstrual symptoms in women.

Trust comment: Randomized double-blind crossover RCT with clear outcome but small sample and modest effect size; limited by short duration and poor MgO absorption.

Study Details

PMID:10746516
Participants:44
Impact:no change reported
Trust score:4/5

cerebrospinal fluid magnesium level

1 evidences

IV magnesium sulfate infusion raised CSF magnesium modestly (sustained for days) in subarachnoid hemorrhage patients.

Trust comment: Small clinical study measuring CSF levels directly; mechanistic/physiologic data but limited sample and no clinical outcome demonstrated.

Study Details

PMID:19658274
Participants:22
Impact:increase +11% to +21% (sustained ≥9 days)
Trust score:3/5

oral opioid use after discharge

1 evidences

Perioperative IV magnesium improved 24‑hour quality of recovery and reduced post-discharge oral opioid use after outpatient segmental mastectomy.

Trust comment: Prospective double-blind RCT with clinically meaningful endpoints and objective opioid use data, although sample is modest.

Study Details

PMID:24491463
Participants:46
Impact:decrease (median 10 mg vs 30 mg morphine equivalents; P<0.001)
Trust score:4/5

postoperative systemic magnesium concentration

1 evidences

Perioperative IV magnesium improved 24‑hour quality of recovery and reduced post-discharge oral opioid use after outpatient segmental mastectomy.

Trust comment: Prospective double-blind RCT with clinically meaningful endpoints and objective opioid use data, although sample is modest.

Study Details

PMID:24491463
Participants:46
Impact:increase (1.25±0.28 vs 0.71±0.11 mmol/L; P<0.0001)
Trust score:4/5

arrhythmia rate

1 evidences

In post-cardiac surgery patients, using ionized magnesium measurement instead of total magnesium did not change arrhythmia rates or amount of magnesium given.

Trust comment: Prospective randomized trial in postoperative patients with clear outcomes, but single-center and moderate sample size limit generalizability.

Study Details

PMID:10178713
Participants:150
Impact:tMg 13/85 (15%) vs iMg 12/65 (18%); no difference
Trust score:4/5

magnesium replacement amount

1 evidences

In post-cardiac surgery patients, using ionized magnesium measurement instead of total magnesium did not change arrhythmia rates or amount of magnesium given.

Trust comment: Prospective randomized trial in postoperative patients with clear outcomes, but single-center and moderate sample size limit generalizability.

Study Details

PMID:10178713
Participants:150
Impact:tMg 1.5 ±0.15 g vs iMg 1.3 ±0.15 g; no difference
Trust score:4/5

mucosal barium coating

1 evidences

In patients undergoing double-contrast barium enema, addition of magnesium improved barium mucosal coating beyond viscosity effects.

Trust comment: Randomized clinical imaging study in humans with clear endpoints, but relevance to systemic magnesium effects is limited.

Study Details

PMID:11519552
Participants:161
Impact:improved in magnesium subgroups vs control (p < 0.008); best in mid-viscosity group
Trust score:3/5

free fluid

1 evidences

In patients undergoing double-contrast barium enema, addition of magnesium improved barium mucosal coating beyond viscosity effects.

Trust comment: Randomized clinical imaging study in humans with clear endpoints, but relevance to systemic magnesium effects is limited.

Study Details

PMID:11519552
Participants:161
Impact:no difference between groups
Trust score:3/5

AOFAS hallux clinical score

1 evidences

A small randomized pilot found degradable magnesium alloy screws produced clinical and radiographic outcomes equivalent to titanium screws at 6 months.

Trust comment: Prospective randomized clinical trial directly testing a magnesium implant, but small sample and short (6-month) follow-up limit generalizability.

Study Details

PMID:23819489
Participants:24
Impact:Improved in both groups; no significant difference between magnesium and titanium
Trust score:4/5

Pain (VAS)

1 evidences

A small randomized pilot found degradable magnesium alloy screws produced clinical and radiographic outcomes equivalent to titanium screws at 6 months.

Trust comment: Prospective randomized clinical trial directly testing a magnesium implant, but small sample and short (6-month) follow-up limit generalizability.

Study Details

PMID:23819489
Participants:24
Impact:Decreased in both groups; no significant difference between magnesium and titanium
Trust score:4/5

Incidence of AMS (prevention trial)

1 evidences

Oral magnesium did not prevent acute mountain sickness; intravenous magnesium modestly reduced symptom scores in established AMS but with limited clinical importance and notable side effects.

Trust comment: Randomized prevention and treatment trials with clear endpoints and adequate reporting, but treatment effects were small and side effects common.

Study Details

PMID:14572305
Participants:61
Impact:No prevention benefit: 20% without AMS (magnesium) vs 16.1% (placebo); prevention failures 40% vs 35.5% (no significant difference)
Trust score:4/5

AMS symptom score (treatment trial)

1 evidences

Oral magnesium did not prevent acute mountain sickness; intravenous magnesium modestly reduced symptom scores in established AMS but with limited clinical importance and notable side effects.

Trust comment: Randomized prevention and treatment trials with clear endpoints and adequate reporting, but treatment effects were small and side effects common.

Study Details

PMID:14572305
Participants:61
Impact:Mean score decreased 11.6 → 9.0 with IV magnesium (mean change -2.6 points; P=0.009); 25% treatment success vs 0% with placebo
Trust score:4/5

adverse effects

1 evidences

Oral magnesium did not prevent acute mountain sickness; intravenous magnesium modestly reduced symptom scores in established AMS but with limited clinical importance and notable side effects.

Trust comment: Randomized prevention and treatment trials with clear endpoints and adequate reporting, but treatment effects were small and side effects common.

Study Details

PMID:14572305
Participants:61
Impact:Oral: loose stools 38.2% (magnesium) vs 11.8% (placebo); IV: transient flushing 75% (magnesium) vs 7.7% (placebo)
Trust score:4/5

mood (POMS: depression, tension, vigour, global score)

1 evidences

A low-sodium, high-potassium diet improved several mood measures versus a DASH-type diet; higher urinary magnesium showed weak associations with increased vigour and lower fatigue.

Trust comment: Crossover dietary intervention with validated mood scales, urine compliance measures, and reasonable sample size.

Study Details

PMID:18466657
Participants:94
Impact:greater improvement on low-sodium, high-potassium diet vs OD (P<0.05)
Trust score:4/5

urinary magnesium correlation

1 evidences

A low-sodium, high-potassium diet improved several mood measures versus a DASH-type diet; higher urinary magnesium showed weak associations with increased vigour and lower fatigue.

Trust comment: Crossover dietary intervention with validated mood scales, urine compliance measures, and reasonable sample size.

Study Details

PMID:18466657
Participants:94
Impact:weak correlations with higher vigour and lower fatigue (r = 0.1–0.2)
Trust score:4/5

serum sodium

1 evidences

In borderline hypertensive adults, switching from low to high dietary sodium changed serum electrolytes and renal filtration but did not alter blood pressure.

Trust comment: Randomized 1-month dietary crossover in 48 subjects with clear biochemical measurements and reported significance levels.

Study Details

PMID:15513697
Participants:48
Impact:increase (p < 0.001)
Trust score:4/5

Urinary citrate / stone risk markers

1 evidences

In volunteers on thiazide, potassium-magnesium-citrate prevented magnesium depletion and maintained potassium better than potassium chloride.

Trust comment: Double-blind randomized trial but small sample (n=22) with physiologic and biochemical endpoints reported.

Study Details

PMID:16645424
Participants:22
Impact:increased urinary citrate and reduced undissociated uric acid (alkali load effects)
Trust score:4/5

24 h urinary magnesium excretion

1 evidences

One month of oral magnesium lactate increased 24 h urinary magnesium but did not alter plasma, red cell, muscle or brain intracellular free magnesium measures in healthy men.

Trust comment: Double-blind placebo-controlled trial with noninvasive, objective biodistribution measures but limited by small sample size (n=30).

Study Details

PMID:10594466
Participants:30
Impact:increased (+1.2 mmol/24 h)
Trust score:4/5

plasma, red cell and intracellular free magnesium (muscle/brain)

1 evidences

One month of oral magnesium lactate increased 24 h urinary magnesium but did not alter plasma, red cell, muscle or brain intracellular free magnesium measures in healthy men.

Trust comment: Double-blind placebo-controlled trial with noninvasive, objective biodistribution measures but limited by small sample size (n=30).

Study Details

PMID:10594466
Participants:30
Impact:no change
Trust score:4/5

erythrocyte magnesium content

1 evidences

Doubling magnesium intake for 28 days increased urinary and erythrocyte magnesium but did not change serum minerals, bone turnover markers, or blood pressure in healthy young women.

Trust comment: Randomized, double-blind, placebo-controlled crossover with objective biochemical measures, but small sample limits generalizability.

Study Details

PMID:10334649
Participants:26
Impact:+5%
Trust score:4/5

blood pressure and bone turnover biomarkers

1 evidences

Doubling magnesium intake for 28 days increased urinary and erythrocyte magnesium but did not change serum minerals, bone turnover markers, or blood pressure in healthy young women.

Trust comment: Randomized, double-blind, placebo-controlled crossover with objective biochemical measures, but small sample limits generalizability.

Study Details

PMID:10334649
Participants:26
Impact:no change
Trust score:4/5

erythrocyte magnesium (Mgrbc)

1 evidences

Five years of 300 mg/day magnesium normalized erythrocyte Mg and slowed or reversed progression of peripheral neuropathy compared with controls.

Trust comment: Randomized long-term clinical trial with 5-year follow-up and objective neurophysiological and clinical outcomes.

Study Details

PMID:15319143
Participants:97
Impact:rose to normal levels in supplemented group (p < 0.0001)
Trust score:4/5

peripheral neuropathy (PNP) staging

1 evidences

Five years of 300 mg/day magnesium normalized erythrocyte Mg and slowed or reversed progression of peripheral neuropathy compared with controls.

Trust comment: Randomized long-term clinical trial with 5-year follow-up and objective neurophysiological and clinical outcomes.

Study Details

PMID:15319143
Participants:97
Impact:improved in 39% vs 8% in controls; worsened in 12% vs 61% (Fisher exact p < 0.0001)
Trust score:4/5

relationship: skeletal muscle Mg vs fasting plasma glucose

1 evidences

Changes in skeletal muscle magnesium were inversely associated with changes in fasting plasma glucose during antihypertensive treatment.

Trust comment: Small (n=37) clinical study using rigorous metabolic measures (clamp) but limited sample size limits generalizability.

Study Details

PMID:12160198
Participants:37
Impact:inverse correlation (r = -0.39, P < .05)
Trust score:3/5

insulin sensitivity

1 evidences

Changes in skeletal muscle magnesium were inversely associated with changes in fasting plasma glucose during antihypertensive treatment.

Trust comment: Small (n=37) clinical study using rigorous metabolic measures (clamp) but limited sample size limits generalizability.

Study Details

PMID:12160198
Participants:37
Impact:no significant correlation with skeletal muscle Mg
Trust score:3/5

glucose tolerance

1 evidences

Changes in skeletal muscle magnesium were inversely associated with changes in fasting plasma glucose during antihypertensive treatment.

Trust comment: Small (n=37) clinical study using rigorous metabolic measures (clamp) but limited sample size limits generalizability.

Study Details

PMID:12160198
Participants:37
Impact:no significant correlation with skeletal muscle Mg
Trust score:3/5

postoperative morphine consumption

1 evidences

Intra-articular magnesium plus ropivacaine during knee replacement reduced postoperative morphine use and early pain scores and sped early functional milestones.

Trust comment: Randomized study in 80 TKA patients showing clear analgesic benefit; single-center and combo drug limits attribution to Mg alone.

Study Details

PMID:20146871
Participants:80
Impact:decreased (0–24 h and total 48 h; significant)
Trust score:4/5

pain scores (rest and motion, first 24 h)

1 evidences

Intra-articular magnesium plus ropivacaine during knee replacement reduced postoperative morphine use and early pain scores and sped early functional milestones.

Trust comment: Randomized study in 80 TKA patients showing clear analgesic benefit; single-center and combo drug limits attribution to Mg alone.

Study Details

PMID:20146871
Participants:80
Impact:decreased (significant)
Trust score:4/5

time to straight leg raise and 90° knee flexion

1 evidences

Intra-articular magnesium plus ropivacaine during knee replacement reduced postoperative morphine use and early pain scores and sped early functional milestones.

Trust comment: Randomized study in 80 TKA patients showing clear analgesic benefit; single-center and combo drug limits attribution to Mg alone.

Study Details

PMID:20146871
Participants:80
Impact:shorter (faster recovery)
Trust score:4/5

Treatment response rate

1 evidences

Drinking a sulphate- and magnesium-rich mineral water led to faster and more frequent treatment responses for functional constipation than low-mineral water.

Trust comment: Large multicenter randomized double-blind trial with objective stool measures but some missing concomitant scoring (60%) and short duration.

Study Details

PMID:31170680
Participants:226
Impact:+21 percentage points (50% vs 29% at day 14)
Trust score:4/5

time to treatment response

1 evidences

Drinking a sulphate- and magnesium-rich mineral water led to faster and more frequent treatment responses for functional constipation than low-mineral water.

Trust comment: Large multicenter randomized double-blind trial with objective stool measures but some missing concomitant scoring (60%) and short duration.

Study Details

PMID:31170680
Participants:226
Impact:-0.9 days (mean 6.4 d vs 7.3 d)
Trust score:4/5

postoperative creatinine clearance

1 evidences

Intra-aortic magnesium given during aortic cross-clamping did not change postoperative renal function compared with saline.

Trust comment: Double-blind pilot study but small sample and several exclusions, showing no renal benefit of intra-aortic magnesium.

Study Details

PMID:10786750
Participants:25
Impact:no change (no difference between magnesium and saline)
Trust score:3/5

urinary N-acetyl-β-D-glucosaminidase

1 evidences

Intra-aortic magnesium given during aortic cross-clamping did not change postoperative renal function compared with saline.

Trust comment: Double-blind pilot study but small sample and several exclusions, showing no renal benefit of intra-aortic magnesium.

Study Details

PMID:10786750
Participants:25
Impact:similar perioperative pattern in both groups (no treatment effect)
Trust score:3/5

urinary risk factors for calcium oxalate stones

1 evidences

Crossover study testing mineral waters high vs low in calcium and magnesium; calcium- and magnesium-rich water more effectively reduced urinary risk factors for calcium oxalate stones.

Trust comment: Crossover design with a reasonable sample and within-subject controls, but detailed numeric effect sizes were not provided in the summary.

Study Details

PMID:9594989
Participants:85
Impact:favorably altered by both waters, significantly more and uniquely altered by Ca/Mg-rich water
Trust score:3/5

stone formation risk

1 evidences

Crossover study testing mineral waters high vs low in calcium and magnesium; calcium- and magnesium-rich water more effectively reduced urinary risk factors for calcium oxalate stones.

Trust comment: Crossover design with a reasonable sample and within-subject controls, but detailed numeric effect sizes were not provided in the summary.

Study Details

PMID:9594989
Participants:85
Impact:reduced by consumption of calcium- and magnesium-rich mineral water
Trust score:3/5

plasma nitric oxide (NO)

1 evidences

Magnesium plus vitamin E for 12 weeks reduced hirsutism and inflammation markers and increased nitric oxide and antioxidant capacity in women with PCOS.

Trust comment: Randomized, double-blind, placebo-controlled trial with adequate reporting of effect sizes.

Study Details

PMID:30565017
Participants:60
Impact:increased (β +3.40 μmol/L; 95% CI 1.46, 5.35; P=0.001)
Trust score:5/5

QoR-15 score (quality of recovery)

1 evidences

An IV magnesium infusion before anesthesia improved early postoperative recovery scores and physical comfort after laparoscopic cholecystectomy.

Trust comment: Prospective randomized double-blind trial with a reasonable sample size and clinically relevant recovery endpoints.

Study Details

PMID:33074940
Participants:114
Impact:increased by 8 points on POD1 in magnesium group vs control (134 vs 126; adjP<0.05)
Trust score:4/5

blood lead concentration

1 evidences

In EDTA chelation-treated patients, urinary magnesium excretion decreased (indicating magnesium retention) while blood lead fell substantially.

Trust comment: Double-blind placebo-controlled trial with clear urinary and blood measures but focused on EDTA chelation rather than magnesium supplementation per se.

Study Details

PMID:8969629
Participants:60
Impact:decreased by ~73% after treatment period
Trust score:3/5

number of nocturnal leg cramps

1 evidences

In a double-blind crossover trial, oral magnesium did not reduce number, duration, severity, or sleep disturbance from nocturnal leg cramps compared with placebo.

Trust comment: Well-designed double-blind randomized crossover trial but modest completed sample size.

Study Details

PMID:10907623
Participants:42
Impact:placebo mean 11.1 vs magnesium 11.8 (mean change +0.7 cramps); no significant difference (P=0.59)
Trust score:4/5

resting systolic and diastolic blood pressure

1 evidences

Pilot randomized trial testing hawthorn and magnesium (600 mg) found declines in blood pressure across groups but no significant difference for magnesium versus placebo.

Trust comment: Small randomized pilot study with limited power and mixed interventions, so negative result for magnesium is inconclusive.

Study Details

PMID:11807965
Participants:36
Impact:declined in all groups including placebo; no significant difference for magnesium vs placebo
Trust score:3/5

fasting intracellular (erythrocyte) magnesium

1 evidences

Hypertensive patients with left ventricular hypertrophy had lower intracellular magnesium and reduced insulin-stimulated intracellular magnesium accumulation linked to insulin resistance.

Trust comment: Controlled physiological study with blinded investigators but small sample size limits generalizability.

Study Details

PMID:7783102
Participants:37
Impact:lower in LVH group (1.85 vs 2.07 mM; P < 0.001)
Trust score:4/5

insulin-mediated intracellular magnesium accumulation

1 evidences

Hypertensive patients with left ventricular hypertrophy had lower intracellular magnesium and reduced insulin-stimulated intracellular magnesium accumulation linked to insulin resistance.

Trust comment: Controlled physiological study with blinded investigators but small sample size limits generalizability.

Study Details

PMID:7783102
Participants:37
Impact:reduced in LVH group (17.9% vs 27.3%; P < 0.01)
Trust score:4/5

insulin-mediated glucose disposal (insulin resistance)

1 evidences

Hypertensive patients with left ventricular hypertrophy had lower intracellular magnesium and reduced insulin-stimulated intracellular magnesium accumulation linked to insulin resistance.

Trust comment: Controlled physiological study with blinded investigators but small sample size limits generalizability.

Study Details

PMID:7783102
Participants:37
Impact:reduced in LVH group (24.8 vs 30.1 µM/kg lean body mass/min; P < 0.05)
Trust score:4/5

regional wall motion (RWM)

1 evidences

In patients with acute anterior MI, early magnesium infusion did not produce significant improvement in regional wall motion compared with control; nicorandil did.

Trust comment: Randomized clinical comparison but small sample size (n=40) limits precision of cardioprotective effect estimates.

Study Details

PMID:14993771
Participants:40
Impact:no significant improvement with magnesium (change 0.44 ±0.80); nicorandil showed greater improvement
Trust score:3/5

emergence delirium incidence / PAED score

1 evidences

In 65 children undergoing strabismus surgery, intraoperative magnesium did not reduce emergence delirium or postoperative pain but lowered emergence diastolic and mean blood pressure.

Trust comment: Randomized, double-blind pediatric RCT with prespecified outcomes and appropriate sample size calculation, though single-center.

Study Details

PMID:33208099
Participants:65
Impact:no significant effect (incidence 78.8% control vs 84.4% magnesium; p = 0.56)
Trust score:4/5

postoperative pain (CHEOPS)

1 evidences

In 65 children undergoing strabismus surgery, intraoperative magnesium did not reduce emergence delirium or postoperative pain but lowered emergence diastolic and mean blood pressure.

Trust comment: Randomized, double-blind pediatric RCT with prespecified outcomes and appropriate sample size calculation, though single-center.

Study Details

PMID:33208099
Participants:65
Impact:no significant difference between groups
Trust score:4/5

emergence hemodynamics (diastolic and mean BP)

1 evidences

In 65 children undergoing strabismus surgery, intraoperative magnesium did not reduce emergence delirium or postoperative pain but lowered emergence diastolic and mean blood pressure.

Trust comment: Randomized, double-blind pediatric RCT with prespecified outcomes and appropriate sample size calculation, though single-center.

Study Details

PMID:33208099
Participants:65
Impact:decreased in magnesium group (diastolic −8 mmHg: 68 → 60, p = 0.004; mean −7 mmHg: 84 → 76, p = 0.015)
Trust score:4/5

intragastric pH

1 evidences

In 24 healthy volunteers, two antacids (one containing magnesium carbonate) produced short-lasting increases in stomach pH versus no drug; the liquid formulation had a faster onset.

Trust comment: Randomized, placebo‑controlled crossover with objective pH measurements but small sample (n=24).

Study Details

PMID:17496418
Participants:24
Impact:significant increase vs placebo during first 30 min
Trust score:4/5

onset of antacid action

1 evidences

In 24 healthy volunteers, two antacids (one containing magnesium carbonate) produced short-lasting increases in stomach pH versus no drug; the liquid formulation had a faster onset.

Trust comment: Randomized, placebo‑controlled crossover with objective pH measurements but small sample (n=24).

Study Details

PMID:17496418
Participants:24
Impact:Riopan (liquid) faster onset (significant pH increase within first 5 min)
Trust score:4/5

diastolic BP in white women (subgroup)

1 evidences

In 698 adults with high-normal diastolic BP, daily magnesium supplementation (360 mg) did not significantly change blood pressure at 3 or 6 months overall.

Trust comment: Large randomized, double‑blind, placebo‑controlled trial with high compliance and objective endpoints.

Study Details

PMID:7795837
Participants:698
Impact:possible decrease suggested in subgroup analyses (hypothesis-generating)
Trust score:5/5

ionized magnesium (Mg2+)

1 evidences

In 55 African‑American adults with acute asthma, baseline ionized magnesium was slightly lower and Ca/Mg ratio higher versus controls; IV magnesium corrected all abnormal divalent ion levels.

Trust comment: Randomized, double‑blind, placebo‑controlled IV magnesium trial with objective ion measurements but modest sample size.

Study Details

PMID:16319040
Participants:55
Impact:lower in asthma patients vs controls by 0.03 mmol/L
Trust score:4/5

Ca2+/Mg2+ ratio

1 evidences

In 55 African‑American adults with acute asthma, baseline ionized magnesium was slightly lower and Ca/Mg ratio higher versus controls; IV magnesium corrected all abnormal divalent ion levels.

Trust comment: Randomized, double‑blind, placebo‑controlled IV magnesium trial with objective ion measurements but modest sample size.

Study Details

PMID:16319040
Participants:55
Impact:higher in asthma patients by 0.27 (mean); abnormal ratios corrected by IV magnesium
Trust score:4/5

correction of abnormal divalent ion levels

1 evidences

In 55 African‑American adults with acute asthma, baseline ionized magnesium was slightly lower and Ca/Mg ratio higher versus controls; IV magnesium corrected all abnormal divalent ion levels.

Trust comment: Randomized, double‑blind, placebo‑controlled IV magnesium trial with objective ion measurements but modest sample size.

Study Details

PMID:16319040
Participants:55
Impact:100% of abnormal cases corrected with IV magnesium
Trust score:4/5

eclampsia incidence

1 evidences

Giving magnesium sulfate to women with severe preeclampsia did not prevent eclampsia and was associated with more C‑sections and more babies with low Apgar scores.

Trust comment: Randomized controlled trial in humans with clear outcomes but modest sample size and reported adverse effects lowering confidence.

Study Details

PMID:7900522
Participants:64
Impact:no occurrences in either group (no prevention observed)
Trust score:3/5

cesarean section rate

1 evidences

Giving magnesium sulfate to women with severe preeclampsia did not prevent eclampsia and was associated with more C‑sections and more babies with low Apgar scores.

Trust comment: Randomized controlled trial in humans with clear outcomes but modest sample size and reported adverse effects lowering confidence.

Study Details

PMID:7900522
Participants:64
Impact:increased in magnesium group (statistically significant, p<0.05)
Trust score:3/5

neonatal poor Apgar score

1 evidences

Giving magnesium sulfate to women with severe preeclampsia did not prevent eclampsia and was associated with more C‑sections and more babies with low Apgar scores.

Trust comment: Randomized controlled trial in humans with clear outcomes but modest sample size and reported adverse effects lowering confidence.

Study Details

PMID:7900522
Participants:64
Impact:increased in magnesium group (p=0.019)
Trust score:3/5

plasma ferritin concentration

1 evidences

One-year calcium supplementation in lactating Gambian women did not change urinary magnesium excretion or iron/zinc blood markers.

Trust comment: Randomized double-blind, placebo-controlled trial with complete compliance and repeated measures supports reliability.

Study Details

PMID:9014651
Participants:60
Impact:no significant change vs placebo
Trust score:4/5

plasma zinc concentration

1 evidences

One-year calcium supplementation in lactating Gambian women did not change urinary magnesium excretion or iron/zinc blood markers.

Trust comment: Randomized double-blind, placebo-controlled trial with complete compliance and repeated measures supports reliability.

Study Details

PMID:9014651
Participants:60
Impact:no significant change vs placebo
Trust score:4/5

Survival

1 evidences

Meta-analysis of randomized trials reported a small survival benefit in blinded trials but no effect in a large unblinded multicentre trial for IV magnesium in acute MI.

Trust comment: Meta-analysis includes blinded trials showing benefit but is contradicted by a very large open trial, creating uncertainty about overall effect.

Study Details

PMID:7846788
Participants:57260
Impact:increase ≈+4.9% (RR=1.049, 95% CI 1.020–1.078) in nine blinded trials
Trust score:3/5

ventricular tachyarrhythmia avoidance

1 evidences

Meta-analysis of randomized trials reported a small survival benefit in blinded trials but no effect in a large unblinded multicentre trial for IV magnesium in acute MI.

Trust comment: Meta-analysis includes blinded trials showing benefit but is contradicted by a very large open trial, creating uncertainty about overall effect.

Study Details

PMID:7846788
Participants:57260
Impact:no significant effect (RR=1.041, 95% CI 0.996–1.089, p=0.07)
Trust score:3/5

Platelet P-selectin expression

1 evidences

IV magnesium given after cardiac surgery inhibited platelet function and prolonged bleeding time compared with saline.

Trust comment: Randomized, blinded, placebo-controlled study in post-cardiac surgery patients; modest sample size.

Study Details

PMID:10357321
Participants:39
Impact:-18%
Trust score:4/5

serum phosphorus reduction

1 evidences

In haemodialysis patients, a calcium–magnesium phosphate binder lowered serum phosphorus as effectively as sevelamer, modestly increased serum magnesium, and reduced iPTH.

Trust comment: Large, multicentre, randomized, investigator-masked trial with registered protocol and robust biochemical endpoints.

Study Details

PMID:20530499
Participants:204
Impact:CaMg −0.761 mmol/L vs sevelamer −0.711 mmol/L at Week 25 (non-inferior)
Trust score:5/5

serum magnesium increase

1 evidences

In haemodialysis patients, a calcium–magnesium phosphate binder lowered serum phosphorus as effectively as sevelamer, modestly increased serum magnesium, and reduced iPTH.

Trust comment: Large, multicentre, randomized, investigator-masked trial with registered protocol and robust biochemical endpoints.

Study Details

PMID:20530499
Participants:204
Impact:CaMg +0.304 mmol/L vs sevelamer +0.043 mmol/L; treatment difference 0.2597 mmol/L (P<0.0001)
Trust score:5/5

iPTH

1 evidences

In haemodialysis patients, a calcium–magnesium phosphate binder lowered serum phosphorus as effectively as sevelamer, modestly increased serum magnesium, and reduced iPTH.

Trust comment: Large, multicentre, randomized, investigator-masked trial with registered protocol and robust biochemical endpoints.

Study Details

PMID:20530499
Participants:204
Impact:greater decrease with CaMg; treatment difference −64.48 pg/mL (P=0.0085)
Trust score:5/5

Hamilton anxiety total score

1 evidences

A 3-month double-blind RCT found the plant-extracts-plus-magnesium tablet reduced anxiety more than placebo.

Trust comment: Well-powered double-blind RCT but magnesium was given as part of a fixed combination with plant extracts, so effects cannot be attributed to magnesium alone.

Study Details

PMID:14741074
Participants:264
Impact:-10.6 points (study) vs -8.9 points (placebo); treatment effect ~-1.7 points; p=0.005
Trust score:3/5

Hamilton somatic anxiety score

1 evidences

A 3-month double-blind RCT found the plant-extracts-plus-magnesium tablet reduced anxiety more than placebo.

Trust comment: Well-powered double-blind RCT but magnesium was given as part of a fixed combination with plant extracts, so effects cannot be attributed to magnesium alone.

Study Details

PMID:14741074
Participants:264
Impact:-6.5 points (study) vs -5.7 points (placebo); p=0.054
Trust score:3/5

Subjective patient-rated anxiety

1 evidences

A 3-month double-blind RCT found the plant-extracts-plus-magnesium tablet reduced anxiety more than placebo.

Trust comment: Well-powered double-blind RCT but magnesium was given as part of a fixed combination with plant extracts, so effects cannot be attributed to magnesium alone.

Study Details

PMID:14741074
Participants:264
Impact:-38.5% (study) vs -29.2% (placebo); p=0.005
Trust score:3/5

Proportion meeting K/DOQI serum phosphorus target

1 evidences

In a randomized pilot of hemodialysis patients, magnesium carbonate controlled serum phosphorus similarly to calcium acetate while substantially lowering elemental calcium intake.

Trust comment: Randomized pilot with clear outcomes but small size, open-label design, and selected population limit robustness.

Study Details

PMID:17971314
Participants:30
Impact:70.6% (magnesium carbonate) vs 62.5% (calcium acetate) within target during efficacy phase
Trust score:3/5

Daily elemental calcium intake from binders

1 evidences

In a randomized pilot of hemodialysis patients, magnesium carbonate controlled serum phosphorus similarly to calcium acetate while substantially lowering elemental calcium intake.

Trust comment: Randomized pilot with clear outcomes but small size, open-label design, and selected population limit robustness.

Study Details

PMID:17971314
Participants:30
Impact:908 ± 24 mg/day (magnesium group) vs 1743 ± 37 mg/day (calcium acetate); P < .0001 (~-835 mg/day)
Trust score:3/5

tolerability

1 evidences

In a randomized pilot of hemodialysis patients, magnesium carbonate controlled serum phosphorus similarly to calcium acetate while substantially lowering elemental calcium intake.

Trust comment: Randomized pilot with clear outcomes but small size, open-label design, and selected population limit robustness.

Study Details

PMID:17971314
Participants:30
Impact:Generally well tolerated in selected patients (no major tolerability signal reported)
Trust score:3/5

BMI

1 evidences

250 mg magnesium oxide daily for 8 weeks in women with PCOS modestly reduced BMI and prevented waist increase; increased LH and DHEA; no effect on glycemic or lipid profiles.

Trust comment: Randomized double-blind placebo-controlled trial of moderate size with objective biochemical and anthropometric outcomes.

Study Details

PMID:31960275
Participants:60
Impact:-0.31 kg/m2 (intervention) vs +0.07 kg/m2 (placebo)
Trust score:4/5

waist circumference

1 evidences

250 mg magnesium oxide daily for 8 weeks in women with PCOS modestly reduced BMI and prevented waist increase; increased LH and DHEA; no effect on glycemic or lipid profiles.

Trust comment: Randomized double-blind placebo-controlled trial of moderate size with objective biochemical and anthropometric outcomes.

Study Details

PMID:31960275
Participants:60
Impact:0.02 cm (intervention) vs 1.15 cm (placebo) — prevented increase
Trust score:4/5

serum LH

1 evidences

250 mg magnesium oxide daily for 8 weeks in women with PCOS modestly reduced BMI and prevented waist increase; increased LH and DHEA; no effect on glycemic or lipid profiles.

Trust comment: Randomized double-blind placebo-controlled trial of moderate size with objective biochemical and anthropometric outcomes.

Study Details

PMID:31960275
Participants:60
Impact:increased (P=0.01)
Trust score:4/5

DHEA

1 evidences

250 mg magnesium oxide daily for 8 weeks in women with PCOS modestly reduced BMI and prevented waist increase; increased LH and DHEA; no effect on glycemic or lipid profiles.

Trust comment: Randomized double-blind placebo-controlled trial of moderate size with objective biochemical and anthropometric outcomes.

Study Details

PMID:31960275
Participants:60
Impact:increased (136.32 → 172.37; P=0.01)
Trust score:4/5

glycemic variables and lipid profile

1 evidences

250 mg magnesium oxide daily for 8 weeks in women with PCOS modestly reduced BMI and prevented waist increase; increased LH and DHEA; no effect on glycemic or lipid profiles.

Trust comment: Randomized double-blind placebo-controlled trial of moderate size with objective biochemical and anthropometric outcomes.

Study Details

PMID:31960275
Participants:60
Impact:no significant change
Trust score:4/5

CSF magnesium

1 evidences

Perioperative IV magnesium increased serum magnesium but did not raise CSF magnesium or reduce postoperative analgesic use or pain after hysterectomy.

Trust comment: Randomized controlled perioperative trial with objective biochemical measures and analgesic outcomes; negative result.

Study Details

PMID:11575536
Participants:60
Impact:no significant increase
Trust score:4/5

postoperative analgesic consumption

1 evidences

Perioperative IV magnesium increased serum magnesium but did not raise CSF magnesium or reduce postoperative analgesic use or pain after hysterectomy.

Trust comment: Randomized controlled perioperative trial with objective biochemical measures and analgesic outcomes; negative result.

Study Details

PMID:11575536
Participants:60
Impact:no significant difference
Trust score:4/5

sensory thresholds

1 evidences

Magnesium as an anesthetic supplement modestly affected postoperative sensory thresholds but did not change pain scores or opioid consumption after hysterectomy.

Trust comment: Randomized groups but small sample sizes (n=15 per arm) and reliance on surrogate sensory measures.

Study Details

PMID:9428859
Participants:45
Impact:increased 1–24 h then returned to baseline by Day 5; magnesium showed the least central sensory inhibition compared with fentanyl
Trust score:3/5

pain scores and morphine consumption

1 evidences

Magnesium as an anesthetic supplement modestly affected postoperative sensory thresholds but did not change pain scores or opioid consumption after hysterectomy.

Trust comment: Randomized groups but small sample sizes (n=15 per arm) and reliance on surrogate sensory measures.

Study Details

PMID:9428859
Participants:45
Impact:no significant differences among groups
Trust score:3/5

Creatinine clearance (GFR proxy)

1 evidences

In borderline hypertensive adults, switching from low to high dietary sodium changed serum electrolytes and renal filtration but did not alter blood pressure.

Trust comment: Randomized 1-month dietary crossover in 48 subjects with clear biochemical measurements and reported significance levels.

Study Details

PMID:15513697
Participants:48
Impact:increase (p = 0.004)
Trust score:4/5

pNN50 (parasympathetic activity)

1 evidences

Randomized controlled 90-day trial: daily 400 mg magnesium supplementation increased HRV (parasympathetic markers) and reduced stress indices versus control.

Trust comment: Randomized controlled trial with objective HRV outcomes (n=100) but included exercise co-intervention and limited methodological detail on blinding.

Study Details

PMID:27933574
Participants:100
Impact:increased
Trust score:3/5

LF/HF ratio

1 evidences

Randomized controlled 90-day trial: daily 400 mg magnesium supplementation increased HRV (parasympathetic markers) and reduced stress indices versus control.

Trust comment: Randomized controlled trial with objective HRV outcomes (n=100) but included exercise co-intervention and limited methodological detail on blinding.

Study Details

PMID:27933574
Participants:100
Impact:decreased
Trust score:3/5

stress index

1 evidences

Randomized controlled 90-day trial: daily 400 mg magnesium supplementation increased HRV (parasympathetic markers) and reduced stress indices versus control.

Trust comment: Randomized controlled trial with objective HRV outcomes (n=100) but included exercise co-intervention and limited methodological detail on blinding.

Study Details

PMID:27933574
Participants:100
Impact:decreased
Trust score:3/5

intracellular magnesium concentration

2 evidences

Randomized controlled 90-day trial: daily 400 mg magnesium supplementation increased HRV (parasympathetic markers) and reduced stress indices versus control.

Trust comment: Randomized controlled trial with objective HRV outcomes (n=100) but included exercise co-intervention and limited methodological detail on blinding.

Study Details

PMID:27933574
Participants:100
Impact:no change
Trust score:3/5

Six months of oral magnesium improved endothelial function and exercise tolerance in patients with stable coronary artery disease compared with placebo.

Trust comment: Double-blind, placebo-controlled RCT with objective vascular measures but small sample size (n=50).

Study Details

PMID:11067788
Participants:50
Impact:+3.5 mEq/L (36.2 vs 32.7 mEq/L)
Trust score:4/5

intracellular calcium

1 evidences

Mothers with idiopathic preterm delivery had much lower intracellular (red blood cell) magnesium levels than mothers with term deliveries.

Trust comment: Case-control observational study with reasonable sample size but potential confounding and association only.

Study Details

PMID:23444748
Participants:141
Impact:increased in preterm group
Trust score:3/5

cellular sodium

1 evidences

Mothers with idiopathic preterm delivery had much lower intracellular (red blood cell) magnesium levels than mothers with term deliveries.

Trust comment: Case-control observational study with reasonable sample size but potential confounding and association only.

Study Details

PMID:23444748
Participants:141
Impact:decreased in preterm group
Trust score:3/5

intraoperative hypertension

1 evidences

Intraoperative magnesium infusion reduced episodes of hypertension and improved peripheral microcirculation during cardiac revascularization.

Trust comment: Clinical human study with reasonable sample size and physiological measures but limited design details and no effect sizes reported.

Study Details

PMID:21853612
Participants:77
Impact:reduced incidence (no numeric percent reported)
Trust score:3/5

peripheral microcirculation

1 evidences

Intraoperative magnesium infusion reduced episodes of hypertension and improved peripheral microcirculation during cardiac revascularization.

Trust comment: Clinical human study with reasonable sample size and physiological measures but limited design details and no effect sizes reported.

Study Details

PMID:21853612
Participants:77
Impact:improved (no numeric effect size reported)
Trust score:3/5

central hemodynamics

1 evidences

Intraoperative magnesium infusion reduced episodes of hypertension and improved peripheral microcirculation during cardiac revascularization.

Trust comment: Clinical human study with reasonable sample size and physiological measures but limited design details and no effect sizes reported.

Study Details

PMID:21853612
Participants:77
Impact:assessed (no clear directional change reported)
Trust score:3/5

patients within target level

1 evidences

IV magnesium sulphate 64 mmol/day achieved target serum magnesium (1.0-2.0 mmol/L) in most SAH patients with few discontinuations due to side effects.

Trust comment: Prospective dose-evaluation within a randomized placebo-controlled trial framework with objective lab measurements and clear reporting of discontinuations.

Study Details

PMID:16164489
Participants:94
Impact:81/94 patients remained within target during treatment
Trust score:4/5

treatment discontinuation due to adverse events

1 evidences

IV magnesium sulphate 64 mmol/day achieved target serum magnesium (1.0-2.0 mmol/L) in most SAH patients with few discontinuations due to side effects.

Trust comment: Prospective dose-evaluation within a randomized placebo-controlled trial framework with objective lab measurements and clear reporting of discontinuations.

Study Details

PMID:16164489
Participants:94
Impact:6 patients discontinued (nausea/headache, hypotension, phlebitis, renal failure)
Trust score:4/5

barium mucosal coating

1 evidences

Magnesium sulphate added during bowel prep improved barium mucosal coating during double-contrast barium enema compared with sodium sulfate.

Trust comment: Paired randomized comparison with blinded radiologist assessments and clear statistical results.

Study Details

PMID:10415251
Participants:76
Impact:rated better with magnesium (p = 0.0007)
Trust score:4/5

residual fluid

1 evidences

Magnesium sulphate added during bowel prep improved barium mucosal coating during double-contrast barium enema compared with sodium sulfate.

Trust comment: Paired randomized comparison with blinded radiologist assessments and clear statistical results.

Study Details

PMID:10415251
Participants:76
Impact:no significant difference (p = 0.3198)
Trust score:4/5

colon cleansing

1 evidences

Magnesium sulphate added during bowel prep improved barium mucosal coating during double-contrast barium enema compared with sodium sulfate.

Trust comment: Paired randomized comparison with blinded radiologist assessments and clear statistical results.

Study Details

PMID:10415251
Participants:76
Impact:better with sodium sulfate than with magnesium (p = 0.0166)
Trust score:4/5

postoperative cognitive deficit

1 evidences

Giving IV magnesium during cardiac surgery did not reduce postoperative cognitive problems.

Trust comment: Large (n=389), randomized, double-blind, placebo-controlled trial with appropriate adjustment for covariates.

Study Details

PMID:24105697
Participants:389
Impact:no difference (44.4% vs 44.9%, P=0.93)
Trust score:5/5

cognitive change score

1 evidences

Giving IV magnesium during cardiac surgery did not reduce postoperative cognitive problems.

Trust comment: Large (n=389), randomized, double-blind, placebo-controlled trial with appropriate adjustment for covariates.

Study Details

PMID:24105697
Participants:389
Impact:no difference
Trust score:5/5

platelet and leukocyte activation markers

1 evidences

Giving IV magnesium during cardiac surgery did not reduce postoperative cognitive problems.

Trust comment: Large (n=389), randomized, double-blind, placebo-controlled trial with appropriate adjustment for covariates.

Study Details

PMID:24105697
Participants:389
Impact:no difference
Trust score:5/5

In vitro bleeding time

1 evidences

IV magnesium given after cardiac surgery inhibited platelet function and prolonged bleeding time compared with saline.

Trust comment: Randomized, blinded, placebo-controlled study in post-cardiac surgery patients; modest sample size.

Study Details

PMID:10357321
Participants:39
Impact:+22% (prolonged)
Trust score:4/5

platelet aggregation (ADP- and collagen-induced)

1 evidences

IV magnesium given after cardiac surgery inhibited platelet function and prolonged bleeding time compared with saline.

Trust comment: Randomized, blinded, placebo-controlled study in post-cardiac surgery patients; modest sample size.

Study Details

PMID:10357321
Participants:39
Impact:-13% (ADP), -17% (collagen)
Trust score:4/5

postoperative neurocognitive impairment

1 evidences

Intraoperative IV magnesium reduced the risk of postoperative neurocognitive decline after carotid endarterectomy, especially at low dose.

Trust comment: Randomized trial with 108 patients and control group; subgroup dosing effects reported.

Study Details

PMID:19199498
Participants:108
Impact:reduced (OR 0.27 overall; low-dose OR 0.09)
Trust score:4/5

symptom normalization rate (I-GERQ-R <16)

1 evidences

A two-week magnesium-alginate treatment decreased regurgitation symptoms in infants similarly to thickened formula and at slightly lower direct cost.

Trust comment: Randomized crossover multicenter trial but open-label with parent-reported outcomes and modest sample size.

Study Details

PMID:31861951
Participants:72
Impact:73% normalized with alginate (formula-fed) vs 64% with thickener; 84% in breast-fed on alginate
Trust score:3/5

treatment cost

1 evidences

A two-week magnesium-alginate treatment decreased regurgitation symptoms in infants similarly to thickened formula and at slightly lower direct cost.

Trust comment: Randomized crossover multicenter trial but open-label with parent-reported outcomes and modest sample size.

Study Details

PMID:31861951
Participants:72
Impact:-€4.60 per child over two weeks (alginate vs thickened formula)
Trust score:3/5

postoperative atrial fibrillation (POAF) incidence

1 evidences

Continuous IV magnesium infusion to target serum levels reduced new-onset atrial fibrillation after off-pump CABG and raised serum magnesium.

Trust comment: Prospective randomized controlled single-center trial with adequate sample size but unblinded design and short ICU follow-up.

Study Details

PMID:40629782
Participants:104
Impact:reduced by 17.3 percentage points (control 19.2% -> magnesium 1.9%)
Trust score:4/5

amiodarone use for POAF

1 evidences

Continuous IV magnesium infusion to target serum levels reduced new-onset atrial fibrillation after off-pump CABG and raised serum magnesium.

Trust comment: Prospective randomized controlled single-center trial with adequate sample size but unblinded design and short ICU follow-up.

Study Details

PMID:40629782
Participants:104
Impact:reduced by 13.5 percentage points (control 15.4% -> magnesium 1.9%)
Trust score:4/5

serum magnesium (mean peak)

1 evidences

Continuous IV magnesium infusion to target serum levels reduced new-onset atrial fibrillation after off-pump CABG and raised serum magnesium.

Trust comment: Prospective randomized controlled single-center trial with adequate sample size but unblinded design and short ICU follow-up.

Study Details

PMID:40629782
Participants:104
Impact:increased by 0.914 mmol/L (control 0.710 -> magnesium 1.624 mmol/L; P < .001)
Trust score:4/5

platinum-induced neuropathy (total neuropathy score)

1 evidences

Randomized study comparing IV glutamine versus calcium/magnesium infusions during platinum chemotherapy; neither prevented neuropathy, but glutamine reduced severity in symptomatic patients.

Trust comment: Prospective randomized study but small sample size and subgroup effects; Ca/Mg arm showed no preventive benefit.

Study Details

PMID:25800685
Participants:55
Impact:neither IV glutamine nor Ca/Mg infusion prevented further overall worsening (both groups' mean TNS increased)
Trust score:3/5

severity of symptomatic neuropathy

1 evidences

Randomized study comparing IV glutamine versus calcium/magnesium infusions during platinum chemotherapy; neither prevented neuropathy, but glutamine reduced severity in symptomatic patients.

Trust comment: Prospective randomized study but small sample size and subgroup effects; Ca/Mg arm showed no preventive benefit.

Study Details

PMID:25800685
Participants:55
Impact:reduced with IV glutamine in symptomatic patients (P = 0.045) but no benefit shown for Ca/Mg infusion
Trust score:3/5

whole-body bone density / T-score

1 evidences

Among 224 postmenopausal women given vitamin D and calcium, whole-body bone density and T-scores decreased over 2 years; zinc supplementation effects depended on baseline zinc intake.

Trust comment: Well-powered randomized trial for Zn/Cu but magnesium effect is an observational association from food diaries, limiting causal inference.

Study Details

PMID:21733304
Participants:224
Impact:low Mg intake (<237 mg/day) associated with greater declines/poorer bone health over 2 years
Trust score:3/5

PMS-H (fluid retention) symptoms

1 evidences

Daily 200 mg magnesium for two cycles reduced fluid-retention-related premenstrual symptoms in the second month of supplementation.

Trust comment: Randomized, double-blind, placebo-controlled crossover design with verified compliance, moderate sample size (n=38).

Study Details

PMID:9861593
Participants:38
Impact:greater reduction in month 2 with Mg vs placebo (p = 0.009)
Trust score:4/5

urinary magnesium output (estimated 24-h)

1 evidences

Daily 200 mg magnesium for two cycles reduced fluid-retention-related premenstrual symptoms in the second month of supplementation.

Trust comment: Randomized, double-blind, placebo-controlled crossover design with verified compliance, moderate sample size (n=38).

Study Details

PMID:9861593
Participants:38
Impact:increased during Mg supplementation (100.8 mg vs 74.1 mg on placebo, p = 0.013)
Trust score:4/5

incidence of ventricular tachyarrhythmias

1 evidences

In 100 cardiac surgery patients, perioperative IV magnesium raised serum Mg and substantially reduced ventricular tachyarrhythmias and early CK-MB release.

Trust comment: Randomized controlled trial with 100 patients and clear clinically relevant endpoints, though single-center.

Study Details

PMID:7847975
Participants:100
Impact:decreased from 51.9% to 17.3% (p = 0.0006)
Trust score:4/5

postoperative CK-MB (day 1)

1 evidences

In 100 cardiac surgery patients, perioperative IV magnesium raised serum Mg and substantially reduced ventricular tachyarrhythmias and early CK-MB release.

Trust comment: Randomized controlled trial with 100 patients and clear clinically relevant endpoints, though single-center.

Study Details

PMID:7847975
Participants:100
Impact:reduced (28.4 → 5.3 IU/L; p = 0.001)
Trust score:4/5

insulin sensitivity index (M/I)

1 evidences

In 96 hypertensive patients, changes in serum magnesium and the Ca/Mg ratio during ACE inhibitor therapy were associated with changes in insulin sensitivity and triglycerides.

Trust comment: Analysis of 96 patients from double-blind ACE inhibitor studies showing correlations but not direct magnesium intervention causality.

Study Details

PMID:9037321
Participants:96
Impact:positive correlation with change in serum magnesium (r = 0.24, p < 0.02)
Trust score:3/5

work at 70% 1RM (bench press)

1 evidences

Low-dose creatine increased work during bench-press fatigue sets; magnesium‑creatine chelate performed similarly to creatine alone and did not change one‑rep max.

Trust comment: Double-blind randomized trial in humans but small sample and effects primarily reflect creatine with no added benefit from magnesium chelate.

Study Details

PMID:15142029
Participants:31
Impact:increased in both creatine and Mg‑creatine groups vs placebo (statistically significant)
Trust score:3/5

bench press 1RM

1 evidences

Low-dose creatine increased work during bench-press fatigue sets; magnesium‑creatine chelate performed similarly to creatine alone and did not change one‑rep max.

Trust comment: Double-blind randomized trial in humans but small sample and effects primarily reflect creatine with no added benefit from magnesium chelate.

Study Details

PMID:15142029
Participants:31
Impact:no significant change vs placebo
Trust score:3/5

C3 complement consumption

1 evidences

High-dose IV magnesium after MI blunted early complement consumption, suggesting modulation of the post-infarction inflammatory response.

Trust comment: Randomized treatment groups with biochemical endpoints but small sample limits generalizability.

Study Details

PMID:8737101
Participants:29
Impact:attenuated; significant differences in time-course between groups (delayed decrease to ~24 h)
Trust score:3/5

C4 complement consumption

1 evidences

High-dose IV magnesium after MI blunted early complement consumption, suggesting modulation of the post-infarction inflammatory response.

Trust comment: Randomized treatment groups with biochemical endpoints but small sample limits generalizability.

Study Details

PMID:8737101
Participants:29
Impact:similar trend to C3 (delayed decrease)
Trust score:3/5

CH-100 (total complement activity)

1 evidences

High-dose IV magnesium after MI blunted early complement consumption, suggesting modulation of the post-infarction inflammatory response.

Trust comment: Randomized treatment groups with biochemical endpoints but small sample limits generalizability.

Study Details

PMID:8737101
Participants:29
Impact:depressed from 3 h onward in high-dose group
Trust score:3/5

blood pressure response

1 evidences

In patients with hypertension, the muscle calcium-to-magnesium ratio related to blood pressure response to antihypertensive therapy.

Trust comment: Small clinical study using muscle biopsies showing correlations; observational nature limits causal inference.

Study Details

PMID:8695028
Participants:37
Impact:correlated with baseline muscle Ca/Mg ratio (r = -0.38, p < .02)
Trust score:3/5

change in blood pressure

1 evidences

In patients with hypertension, the muscle calcium-to-magnesium ratio related to blood pressure response to antihypertensive therapy.

Trust comment: Small clinical study using muscle biopsies showing correlations; observational nature limits causal inference.

Study Details

PMID:8695028
Participants:37
Impact:related to change in muscle Ca/Mg ratio during treatment (r = 0.35, p < .05)
Trust score:3/5

return of spontaneous circulation (ROSC)

1 evidences

High-dose magnesium given during out-of-hospital cardiac arrest did not significantly improve return of circulation or survival to discharge.

Trust comment: Prospective randomized double-blind placebo-controlled trial in OHCA with objective clinical endpoints but limited sample.

Study Details

PMID:10203402
Participants:67
Impact:23% magnesium vs 22% placebo (no significant difference)
Trust score:4/5

survival to hospital discharge

1 evidences

High-dose magnesium given during out-of-hospital cardiac arrest did not significantly improve return of circulation or survival to discharge.

Trust comment: Prospective randomized double-blind placebo-controlled trial in OHCA with objective clinical endpoints but limited sample.

Study Details

PMID:10203402
Participants:67
Impact:1/31 magnesium vs 0/36 placebo (no significant difference)
Trust score:4/5

postoperative pain

1 evidences

Adding 50 mg magnesium to caudal ropivacaine in children did not change postoperative pain or analgesic needs.

Trust comment: Randomized clinical study in pediatric patients with adequate measures but uneven group sizes and moderate sample size.

Study Details

PMID:17021740
Participants:60
Impact:no effect (POPS, CHEOPS similar between groups)
Trust score:4/5

analgesia duration / analgesic need

1 evidences

Adding 50 mg magnesium to caudal ropivacaine in children did not change postoperative pain or analgesic needs.

Trust comment: Randomized clinical study in pediatric patients with adequate measures but uneven group sizes and moderate sample size.

Study Details

PMID:17021740
Participants:60
Impact:no effect
Trust score:4/5

motor block (Bromage scale)

1 evidences

Adding 50 mg magnesium to caudal ropivacaine in children did not change postoperative pain or analgesic needs.

Trust comment: Randomized clinical study in pediatric patients with adequate measures but uneven group sizes and moderate sample size.

Study Details

PMID:17021740
Participants:60
Impact:no effect
Trust score:4/5

Serum PTH

1 evidences

In 21 postmenopausal women, high-calcium drinks reduced bone resorption markers; adding magnesium produced no distinguishable additional effect.

Trust comment: Randomized cross-over study with direct biochemical measures but small sample size limits power to detect small magnesium-specific effects.

Study Details

PMID:12548298
Participants:21
Impact:Decreased after TCP and after high-calcium skim milk; no significant difference when magnesium was added
Trust score:4/5

Serum C-telopeptides (bone resorption marker)

1 evidences

In 21 postmenopausal women, high-calcium drinks reduced bone resorption markers; adding magnesium produced no distinguishable additional effect.

Trust comment: Randomized cross-over study with direct biochemical measures but small sample size limits power to detect small magnesium-specific effects.

Study Details

PMID:12548298
Participants:21
Impact:Decreased for all high-calcium drinks at 5 h (apple 0.22 ng/ml vs TCP 0.15, HCSM 0.14, HCSM+Mg 0.16)
Trust score:4/5

ventricular premature beats (VPBs)

1 evidences

Oral magnesium plus potassium for 3 weeks produced a moderate but significant reduction in ventricular premature beats in patients with frequent ventricular arrhythmias.

Trust comment: Large randomized double-blind trial with objective arrhythmia outcomes.

Study Details

PMID:9120155
Participants:232
Impact:median -17.4% reduction (active vs baseline; p=0.001)
Trust score:5/5

>=60% suppression rate

1 evidences

Oral magnesium plus potassium for 3 weeks produced a moderate but significant reduction in ventricular premature beats in patients with frequent ventricular arrhythmias.

Trust comment: Large randomized double-blind trial with objective arrhythmia outcomes.

Study Details

PMID:9120155
Participants:232
Impact:25% vs 15% (absolute +10 percentage points, active vs placebo; p=0.044)
Trust score:5/5

atracurium recovery duration

1 evidences

During surgery plasma magnesium fell; low magnesium levels were associated with prolongation of some atracurium recovery phases.

Trust comment: Prospective randomized study with objective lab and neuromuscular measures, reported as associations.

Study Details

PMID:19856686
Participants:119
Impact:some recovery phases prolonged in association with low magnesium
Trust score:4/5

neurological abnormalities at discharge

1 evidences

In term neonates with perinatal asphyxia, postnatal magnesium sulfate infusion improved short-term neurological outcomes at discharge versus placebo.

Trust comment: Randomized single-blind controlled neonatal trial showing clinically relevant outcomes but limited by small size and single-blind design.

Study Details

PMID:24292304
Participants:50
Impact:26% vs 61% (absolute -35 percentage points, experimental vs control)
Trust score:4/5

good short-term outcome at discharge

1 evidences

In term neonates with perinatal asphyxia, postnatal magnesium sulfate infusion improved short-term neurological outcomes at discharge versus placebo.

Trust comment: Randomized single-blind controlled neonatal trial showing clinically relevant outcomes but limited by small size and single-blind design.

Study Details

PMID:24292304
Participants:50
Impact:60% vs 32% (absolute +28 percentage points, experimental vs control)
Trust score:4/5

erythrocyte/serum/urinary magnesium concentrations

1 evidences

In postmenopausal women, a low-magnesium diet lowered magnesium measures and increased supraventricular (and combined supraventricular+ventricular) ectopic beats on Holter monitoring.

Trust comment: Controlled, randomized, double-blind metabolic crossover with electrophysiologic outcomes, though small sample size.

Study Details

PMID:11864862
Participants:22
Impact:decreased (significant)
Trust score:4/5

supraventricular ectopic beats

1 evidences

In postmenopausal women, a low-magnesium diet lowered magnesium measures and increased supraventricular (and combined supraventricular+ventricular) ectopic beats on Holter monitoring.

Trust comment: Controlled, randomized, double-blind metabolic crossover with electrophysiologic outcomes, though small sample size.

Study Details

PMID:11864862
Participants:22
Impact:increased (significant)
Trust score:4/5

supraventricular plus ventricular beats

1 evidences

In postmenopausal women, a low-magnesium diet lowered magnesium measures and increased supraventricular (and combined supraventricular+ventricular) ectopic beats on Holter monitoring.

Trust comment: Controlled, randomized, double-blind metabolic crossover with electrophysiologic outcomes, though small sample size.

Study Details

PMID:11864862
Participants:22
Impact:increased (significant)
Trust score:4/5

Fagerstrom nicotine dependence score

1 evidences

28-day magnesium supplementation was associated with reduced nicotine dependence scores and cigarette consumption and raised plasma magnesium in psychiatric smokers.

Trust comment: Small clinical cohort with measurable biomarker and behavioral changes but potential confounding (concomitant benzodiazepines) and limited control details.

Study Details

PMID:15724865
Participants:53
Impact:decreased from 7.93 ± 0.17 to 6.78 ± 0.18 after 28 days (P < 0.05)
Trust score:3/5

cigarette consumption

1 evidences

28-day magnesium supplementation was associated with reduced nicotine dependence scores and cigarette consumption and raised plasma magnesium in psychiatric smokers.

Trust comment: Small clinical cohort with measurable biomarker and behavioral changes but potential confounding (concomitant benzodiazepines) and limited control details.

Study Details

PMID:15724865
Participants:53
Impact:decreased (no absolute count reported)
Trust score:3/5

analgesic requirement

1 evidences

Adding magnesium to levobupivacaine reduced postoperative pain scores and analgesic needs in children after tonsillectomy.

Trust comment: Randomized pediatric trial with clear outcome measures but modest sample size (n=75) limits precision.

Study Details

PMID:18325601
Participants:75
Impact:decreased (significantly lower in levobupivacaine+Mg group vs levobupivacaine alone, p<0.05)
Trust score:3/5

postoperative pain scores (mCHEOPS)

1 evidences

Adding magnesium to levobupivacaine reduced postoperative pain scores and analgesic needs in children after tonsillectomy.

Trust comment: Randomized pediatric trial with clear outcome measures but modest sample size (n=75) limits precision.

Study Details

PMID:18325601
Participants:75
Impact:lower than control in treatment groups
Trust score:3/5

laryngospasm incidence

1 evidences

Adding magnesium to levobupivacaine reduced postoperative pain scores and analgesic needs in children after tonsillectomy.

Trust comment: Randomized pediatric trial with clear outcome measures but modest sample size (n=75) limits precision.

Study Details

PMID:18325601
Participants:75
Impact:no observed events in Mg group (difference not statistically significant)
Trust score:3/5

Plasma zinc

1 evidences

Feeding preterm infants a nutrient-enriched formula normalized plasma zinc by 2 months past term without disrupting overall mineral homeostasis.

Trust comment: Prospective feeding trial in preterm infants (n=33) with laboratory mineral measurements but modest sample size.

Study Details

PMID:7752008
Participants:33
Impact:normalized by at least 2 months past term
Trust score:3/5

plasma magnesium / mineral homeostasis

1 evidences

Feeding preterm infants a nutrient-enriched formula normalized plasma zinc by 2 months past term without disrupting overall mineral homeostasis.

Trust comment: Prospective feeding trial in preterm infants (n=33) with laboratory mineral measurements but modest sample size.

Study Details

PMID:7752008
Participants:33
Impact:no adverse effects reported (homeostasis preserved)
Trust score:3/5

liver function indices

1 evidences

In 52 men after CABG, daily small-dose beer raised plasma magnesium without obvious liver harm over 30 days.

Trust comment: Randomized trial in clinically stable post-CABG men; small sample and short duration limit generalizability.

Study Details

PMID:10730110
Participants:52
Impact:no change detected
Trust score:4/5

perioperative analgesic requirements

1 evidences

Adding intrathecal and epidural magnesium to spinal anesthesia for lower-extremity surgery reduced perioperative analgesic needs and prolonged anesthesia.

Trust comment: Randomized trial (40 vs 40) with clear effect on analgesic requirements; limited detail on blinding and longer-term outcomes.

Study Details

PMID:18637602
Participants:80
Impact:-38.3% (less than control)
Trust score:4/5

duration of anesthesia / analgesia

1 evidences

Adding intrathecal and epidural magnesium to spinal anesthesia for lower-extremity surgery reduced perioperative analgesic needs and prolonged anesthesia.

Trust comment: Randomized trial (40 vs 40) with clear effect on analgesic requirements; limited detail on blinding and longer-term outcomes.

Study Details

PMID:18637602
Participants:80
Impact:prolonged
Trust score:4/5

pain scores (VAS)

1 evidences

Adding intrathecal and epidural magnesium to spinal anesthesia for lower-extremity surgery reduced perioperative analgesic needs and prolonged anesthesia.

Trust comment: Randomized trial (40 vs 40) with clear effect on analgesic requirements; limited detail on blinding and longer-term outcomes.

Study Details

PMID:18637602
Participants:80
Impact:lower in magnesium group
Trust score:4/5

endothelial function (FMD)

1 evidences

Six months of oral magnesium improved endothelial function and exercise tolerance in patients with stable coronary artery disease compared with placebo.

Trust comment: Double-blind, placebo-controlled RCT with objective vascular measures but small sample size (n=50).

Study Details

PMID:11067788
Participants:50
Impact:+15.5% postintervention vs +4.4% placebo (improvement)
Trust score:4/5

exercise tolerance (Bruce protocol)

1 evidences

Six months of oral magnesium improved endothelial function and exercise tolerance in patients with stable coronary artery disease compared with placebo.

Trust comment: Double-blind, placebo-controlled RCT with objective vascular measures but small sample size (n=50).

Study Details

PMID:11067788
Participants:50
Impact:+~2.0 minutes (9.3 ±2.0 vs 7.3 ±3.1 minutes)
Trust score:4/5

ventricular tachycardia incidence

1 evidences

Intraoperative measurement-guided correction of ionized magnesium reduced early postoperative ventricular arrhythmias after cardiopulmonary bypass.

Trust comment: Randomized controlled trial showing large, clinically meaningful reductions in arrhythmia with targeted magnesium correction.

Study Details

PMID:12351253
Participants:85
Impact:-23 percentage points (7% vs 30% in first 24 h)
Trust score:4/5

continuous sinus rhythm (Lown Grade 0)

1 evidences

Intraoperative measurement-guided correction of ionized magnesium reduced early postoperative ventricular arrhythmias after cardiopulmonary bypass.

Trust comment: Randomized controlled trial showing large, clinically meaningful reductions in arrhythmia with targeted magnesium correction.

Study Details

PMID:12351253
Participants:85
Impact:+29 percentage points (34% vs 5% in first 24 h)
Trust score:4/5

post-reperfusion syndrome duration

1 evidences

Magnesium given before reperfusion shortened post-reperfusion syndrome and shifted cytokine responses toward a Th2 profile in liver transplant patients.

Trust comment: Controlled clinical study with objective cytokine measurements but small sample and limited clinical endpoints.

Study Details

PMID:23816766
Participants:40
Impact:shorter duration with magnesium (p=0.038)
Trust score:3/5

Th1/Th2 cytokine balance

1 evidences

Magnesium given before reperfusion shortened post-reperfusion syndrome and shifted cytokine responses toward a Th2 profile in liver transplant patients.

Trust comment: Controlled clinical study with objective cytokine measurements but small sample and limited clinical endpoints.

Study Details

PMID:23816766
Participants:40
Impact:lower IFN-γ and higher IL-6, IL-4, IL-10 after reperfusion (shift toward Th2)
Trust score:3/5

postoperative arrhythmia incidence

2 evidences

Continuous magnesium infusion after cardiopulmonary bypass lowered postoperative arrhythmias and kept blood magnesium levels higher than placebo.

Trust comment: Randomized placebo-controlled trial with clear endpoints and statistically significant effects, single-center but well-reported.

Study Details

PMID:12774159
Participants:131
Impact:-13.5 percentage points (12.3% vs 25.8%; 8/65 vs 17/66; P=0.05)
Trust score:4/5

Preoperative oral magnesium (1,600 mg) was as effective as IV magnesium (2 g) in preventing post-CABG hypomagnesemia and arrhythmia up to 48 hours.

Trust comment: Randomized, blinded clinical study with clear endpoints and moderate sample size; some exclusions and short follow-up limit generalizability.

Study Details

PMID:30517252
Participants:67
Impact:no significant difference between oral and IV groups
Trust score:4/5

serum/ionized magnesium concentration

1 evidences

Continuous magnesium infusion after cardiopulmonary bypass lowered postoperative arrhythmias and kept blood magnesium levels higher than placebo.

Trust comment: Randomized placebo-controlled trial with clear endpoints and statistically significant effects, single-center but well-reported.

Study Details

PMID:12774159
Participants:131
Impact:+0.34 mmol/L post-op (0.54 -> 0.88 mmol/L); levels maintained in treatment vs returned to baseline in controls (P<0.001)
Trust score:4/5

ventricular ectopic beats

1 evidences

In heart failure patients with complex ventricular arrhythmias, intravenous magnesium significantly reduced ectopic beats and nonsustained VT episodes.

Trust comment: Double-blind randomized supplementation study in a clinical population with clear, highly significant arrhythmia reductions, moderate completion rate (68 completed).

Study Details

PMID:10672134
Participants:68
Impact:significant decrease (P<0.0001)
Trust score:4/5

episodes of nonsustained ventricular tachycardia

1 evidences

In heart failure patients with complex ventricular arrhythmias, intravenous magnesium significantly reduced ectopic beats and nonsustained VT episodes.

Trust comment: Double-blind randomized supplementation study in a clinical population with clear, highly significant arrhythmia reductions, moderate completion rate (68 completed).

Study Details

PMID:10672134
Participants:68
Impact:significant decrease (P<0.01)
Trust score:4/5

HDL-cholesterol and apolipoprotein AI

1 evidences

Four weeks of oral magnesium increased urinary magnesium and lowered both systolic and diastolic blood pressure and improved some lipid markers compared with placebo.

Trust comment: Double-blind placebo-controlled trial but very small sample size, limiting generalizability despite randomized design.

Study Details

PMID:9389897
Participants:33
Impact:significant increases after Mg supplementation
Trust score:3/5

odds of elevated HOMA-IR (>3.6)

1 evidences

Higher dietary magnesium intake was associated with lower insulin resistance (HOMA-IR) over 12 months in non-diabetic adults with metabolic syndrome.

Trust comment: Longitudinal analysis of a randomized dietary trial with moderate sample size and multivariable adjustment, showing consistent associations.

Study Details

PMID:24084051
Participants:234
Impact:highest magnesium quartile had 71% lower odds (Adjusted OR 0.29; 95% CI 0.12–0.72) vs lowest quartile
Trust score:4/5

conversion to sinus rhythm

1 evidences

Intravenous magnesium sulfate was superior to amiodarone for converting acute atrial tachyarrhythmias to sinus rhythm over 24 hours in critically ill patients.

Trust comment: Prospective randomized ICU study with objective clinical endpoints and clear superiority of magnesium for rhythm conversion, though small sample.

Study Details

PMID:7587256
Participants:42
Impact:+16% at 4 hr (0.60 vs 0.44), +22% at 12 hr (0.72 vs 0.50), +28% at 24 hr (0.78 vs 0.50) for magnesium vs amiodarone
Trust score:4/5

ventricular response rate in non-converters

1 evidences

Intravenous magnesium sulfate was superior to amiodarone for converting acute atrial tachyarrhythmias to sinus rhythm over 24 hours in critically ill patients.

Trust comment: Prospective randomized ICU study with objective clinical endpoints and clear superiority of magnesium for rhythm conversion, though small sample.

Study Details

PMID:7587256
Participants:42
Impact:initial decrease (~19 beats/min at 0.5 hr) with no difference between treatments thereafter
Trust score:4/5

fructosamine

1 evidences

In type 2 diabetics, high-dose oral magnesium oxide (41.4 mmol/day) for 30 days slightly lowered fructosamine; lower dose and placebo showed no change.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample but short duration (30 days) limits long-term conclusions.

Study Details

PMID:9589224
Participants:128
Impact:-0.3 mmol/l (4.1 ± 0.8 to 3.8 ± 0.7 mmol/l) with 41.4 mmol/day
Trust score:4/5

plasma/cellular/urine magnesium

1 evidences

In type 2 diabetics, high-dose oral magnesium oxide (41.4 mmol/day) for 30 days slightly lowered fructosamine; lower dose and placebo showed no change.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample but short duration (30 days) limits long-term conclusions.

Study Details

PMID:9589224
Participants:128
Impact:increase (trend) with 41.4 mmol/day
Trust score:4/5

intracellular magnesium (associated conditions)

1 evidences

In type 2 diabetics, high-dose oral magnesium oxide (41.4 mmol/day) for 30 days slightly lowered fructosamine; lower dose and placebo showed no change.

Trust comment: Randomized double-blind placebo-controlled trial with adequate sample but short duration (30 days) limits long-term conclusions.

Study Details

PMID:9589224
Participants:128
Impact:lower in patients with neuropathy or coronary disease (1.2 vs 1.5 μg/mg)
Trust score:4/5

Mean blood pressure

1 evidences

In type 2 diabetics, combined minerals + vitamins (including Mg+Zn) for 3 months lowered systolic, diastolic and mean blood pressure; Mg+Zn alone did not.

Trust comment: Randomized double-blind placebo-controlled design but small group sizes limit precision and subgroup inference for magnesium-specific effects.

Study Details

PMID:15190052
Participants:69
Impact:-7 mmHg (99 ± 13 to 92 ± 9 mmHg) in MV group
Trust score:3/5

arterial calcification progression

1 evidences

In hemodialysis patients, a magnesium-containing phosphate binder raised serum magnesium and was associated with more radiographic improvements and a non-significant trend toward less progression of arterial calcifications.

Trust comment: Randomized pilot trial with objective radiographic endpoints but small sample and limited power.

Study Details

PMID:25118610
Participants:59
Impact:worsened in 28.1% (Mg) vs 44.4% (Ca), p = 0.276 (ns)
Trust score:3/5

arterial calcification improvement

1 evidences

In hemodialysis patients, a magnesium-containing phosphate binder raised serum magnesium and was associated with more radiographic improvements and a non-significant trend toward less progression of arterial calcifications.

Trust comment: Randomized pilot trial with objective radiographic endpoints but small sample and limited power.

Study Details

PMID:25118610
Participants:59
Impact:improved in 15.6% (Mg) vs 0% (Ca), p = 0.040
Trust score:3/5

estimated blood loss

1 evidences

Intravenous magnesium sulfate during lumbar discectomy reduced estimated blood loss and improved surgical field conditions compared with placebo.

Trust comment: Randomized controlled trial with clear, clinically relevant endpoints though limited sample size.

Study Details

PMID:21974796
Participants:40
Impact:-172 ml (190 ± 95 ml vs 362 ± 170 ml; mean difference 172 ml, 95% CI 84–260 ml)
Trust score:4/5

surgical conditions (Fromme scale)

1 evidences

Intravenous magnesium sulfate during lumbar discectomy reduced estimated blood loss and improved surgical field conditions compared with placebo.

Trust comment: Randomized controlled trial with clear, clinically relevant endpoints though limited sample size.

Study Details

PMID:21974796
Participants:40
Impact:median 2 vs 3 (better conditions with magnesium), p < 0.05
Trust score:4/5

activated partial thromboplastin time (aPTT)

1 evidences

Intravenous magnesium sulfate during lumbar discectomy reduced estimated blood loss and improved surgical field conditions compared with placebo.

Trust comment: Randomized controlled trial with clear, clinically relevant endpoints though limited sample size.

Study Details

PMID:21974796
Participants:40
Impact:prolonged immediately postoperatively and at 6 h with magnesium
Trust score:4/5

HDL cholesterol

1 evidences

In type 2 diabetic patients, combined mineral (Mg+Zn) plus vitamins C+E increased HDL cholesterol and apolipoprotein A1 over 3 months; Mg+Zn alone showed no significant changes.

Trust comment: Randomized double-blind placebo-controlled trial with small group sizes; results credible for combined supplementation but limited by subgroup sizes.

Study Details

PMID:15163474
Participants:69
Impact:+24% (increase in minerals+vitamins group)
Trust score:4/5

Apolipoprotein A1

1 evidences

In type 2 diabetic patients, combined mineral (Mg+Zn) plus vitamins C+E increased HDL cholesterol and apolipoprotein A1 over 3 months; Mg+Zn alone showed no significant changes.

Trust comment: Randomized double-blind placebo-controlled trial with small group sizes; results credible for combined supplementation but limited by subgroup sizes.

Study Details

PMID:15163474
Participants:69
Impact:+8.8% (increase in minerals+vitamins group)
Trust score:4/5

Platelet-dependent thrombosis

1 evidences

In coronary artery disease patients, lower intracellular magnesium was associated with higher platelet-dependent thrombosis; apolipoprotein B also correlated positively with thrombosis.

Trust comment: Prospective observational study with modest sample size; shows associations but cannot prove causation.

Study Details

PMID:10754344
Participants:42
Impact:Positive correlation with apolipoprotein B (r = 0.41, p = 0.009)
Trust score:3/5

Office systolic blood pressure

1 evidences

In hypertensive patients, oral magnesium (20 mmol/day) produced small but statistically significant reductions in office, home, and 24‑hour blood pressures versus control.

Trust comment: Randomized crossover trial with objective BP measurements; effects small but statistically significant.

Study Details

PMID:9719052
Participants:60
Impact:-3.7 ±1.3 mmHg (systolic) and -1.7 ±0.7 mmHg (diastolic) vs control
Trust score:4/5

24-hour systolic blood pressure

1 evidences

In hypertensive patients, oral magnesium (20 mmol/day) produced small but statistically significant reductions in office, home, and 24‑hour blood pressures versus control.

Trust comment: Randomized crossover trial with objective BP measurements; effects small but statistically significant.

Study Details

PMID:9719052
Participants:60
Impact:-2.5 ±1.0 mmHg (systolic) and -1.4 ±0.6 mmHg (diastolic) vs control
Trust score:4/5

Opioid (tramadol) consumption

1 evidences

In abdominal hysterectomy patients, single-dose IV magnesium given before surgery reduced postoperative pain scores, opioid (tramadol) consumption, and periincisional hyperalgesia compared with saline.

Trust comment: Randomized controlled design with clear clinical endpoints; limited to single surgery type and reported without detailed numeric values in abstract.

Study Details

PMID:22399124
Participants:60
Impact:Reduced over 24–48 h in magnesium group (significantly lower, p<0.05)
Trust score:4/5

Periincisional pain threshold

1 evidences

In abdominal hysterectomy patients, single-dose IV magnesium given before surgery reduced postoperative pain scores, opioid (tramadol) consumption, and periincisional hyperalgesia compared with saline.

Trust comment: Randomized controlled design with clear clinical endpoints; limited to single surgery type and reported without detailed numeric values in abstract.

Study Details

PMID:22399124
Participants:60
Impact:Higher (less hyperalgesia) in magnesium group at 24–48 h
Trust score:4/5

total premenstrual symptoms

1 evidences

Randomized double-blind crossover trial in 85 women testing magnesium vs sorbitol placebo for premenstrual symptoms; sorbitol unexpectedly reduced symptoms.

Trust comment: Well-designed randomized double-blind crossover with 85 participants and significant p-values, but an active placebo complicates interpretation of magnesium's effect.

Study Details

PMID:12018972
Participants:85
Impact:reduced by sorbitol vs magnesium (P<0.001)
Trust score:4/5